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We investigate the utility of modern kernel-based machine learning methods for ligand-
based virtual screening. In particular, we introduce a new graph kernel based on iterative
graph similarity and optimal assignments, apply kernel principle component analysis to
projection error-based novelty detection, and discover a new selective agonist of the
peroxisome proliferator-activated receptor γ using Gaussian process regression.
Virtual screening, the computational ranking of compounds with respect to a pre-
dicted property, is a cheminformatics problem relevant to the hit generation phase of
drug development. Its ligand-based variant relies on the similarity principle, which states
that (structurally) similar compounds tend to have similar properties. We describe the
kernel-based machine learning approach to ligand-based virtual screening; in this, we
stress the role of molecular representations, including the (dis)similarity measures de-
ﬁned on them, investigate eﬀects in high-dimensional chemical descriptor spaces
and their consequences for similarity-based approaches, review literature recommen-
dations on retrospective virtual screening, and present an example workﬂow.
Graph kernels are formal similarity measures that are deﬁned directly on graphs,
such as the annotated molecular structure graph, and correspond to inner products.
We review graph kernels, in particular those based on random walks, subgraphs, and
optimal vertex assignments. Combining the latter with an iterative graph similarity
scheme, we develop the iterative similarity optimal assignment graph kernel,
give an iterative algorithm for its computation, prove convergence of the algorithm and
the uniqueness of the solution, and provide an upper bound on the number of iterations
necessary to achieve a desired precision. In a retrospective virtual screening study,
our kernel consistently improved performance over chemical descriptors as well as other
optimal assignment graph kernels.
Chemical data sets often lie on manifolds of lower dimensionality than the embed-
ding chemical descriptor space. Dimensionality reduction methods try to identify these
manifolds, eﬀectively providing descriptive models of the data. For spectral methods
based on kernel principle component analysis, the projection error is a quantita-
tive measure of how well new samples are described by such models. This can be used for
the identiﬁcation of compounds structurally dissimilar to the training samples, leading
to projection error-based novelty detection for virtual screening using only
positive samples. We provide proof of principle by using principle component analysis
to learn the concept of fatty acids.
The peroxisome proliferator-activated receptor (PPAR) is a nuclear transcription
factor that regulates lipid and glucose metabolism, playing a crucial role in the develop-
ment of type 2 diabetes and dyslipidemia. We establish a Gaussian process regression
model for PPARγ agonists using a combination of chemical descriptors and the iterative
similarity optimal assignment kernel via multiple kernel learning. Screening of a vendor
library and subsequent testing of 15 selected compounds in a cell-based transactivation
assay resulted in 4 active compounds (27% hit rate). One compound, a natural prod-
uct with cyclobutane scaﬀold, is a full selective PPARγ-agonist (EC50 = 10 ± 0.2µM,
inactive on PPARα and PPARβ/δ at 10µM). The study delivered a novel PPARγ
agonist, de-orphanized a natural bioactive product, and, hints at the natural product
origins of pharmacophore patterns in synthetic ligands.Contents
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I would rather discover one scientiﬁc fact
than become king of Persia.
Democritus (430 B.C.)
In this doctoral thesis, I present results from three years of my research into kernel-based
learning methods for ligand-based virtual screening. Most of all, it was a great time, and
I hope to convey to you, the reader, part of the excitement, curiosity, and satisfaction
that I experienced during this time.
Scope and contribution
The central theme of this thesis is the investigation of the utility of modern kernel-based
machine learning methods for ligand-based virtual screening. This includes the modiﬁca-
tion and further development of these methods with respect to the speciﬁc requirements
of this application. The underlying hypothesis is that ligand-based virtual screening can
beneﬁt from modern kernel learning methods. Four thematically self-contained chapters
address diﬀerent aspects of this theme. The contributions of this thesis are
• Chapter 1 (ligand-based virtual screening): An introduction to ligand-based virtual
screening, an investigation of distance phenomena in high-dimensional chemical de-
scriptor spaces, a survey of literature recommendations on retrospective validation.
• Chapter 2 (iterative similarity optimal assignment graph kernel): A survey of graph
kernels, development and retrospective validation of a new graph kernel.
• Chapter 3 (dimensionality reduction and novelty detection): An introduction to kernel
principle component analysis, proof of principle for projection error-based novelty
detection for ligand-based virtual screening using only positive samples.
• Chapter 4 (peroxisome proliferator-activated receptor): A survey of this receptor,
a prospective virtual screening study using Gaussian process regression yielding a
selective agonist of the peroxisome proliferator-activated receptor γ with new scaﬀold.
In recognition of others’ contributions, and to maintain the habitual style of the scientiﬁc
literature, the thesis is written in the ﬁrst person plural. Speciﬁc contributions by others:
• Dr. Ewgenij Proschak performed the docking experiments (Figure 4.12).
• Dr. Oliver Rau, Heiko Zettl, Stephan Bihler, Ramona Steri, and Michaela Dittrich
determined the stereochemistry of Compound MR16 (p. 169; Figures A.1–A.4).
• Timon Schroeter and Katja Hansen, with help of Fabian Rathke and Peter Vascovic,
ran the Gaussian process computations (Subsection 4.2.6).
• Ramona Steri carried out the transactivation assay measurements (Subsection 4.3.2).18 Preface
Parts of this thesis have been published:
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proliferator-activated receptor γ activators, submitted, 2010.
• Matthias Rupp, Gisbert Schneider: Graph kernels for molecular similarity, submitted,
2010.
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Katja Hansen, Oliver Rau, Oliver Schwarz, Lutz M¨ uller-Kuhrt, Manfred Schubert-
Zsilavecz, Klaus-Robert M¨ uller, Gisbert Schneider: From machine learning to bioac-
tive natural products selectively activating transcription factor PPARγ, ChemMed-
Chem 5(2): 191–194, Wiley, 2010.
• Matthias Rupp, Timon Schroeter, Ramona Steri, Ewgenij Proschak, Katja Hansen,
Heiko Zettl, Oliver Rau, Manfred Schubert-Zsilavecz, Klaus-Robert M¨ uller, Gisbert
Schneider: Kernel learning for virtual screening: discovery of a new PPARγ agonist,
poster, 5th German Conference on Chemoinformatics, Goslar, Germany, 2009.
• Matthias Rupp, Petra Schneider, Gisbert Schneider: Distance phenomena in high-
dimensional chemical descriptor spaces: consequences for similarity-based approaches,
Journal of Computational Chemistry 30(14): 2285–2296, Wiley, 2009.
• Matthias Rupp, Petra Schneider, Gisbert Schneider: Distance phenomena in chemical
spaces: consequences for similarity approaches, poster, 4th German Conference on
Chemoinformatics, Goslar, Germany, 2008.
• Matthias Rupp, Ewgenij Proschak, Gisbert Schneider: Kernel approach to molecular
similarity based on iterative graph similarity, Journal of Chemical Information and
Modeling 47(6): 2280–2286, American Chemical Society, 2007.
• Matthias Rupp, Ewgenij Proschak, Gisbert Schneider: Molecular similarity for ma-
chine learning in drug development, poster, 3rd German Conference on Chemoinfor-
matics, Goslar, Germany, 2007. Best poster award.
Other publications during this time:
• Ramona Steri, Petra Schneider, Alexander Klenner, Matthias Rupp, Manfred Schubert-
Zsilavecz, Gisbert Schneider: Target proﬁle prediction: cross-activation of peroxisome
proliferator-activated receptor (PPAR) and farnesoid X Receptor (FXR), Molecular
Informatics, accepted, Wiley, 2009.
• Ewgenij Proschak, Matthias Rupp, Swetlana Derksen, Gisbert Schneider: Shapelets:
Possibilities and limitations of shape-based virtual screening, Journal of Computational
Chemistry 29(1): 108-114, Wiley, 2008.
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Virtual screening is a general term describing the computer-based evaluation of chem-
ical compounds with regard to various properties, often related to drug development.
In this chapter, we describe virtual screening in this context and present the (kernel-
based) machine learning approach to its ligand-based variant. In doing so, we stress the
importance of molecular representations, of the measures of (dis)similarity deﬁned on
them, and of sound retrospective validation. We summarize literature recommendations
on retrospective virtual screening and present an example workﬂow.
1.1 Introduction
The term virtual screening denotes several related but distinct tasks, each with diﬀering
assumptions (p. 24). These tasks are in general well suited for machine learning ap-




Virtual screening comprises aspects of computer science as well as of pharmacology,
biochemistry, biology, and medicine. It belongs to the ﬁeld of cheminformatics (also
chemoinformatics; Bajorath, 2004), which is “the application of informatics methods
to solve chemical problems” (Gasteiger, 2006), with the distinction to the neighboring
disciplines of computational chemistry and bioinformatics not always clear-cut.
Important aspects of cheminformatics in general and virtual screening in particular
include compound database processing, motivated by the huge amount of chemical data
involved, and inductive learning approaches, motivated by the computational infeasibil-
ity of ﬁrst principles approaches (p.32). Cheminformatics applications that relate to
virtual screening include:22 1 Ligand-based virtual screening
• Quantitative structure-activity relationships (QSAR; Kubinyi, 2003) and quantitative
structure-property relationships (QSPR; Jurs, 2003): The establishment of statis-
tical models that relate molecular representations to either activity on a given tar-
get or to physico-chemical properties. This often involves feature selection on de-
scriptors. Examples of physico-chemical properties are solubility measured by the
octanol/water partition coeﬃcient, as well as absorption, distribution, metabolism,
excretion (ADME), oral bioavailability, and toxicity. Since these are selection criteria
related to drug development, QSAR/QSPR models can be used for virtual screening.
• Diversity analysis for focused library design (Ghose and Viswanadhan, 2001): On
the one hand, virtual screening can be used to create small diverse compound libraries
geared towards a speciﬁc target, for use with bioassay tests. On the other hand,
diversity is an important aspect in data set design for virtual screening purposes.
• De novo design (Schneider and Fechner, 2005): Molecules are virtually created from
scratch, e.g., by the application of synthesis rules to fragment libraries. The resulting
virtual compounds can be used as input for virtual screening. Alternatively, compound
creation can be guided by the predicted property.
For further information on cheminformatics, see the review by Gasteiger (2006).
Drug development
Virtual screening is used mainly for the development of new drugs, during the hit gen-
eration phase (Figure 1.1).1 There, small compounds are sought that interact in the
desired way with an identiﬁed and conﬁrmed molecular target, e.g., a receptor, channel,
gene, or other biopolymer.2 This is done by screening, the systematic investigation of a
large number of compounds with respect to the desired target interaction.
Compounds are called hits if their activity is experimentally conﬁrmed. Hits with
improvement potential become leads, and are further optimized, some eventually becom-
ing drug candidates. Properties relevant to lead selection include activity on the target,
selectivity, drug-likeness, solubility, cytotoxicity, freedom to operate, synthetic accessi-
bility, availability, and metabolization, as well as more speciﬁc aspects like interference
with cytochrome P450 and binding to human serum albumin (Thomas, 2003).
For large compound numbers, the manual performance of bioassay tests is not fea-
sible. There are two approaches to this problem: prioritization of compounds, leading
to virtual screening, and, automated assay tests, leading to high throughput screening
(HTS; Janzen, 2004). There, large numbers of compounds (on the order of 106; Schnei-
der and Baringhaus, 2008) are tested automatically using robots, computers, handling
devices, and sensors. HTS is an eﬀective, but not an eﬃcient process, in the sense that it
provides hits, but at high costs. For this reason, it has traditionally been the domain of
larger pharmaceutical companies.3 Hit rates for HTS have been reported at 0.01–0.1%
(Sills et al., 2002) and 0.5–1% (Assay Drug Dev. Technol., 2008).
1In drug development, it is also used to a lesser extent for lead optimization. Another motivation
is the development of molecular tools for pharmacology, (molecular) biology, and medicine. The re-
lated disciplines of QSAR/QSPR are relevant to chemical manufacturers, pharmaceutical companies
and government agencies, particularly with respect to the European Unions registration, evaluation,
authorization and restriction of chemicals legislative (REACH; regulation EC 1907/2006).
2This is the dominant approach employed in drug development today. Other approaches, e.g., to
start with a traditional medicine, to identify and to isolate the active pharmaceutical ingredient, and,
to synthesize it, have their own merits (Sams-Dodd, 2005).
3Some universities established HTS facilities, e.g., Harvard Medical School (Boston, Massachusetts),
University of California (Los Angeles, California), University of Texas Southwestern Medical Center





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.24 1 Ligand-based virtual screening
1.1.2 Deﬁnition
Virtual screening has been deﬁned as
• “automatically evaluating very large libraries of compounds [using a computer pro-
gram] ... [to] decide what to synthesize.” (Walters et al., 1998)
• “computational methods to prioritize the selection and testing of large chemical da-
tasets so as to ensure that those molecules that have the largest a priori probabilities
of activity are assayed ﬁrst.” (Willett, 2006b)
• “the computational equivalent of (experimental) high-throughput screening, wherein
a large number of samples are quickly assayed to discriminate active samples from
inactive samples.” (Truchon and Bayly, 2007)
• “the search for the molecules within a database of compounds that match a given
query.” (Seifert and Lang, 2008)
• “any method that ranks a set of compounds by some score, [...] usually deﬁned as
active against a target protein.” (Hawkins et al., 2008)
Some deﬁnitions stress compound numbers, some emphasize speed, others diﬀer in the
task (classiﬁcation versus ranking). Hristozov et al. (2007) investigated diﬀerent vir-
tual screening scenarios: compound prioritization for HTS, compound selection for lead
optimization, deciding whether a compound is active, and, identiﬁcation of the most
active compound. These scenarios have slightly diﬀerent requirements, e.g., few false
negatives, early recognition, conﬁdence estimates, and, correlation of rank with activity.
For our purposes, we deﬁne virtual screening as the computational ranking of a
compound data set. We do not refer to data set size or processing speed because the
meaning of “large” and “fast” changes over time and quantiﬁcation would be arbitrary.4
Note that ranking can be done by scoring, and includes classiﬁcation via ties.
Targets and ligands
Virtual screening needs a rational starting point, either a model of the target structure,
or, known ligands, leading to structure-based and ligand-based virtual screening.
Structure-based virtual screening (also receptor-based virtual screening; Klebe, 2006)
uses structural information about the target, e.g., crystal structures (models ﬁtted to
electron densities derived from diﬀraction data; see Figure 4.1 for an example), structures
derived by nuclear magnetic resonance spectroscopy (W¨ uthrich, 2003), or homology
models (model interpolations based on related targets with high sequence similarity).
The most prominent technique is docking (Kitchen et al., 2004), where the compound
is placed within a binding site of the target (pose prediction) and the binding aﬃnity of
the resulting pose is estimated (scoring).5
In practice, problems have been associated with structure-based virtual screening.
Several frequent assumptions like correctness and relevance of the protein-ligand crystal
structure are not always met (Davis et al., 2008), and scoring functions are often biased
towards positive samples (Pham and Jain, 2006). In a comparison of 10 docking pro-
4Asymptotic worst-case runtime is no solution either: Because ligands are small, runtime is dominated
by constant factors, allowing algorithms that are asymptotically slower to outperform others for the input
sizes of interest.
5Technically, docking is only the placement of the ligand in a binding pocket, and scoring is the









Pargyline (N-methyl-N-2-propynylbenzylamine), a potent irreversible inhibitor of
monoamine oxidase, and three derivatives diﬀering only by an additional methyl group













Isoproterenol is an agonist of the α-
adrenergic receptor. Substitution
of two hydroxy groups by chlorine
yields dichloro-isoproterenol, a β-
adrenergic antagonist.
Scheme 1.1 Examples of similarity principle violations (similar compounds, disparate
activities; Schneider and Baringhaus, 2008). For more examples, see Kubinyi (1998).
grams and 37 scoring functions, Warren et al. (2006) found no statistically signiﬁcant
relationship between scores and ligand aﬃnity.
Ligand-based virtual screening (Douguet, 2008) is based on the similarity principle
(Johnson and Maggiora, 1990), which states that (structurally) similar compounds ex-
hibit similar biological activities. Besides exceptions (Scheme 1.1), the validity of this
assumption depends on the choice of compound similarity, i.e., the choice of molecular
representation and similarity measure (Section 1.3). Quantitative investigations (Martin
et al., 2002) have conﬁrmed the similarity principle, albeit with large variance.6
In practice, ligand-based methods have been reported to outperform docking in vir-
tual screening (Hawkins et al., 2006; McGaughey et al., 2007), especially with regard
to false positives. However, ligand-based approaches do not use information about the
target structure, even if it is available, and do not provide insight into binding pose, or
mechanism of action. Table 1.1 contrasts advantages and disadvantages of structure-
and ligand-based virtual screening.
Several strategies have been proposed to combine both approaches. In hybrid vir-
tual screening protocols (Sperandio et al., 2008), ligand-based virtual screening hits are
further investigated by docking methods. Combining the results of multiple methods,
known as data fusion (Willett, 2006a), or consensus scoring in docking (Feher, 2006),7
can lead to performance superior to that of the individual methods alone. Pseudo-
receptor models (Tanrikulu and Schneider, 2008) are receptor surrogates for virtual
screening derived from the alignment of ligand conformations. Note that combina-
tions of structure- and ligand-based virtual screening also inherit combinations of their
(dis)advantages.
6The frequency with which a compound similar to an active was itself active has been estimated
at 0.012–0.5, 0.3, 0.4–0.6, 0.8 (Unity ﬁngerprints, Tanimoto similarity ≥ 0.85), 0.43–0.7 (topological
torsions, atom pair ﬁngerprints, clustering), and 0.67 (Daylight ﬁngerprints, Tanimoto similarity ≥ 0.85);
all numbers as given by Martin et al. (2002). Part of the variance has been traced back to diversity
issues in the used data sets.
7Other methods for combining multiple models exist outside of cheminformatics, e.g., forecast combi-
nation by encompassing tests in econometrics (Newbold and Harvey, 2002), where a linear combination
of predictive models is sought such that no model is contained (encompassed) by another.26 1 Ligand-based virtual screening




• No restriction to known ligands
• Use of target information
• Low false negative rate
• Requires model of target structure
• High computational complexity
• Scoring functions often do not con-
sider entropy, desolvation energy,
metal ions, polarization eﬀects, ...
• Protein ﬂexibility is often not suﬃ-
ciently treated to model induced ﬁt
phenomena
• High false positive rate
Ligand-
based
• Low computational complexity
• No target information required
• Chemical diversity is limited to the
known ligands
• Target information is not used
• 3D methods depend on conformer
generation
For further information on virtual screening, see B¨ ohm and Schneider (2000); Alvarez
and Shoichet (2005). An extensive list of successful virtual screening applications is given
by Kubinyi (2006); Seifert and Lang (2008).
1.2 The machine learning approach
Ligand-based virtual screening lends itself naturally to machine learning approaches,
with diﬀerent variants requiring diﬀerent paradigms, models, and methods of learning.
Inductive machine learning (also pattern recognition) is the algorithmic search for
patterns in data, a ﬁeld closely connected to statistics, information theory, and compres-
sion.8,9 The investigated data, called training data, are given in the form of examples,
or samples, corresponding to the known ligands. Explicit prior information can be ex-
ploited, both in terms of the used molecular representation10 and the sought pattern11.
A learned pattern can be applied to new data, called the test data, corresponding to the
screened compound library.
8A pattern (or regularity) in some data enables, via exploitation of the pattern, a shorter representa-
tion of this data. Vice versa, a shorter representation implies regularity. For further information on the
connections between information theory, compression, and inductive learning, see MacKay (2003).
9Induction is diﬀerent from transduction (also instance-based learning), where reasoning is directly
from samples (training data) to other samples (test data), without an intermediate search for a pattern
(Vapnik, 1998). An example is k-nearest neighbor classiﬁcation.
10Consider a substructure-based model for activity on a given receptor. If there are known steric
constraints, incorporation of spatial information into the description may improve predictions.
11See Section 3.3 for an example where a linear pattern is known a priori to be suﬃcient. If the type
of pattern is not known in advance, universal kernels like the Gaussian kernel (p. 30) may be used.1.2 The machine learning approach 27
We focus on inductive kernel-based machine learning approaches to ligand-based
virtual screening. Other approaches such as deductive, i.e., logic-based, machine learning
(Russell and Norvig, 2002), or, inductive methods not based on kernels such as artiﬁcial
neural networks (Bishop, 1996) and decision trees (Rokach and Maimon, 2008), have
been applied to ligand-based virtual screening, but are outside the scope of this work.
For further information on inductive machine learning, see the text books by Duda
et al. (2001); Hastie et al. (2003); Bishop (2006).
1.2.1 Learning paradigms
Machine learning problems can be classiﬁed with regard to various aspects. Depending
on data quality and availability, virtual screening scenario, and experimental setup,
ligand-based virtual screening can be formulated within many of these problem settings.
Supervised, semi-supervised, and unsupervised learning
Supervised learning (Kotsiantis, 2007) is the classic inductive learning scenario, where
each training sample is associated with a label, and the task is to infer the unknown
labels of test samples. In semi-supervised learning (Chapelle et al., 2006), only some
of the training samples have labels, and the unlabeled samples are used to improve the
prediction of test sample labels. In unsupervised learning (Ghahramani, 2004), samples
are not associated with labels. Tasks include density estimation and the discovery of
structure, e.g., via clustering. Spectral dimensionality reduction methods (Section 3.2)
and Gaussian processes (Subsection 4.2.4) are examples of unsupervised and supervised
learning techniques, respectively.
Regression, classiﬁcation, and novelty detection
In supervised learning, one diﬀerentiates by the type of label associated with samples.
In regression, each sample is associated with a real number. Examples are QSAR/
QSPR, and, analysis of HTS data. For regression, the accuracy of the data (p.41) is
important. The latter is often surprisingly low for biochemical experimental data (Foot-
note 17, p.41). Chapter 4 describes a virtual screening experiment based on Gaussian
process regression.
In classiﬁcation, only categorical information is available, i.e., the labels belong to
a ﬁnite set of two or more classes. Binary classiﬁcation, e.g., active versus inactive
samples, is a special case. Classiﬁcation is often used as a ﬁrst approximation based on
an activity cut-oﬀ, or, when combining data from diﬀerent sources due to accuracy issues,
e.g., if compound activity was measured in diﬀerent assays, as is typical when data is
collected from the scientiﬁc and patent literature. Another example is the classiﬁcation
of drugs versus non-drugs (Hutter, 2009).
In novelty detection, only samples from one class are available. The task is to decide
whether new samples were drawn from the same distribution as the training data, i.e.,
whether they are novel or not. This scenario can be appropriate for new targets with
few known ligands, especially if resources are limited or an HTS assay is not available.
Another reason is publication bias: Since negative results are not published, it is often
diﬃcult to obtain data about experimentally veriﬁed inactive compounds.28 1 Ligand-based virtual screening
Negative samples problem
The unavailability of veriﬁed negative samples is often addressed by substituting ran-
domly sampled compounds, usually from the test samples to be screened. On the one
hand, this introduces additional information in the form of (supposedly) negative sam-
ples, and, turns the novelty detection problem into a binary classiﬁcation problem, for
which more algorithms exist. On the other hand, this also introduces property bias
(p.39), as well as errors in the form of negative training samples which are actually ac-
tive (the test set is assumed to contain actives, otherwise it would be pointless to screen
it). It can also be argued that, when studying a ligand class, it is more interesting to
characterize it than to separate it from an (arbitrary) fraction of chemical space (the
screening library).
Together, these reasons commend the use of novelty detection approaches to ligand-
based virtual screening. We introduce dimensionality reduction based on kernel principle
component analysis as such an approach in Chapter 3.
Other criteria
In a batch setting, all training samples are available from the beginning, whereas in an
on-line setting, samples are successively made available. In passive learning, training
samples are given; in active learning, the learning algorithm may request labeling of
unlabeled samples. Most machine learning applications in virtual screening take place
in passive batch settings.
1.2.2 Kernel-based learning
Since their introduction in the 1990s,12 kernel-based machine learning methods have been
widely applied in both science and industry, and have become an active area of research.
We introduce only the concepts required for this and the following chapters. For a recent
review of kernel-based learning, see Hofmann et al. (2008); for an introductory text, see
the books by Sch¨ olkopf and Smola (2002); Shawe-Taylor and Cristianini (2004).
Idea
The basic idea of kernel-based machine learning methods is to turn linear algorithms,
e.g., least squares regression (p. 157) or principle component analysis (Subsection 3.2.1),
into non-linear algorithms in a systematic way. This is done by (implicitly) mapping the
input samples into a higher-dimensional space, and applying the linear algorithm there
(Figure 1.2). This approach has two immediate problems: Computational complexity,
and how to ﬁnd the right mapping.
The kernel trick
Consider the mapping φ : Rp → Rpd
which maps x to the space of all ordered monomials






2). The size pd of the
space mapped into (the feature space) depends polynomially on the size p of the input
space. For a typical input space dimensionality of p = 120 (Table 1.3a) and d = 3, the
size of the target space is already 1203 = 1728000. Other mappings are into feature
12Support vector machines (Subsection 2.4.3), the ﬁrst widely successful kernel algorithm, were intro-
duced by Boser et al. (1992). The involved concepts had been investigated since the 1960s, e.g., the ﬁrst
use of kernels in machine learning by Aizerman et al. (1964). See Cristianini and Shawe-Taylor (2000).1.2 The machine learning approach 29
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(a) Linear inseparability in input space.





(b) Linear separability in transformed space.
Figure 1.2 Linear separability via a non-linear mapping into a higher-dimensional space.
In the input space R, samples from the two classes (blank and grey disks) are not
linearly separable. The non-linear function x 7→ (x,sinx) maps the samples into the
higher-dimensional space R2, where samples are linearly separable (by the x-axis).
spaces of inﬁnite dimension. For these mappings, explicit computations in feature space
are computationally either infeasible or impossible.
The kernel trick is to replace computations in feature space by computations in input
space that give the same results. This is achieved by the use of inner products, which
generalize geometric concepts like length, angle, and orthogonality. For a real vector
space X, a function h·,·i : X × X → R is an inner product iﬀ for all x,y,z ∈ X, α ∈ R
holds
• hx,xi ≥ 0 (non-negativity) and hx,xi = 0 ⇔ x = 0,
• hx,yi = hy,xi (symmetry),
• hx + y,zi = hx,zi + hy,zi and hαx,yi = αhx,yi (linearity).
The pair (X,h·,·i) is called an inner product space. Two vectors x,y ∈ X are orthogonal
iﬀ their inner product is zero, x ⊥ y ⇔ hx,yi = 0. In a real inner product space X, the
angle (measured in radians) between two non-zero x,y ∈ X is deﬁned as




An inner product h·,·i can be used to construct a norm (and corresponding metric) via
kxk =
p
hx,xi. Conversely, given a norm k·k on X, kxk
2 = hx,xi iﬀ the parallelogram
identity kx + yk
2 + kx − yk
2 = 2(kxk
2 + kyk
2) holds; the Euclidean norm is the only
Lp-norm satisfying this identity (Meyer, 2001).
Many machine learning algorithms can be expressed in terms of the lengths, angles,
and distances between input samples; in other words, they can be rewritten to use only
inner products of input samples. For a worked-through example of how to turn principle
component analysis, a linear algorithm, into its kernel variant, see Chapter 3.
Kernels
A function k : X × X → R is a kernel iﬀ there exists a map φ : X → H such that
∀x,y ∈ X : k(x,y) = hφ(x),φ(y)i, (1.2)
i.e., if it corresponds to an inner product in some feature space H. It is not necessary
to know φ or H explicitly, their existence is suﬃcient. Using a kernel, one can implicitly
compute inner products in high-dimensional feature spaces by computing kernel values
in input space, thereby alleviating the computational complexity issue due to feature
space dimensionality.30 1 Ligand-based virtual screening
As an example, let φ : Rp → Rpd
denote the map to the space of ordered monomials
as before, and consider the homogeneous polynomial kernel k = hx,yi

























xi1xi2 ···xid yi1yi2 ···yid = hφ(x),φ(y)i.
(1.3)
A kernel algorithm is only allowed to use inner products of input samples x1,...,xn ∈
X. The matrix K ∈ Rn×n, Ki,j = k(xi,xj) is called the kernel matrix (also Gram ma-
trix). It contains all the information about the input samples accessible to the algorithm.
Positive deﬁniteness
A symmetric matrix K ∈ Rn×n is positive deﬁnite iﬀ
∀c ∈ Rn : cTKc =
n X
i,j=1
cicjKi,j ≥ 0. (1.4)
K is strictly positive deﬁnite iﬀ equality occurs only for c = 0.13 A function k : X ×X →
R that has (strictly) positive deﬁnite Gram matrix for all x1,...,xn ∈ X, n ∈ N is called












Vice versa, it can be shown that every positive deﬁnite function corresponds to an inner
product in some inner product space (via reproducing kernel Hilbert spaces and the
Moore-Aronszajn theorem, Aronszajn, 1950). Proper kernels are therefore characterized
by the positive deﬁniteness property.14
Criteria for the positive deﬁniteness of matrices other than Equation 1.4 include
Sylvester’s criterion, 15 and, the eigenspectrum of a matrix: K is (strictly) positive deﬁ-
nite iﬀ all of its eigenvalues are non-negative (positive).
The Gaussian kernel
The kernel has to transform the input data in a way that allows successful application
of a linear algorithm in feature space. There are two basic approaches to this: Problem
domain-speciﬁc kernels and generic kernels. Chapter 2 describes a kernel on molecular
structure graphs developed for ligand-based virtual screening. A good default choice on
vectorial input data such as molecular descriptors is the Gaussian kernel (also radial








13Positive deﬁnite and strictly positive deﬁnite matrices are also called positive semideﬁnite and positive
deﬁnite matrices, respectively; corresponding care has to be taken when consulting the literature.
14Historically, kernels satisfying the theorem of Mercer (1909) were used. Such functions correspond
to inner products, but not all functions corresponding to inner products satisfy the theorem’s conditions.
15K is strictly positive deﬁnite iﬀ its leading principal minors are positive; it is positive semideﬁnite
iﬀ all of its principal minors are non-negative (Kerr, 1990).1.2 The machine learning approach 31






(a) σ = 0.4.






(b) σ = 1.






(c) σ = 10.
Figure 1.3 The behavior of the Gaussian kernel. Shown are 5 isolines (having dif-




i=1 rbf(xi,x) for three data points x1, x2, x3 (orange disks), where rbf indicates
the kernel function from Equation 1.6. Graylevels indicate the density of g, with darker
values corresponding to higher densities.
where σ > 0 is the kernel width. This kernel maps into an inﬁnite-dimensional feature
space (Steinwart et al., 2006).
To understand the behavior of the Gaussian kernel, consider the limiting cases of
the kernel width. For σ → ∞, the kernel matrix becomes the all-ones matrix 1n×n,
i.e., all samples are mapped into a single point, leading to underﬁtting. For σ → 0,
the kernel matrix becomes the identity matrix In×n, i.e., all samples are mapped into
diﬀerent dimensions orthogonal to each other, leading to overﬁtting. For intermediate
values of σ, the kernel value depends on kx − yk, approaching 1 for kx − yk → 0, and 0
for kx − yk → ∞. Samples that are close in input space are therefore correlated in
feature space, whereas faraway samples are mapped to orthogonal subspaces. In this
way, the Gaussian kernel can be seen as a local approximator, with scale dependent on σ
(Figure 1.3).
Remarks
The input space X can be any non-empty set with suﬃcient structure to allow the
deﬁnition of a kernel; in particular, X does not have to be a vector space (for kernels on
structured data, see p. 59). In contrast to other methods like neural networks, kernel
methods are often deterministic and globally optimal with respect to the optimization
problem they solve, e.g., kernel principle component analysis (Subsection 3.2.2) and
support vector machines (Subsection 2.4.3). The property of positive deﬁniteness, which
guarantees the existence of an inner product feature space, is often also the property
required to ensure convexity of these optimization problems.
Examples
In Chapter 3, an unsupervised kernel-based machine learning algorithm for dimension-
ality reduction, kernel principle component analysis, is formally derived and used for
visualization and novelty detection. In Chapter 4, a kernel-based regression algorithm,
Gaussian process regression, is applied in a prospective virtual screening study.32 1 Ligand-based virtual screening
1.3 Representation and similarity of molecules
Success in virtual screening depends primarily on how well the used molecular repre-
sentation and (dis)similarity measure capture characteristics relevant to the target. If
crucial information is not encoded in the input representation, all methods fail, whereas
simple methods such as similarity search (Willett, 1998) can perform well with the right
representation.
1.3.1 Molecular representations
The abundance of available molecular representations — the handbook of molecular de-
scriptors (Todeschini and Consonni, 2000) lists more than 1600 of them — is caused by
the necessity to selectively model molecular properties relevant to the speciﬁc target in-
teraction under investigation. This necessity originates from the computational demands
of ﬁrst principles methods, which make them infeasible in large scale applications. The
selection of a molecular representation for a speciﬁc task is a problem in itself.
Limits of quantum theoretical representations
Quantum mechanics (Cohen-Tannoudji et al., 2006) is concerned with matter and energy
on an atomic scale, and constitutes the most fundamental and accurate theory available
to date. Its application to chemistry, quantum chemistry (McQuarrie, 2007), provides a
theoretical foundation for the description of molecular interactions, e.g., between ligand
and receptor.
In quantum mechanics, a system is completely described by its wave function (and
the evolution of it over time). Theoretically, no other molecular representation is needed.
In practice, the underlying Schr¨ odinger equation, essentially a many-body problem, can
be solved analytically only for the hydrogen atom. Numerical (ab-initio) solutions are
presently limited to a few dozen electrons for computational reasons, i.e., a computa-
tional complexity exponential in the number of electrons (Friesner, 2005).
Necessity of diﬀerent representations
Virtual screening involves large numbers of compounds, and therefore requires methods
of low computational complexity. This severely limits the applicability of exact quantum
mechanical representations and necessitates more abstract representations, i.e., repre-
sentations that contain only the information relevant to the target. Such representations
are computationally less complex to obtain, since only speciﬁc molecular characteristics
have to be computed; for the same reasons, they are also speciﬁc to targets, or target
classes. Along with the number of targets — Overington et al. (2006) identiﬁed 324
targets of approved therapeutic drugs alone — this is one cause for the abundance of
available molecular representations.
Descriptors
Diﬀerent classiﬁcation systems for molecular representations are in use, e.g., by dimen-
sionality (sometimes of the representation, sometimes of the property; e.g., line notations
and molecular weight have both been called one-dimensional), by the used data struc-
ture (e.g., string, vector, graph), or, by the property described (e.g., shape, charge,
connectivity).1.3 Representation and similarity of molecules 33
A popular category of molecular representations are chemical descriptors (Todes-
chini and Consonni, 2000), which describe molecules with numerical attributes, either
experimentally determined or computed ones. The corresponding mathematical ab-
straction are vector spaces (Meyer, 2001), resulting in chemical descriptor spaces (Sub-
section 1.3.2). Vectorial representations have several advantages: They are widely used
across disciplines, vector spaces are mathematically well developed, and many algorithms
are available. For these reasons, vector representations were used in the ﬁrst applications
of machine learning methods in ligand-based virtual screening. Later, structured data
representations such as graphs were used.
Spatial information
Many descriptors depend only on a molecule’s constitution (e.g., molecular weight, num-
ber of rotatable bonds) or its topology (e.g., graph diameter, connectivity indices). The
incorporation of spatial aspects should lead to more realistic models, improving perfor-
mance. Empirical investigations, however, showed little or no advantage of 3D descrip-
tors over topological ones (Hristozov et al., 2007).
In part, this has been ascribed to inductive bias, i.e., a bias towards 2D similarity in
existing data sets, caused by a corresponding bias in human experts who created them
and extensive use of 2D similarity methods in their creation (Cleves and Jain, 2008).
Conformational isomers (also conformers) are stereoisomers (molecules with iden-
tical constitution, but diﬀerent arrangement in space) due to rotation around σ-bonds
(single bonds; Moss, 1996). In principle, the performance of ligand-based 3D virtual
screening methods depends on the used conformations of the training compounds. In
empirical investigations, however, source and number of conformations had little eﬀect
on performance (Hristozov et al., 2007; McGaughey et al., 2007).
Measures of (dis)similarity
Besides the molecular representation itself, the applicability of the similarity principle
depends on the measure of (dis)similarity used to compare two such representations.
Diﬀerent measures are available, and their choice inﬂuences virtual screening results
(Fechner and Schneider, 2004; Rupp et al., 2009). Many measures of (dis)similarity
exist; the most common categories are norms, which measure length, metrics, which
measure distance, inner products, which encode information about length, angle, and
orthogonality, and, similarity coeﬃcients, which measure similarity, but lack some formal
properties of the others. See Table 1.2 for examples and Meyer (2001) for details.
1.3.2 Distance phenomena in high-dimensional descriptor spaces
Real-valued chemical descriptor spaces are widely used in ligand-based virtual screening
and QSAR modeling. Although a successful concept, some problems have been associ-
ated with high-dimensional descriptor spaces, e.g., chance correlations in QSAR (Topliss
and Edwards, 1979; Mager, 1982). Other problems, sometimes summarized under the
umbrella term curse of dimensionality (coined by Bellman, 1957), have been recognized
both within (Willett et al., 1998) and outside (Fran¸ cois, 2007) of chemistry, e.g., in
the database community, where they are relevant to indexing and retrieval. The root
cause of these phenomena is that distance is measured across volume, which increases
exponentially with dimension.34 1 Ligand-based virtual screening
Table 1.2 Common norms, metrics, inner products, and similarity coeﬃcients. For
Minkowski distances with 0 ≤ p < 1, the triangle inequality is reversed. The Frobenius
matrix norm is the L2 norm applied to the concatenated rows or columns of a matrix A.
Vectors are over the domain Rm; for matrices, A,B ∈ Rk×m, and M ∈ Rm×m. Similarity
coeﬃcients have range [−1,1], except for the Tanimoto coeﬃcient, which has range
[−1
3,1]. A
T = transpose of matrix A, tr(A) = trace of matrix A, covar(x,y) = (empirical)






, p ≥ 1 Lp norm k·kp Pm
i=1 |xi| L1 norm k·k1, grid norm, sum norm
pPm
i=1 |xi|2 L2 norm k·k2, Euclidean norm







maxkxk=1 kAxk Matrix norm induced by k·k
Metrics
³Pm
i=1 |xi − yi|p
´1/p
, p ≥ 1 Lp norm induced metric, Minkowski distance
Pm
i=1 |xi − yi| Manhattan metric (L1 norm-based)
pPm
i=1 |xi − yi|2 Euclidean metric (L2 norm-based)
max1≤i≤m |xi − yi| Maximum (Chebyshev) metric (L∞ norm-based)
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i=1 xiyi Standard inner product, dot product
tr(ATB) Matrix standard inner product
xTMy, M s.p.d. Weighted inner product
R b
a f(t)g(t)dt Inner product of continuous functions on [a,b]
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X f(t)g(t)dt Inner product of square integrable functions
Similarity coeﬃcients
covar(x,y) √
var(x)var(y) Product-moment (Pearsons) correlation coeﬃcient
2hx,yi
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Table 1.3 Descriptor dimensionalities and data set sizes.
(a) Dimensionality d of common descriptor spaces.
d Descriptor
∼ 50 Mini-ﬁngerprints (Xue et al., 1999, 2000)
72 VolSurf descriptor (Cruciani et al., 2000)
120 Ghose-Crippen fragment descriptors (Viswanadhan et al., 1989)
150 CATS2D pharmacophore descriptor (p. 154)
184 MOE 2D descriptors (p. 156)
(b) Typical data set sizes n with maximum covered dimension maxd = blog2(n)c.
n maxd Description
102 6 Virtual screening training set
104 13 COBRA drug database (p. 88)
105 16 Known drugs
106 19 High-throughput screening data set
107 23 CAS REGISTRY database (Weisgerber, 1997)
Empty space phenomenon
Consider a ﬁnite sample x1,...,xn ∈ Rd. A partitioning of each dimension into two
parts, such that each part contains at least one sample, results in a partitioning of Rd
into 2d compartments. Since the number of compartments grows exponentially with the
dimension d, an exponential number of samples is needed to (binary) cover Rd in the
sense that each compartment contains at least one sample. This is a reason why density
estimation in high dimensions is diﬃcult (Scott and Thompson, 1983).
For practical scenarios, almost all of the compartments will be empty. As an example,
consider a compound library with 108 compounds described by Ghose-Crippen fragment
descriptors, for which d = 120, a common dimensionality of chemical descriptor spaces
(Table 1.3a). Although the data set is large (Table 1.3b), the fraction of compartments
covered is at most 108/2120 ≈ 10−28 ≈ 0. The maximum dimension that could be covered
by this data set is blog2(108)c = 26. From Table 1.3, it is clear that in typical scenarios
the chemical space spanned by a descriptor will be empty in terms of data set coverage.
The distribution of the samples is another matter. Compound collections usually
exhibit structure due to selection bias, which suggests that they lie on lower-dimensional
manifolds in descriptor space.
Consider n ≤ 2d samples drawn independently and uniformly distributed from
[0,1]d ⊂ Rd, where each dimension is partitioned into intervals [0, 1
2] and (1
2,1]. The prob-





where m = 2d. For the COBRA data set (p. 88) and the CATS2D descriptor (p. 154;
n = 9705, d = 141 after removal of constant components), this is ≈ 1.689 · 10−35 ≈ 0.
Rescaling this data set to the range [0,1]141, however, leads to 1016 compartments with
two samples or more. Values for MOE 2D descriptors (p. 156; n = 9950, d = 165 after
removal of constant components) are comparable (1.058 · 10−42, 1072). This statisti-
cal test shows that the COBRA compounds were not sampled uniformly and identically
distributed from either the CATS2D or MOE 2D descriptor spaces.36 1 Ligand-based virtual screening








(a) Volume VSd,1 of the unit sphere as a func-
tion of the dimension d. The maximum is at
≈ 5.257, and, VS5,1 = 8
15π. V = volume, d =
dimension.









(b) Average number of samples included in a
unit sphere centered on each of 300 random
samples in [0,1]d. Shown are Lp norm-based
metrics for p=1 (solid line), p=2 (dashed line),
p=4 (dotted line); in the limit p → ∞ (dash-
dotted line), the unit sphere becomes a cube.
# = number of samples, d = dimension.
Figure 1.4 The dependence of sphere volume on dimension. Because sphere volume
vanishes with increasing dimension (a), spherical neighborhoods of ﬁxed radius contain
less and less neighbors (b).
Another way to look at this is that n samples can span (if the embedding space allows
it) a subspace of dimension at most n, but they can only cover a subspace of dimension
blog2(n)c. These ﬁndings suggest the usefulness of feature selection (Guyon and Elisseeﬀ,
2003) and dimensionality reduction (Fodor, 2002) for chemical data sets. Indeed, feature
selection is common practice in quantitative structure-activity relationship modeling.
Sphere volumes




¯ kxk2 = r
ª
of radius r ≥ 0 has volume
VSd,r = (πd/2rd)/Γ(1 + d
2), where Γ denotes the gamma function (Hamming, 1980).
VSd,r goes to zero for d → ∞ (Figure 1.4a). As a consequence, for a ﬁnite sample
x1,...,xn ∈ Rd and ﬁxed radius r, there is a dimension d after which a sphere of
radius r centered on xi contains only xi and no other sample (Figure 1.4b).
The unit cube {x | −1 ≤ xi ≤ 1} = {x | kxk∞ ≤ 1} (the unit sphere as measured by
the max norm) circumscribes the Euclidean unit sphere; its volume 2d goes to inﬁnity.
Therefore, for d → ∞ a sample drawn uniformly from this cube is almost surely located
at its corners, i.e., in the cube, but outside of the sphere. For two spheres with radii
r < r0, the ratio of their volumes VSd,r/VSd,r0 =
¡ r
r0
¢d decreases exponentially with d.
Samples drawn uniformly from the larger sphere will therefore lie outside of the smaller
sphere with probability 1 − ( r
r0)d d→∞ − − − → 1.
From the previous considerations, it is clear that both norm and dimension should be
considered when choosing radii in spherical neighborhood computations, e.g., k-nearest
neighbor classiﬁcation. In this work, we mainly use the Euclidean distance due to its
close connection with inner products (p.29), while the dimension d is given by the used
descriptor space. The radius r can be determined by solving an optimization problem
(Balasubramanian, 2002).1.3 Representation and similarity of molecules 37








(a) Probability mass of the d-dimensional stan-
dard normal distribution contained in a sphere
of radius 2, measured by the grid norm (solid
line), the Euclidean norm (dashed line), the L4
norm (dotted line), and, the max norm (dash-
dotted line). Numerical estimation with 106
samples.








(b) Distribution of the Euclidean norm of sam-
ples drawn from a standard normal distribution
in d dimensions. The L2 norm follows a χ-
distribution with d degrees of freedom. Shown
are probability densities for d = 1 (solid line),
d = 2 (dashed line), d = 5 (dotted line), and,
d = 10 (dash-dotted line).
Figure 1.5 The multivariate standard normal distribution and dimensionality. With
increasing dimension, less probability mass is found within a ﬁxed radius around the
mean (a), and samples center on a sphere surface (b). P = probability, d = dimension.
The normal distribution
Phenomena related to spherical or ellipsoidal volumes also aﬀect statistics. Consider a
d-dimensional standard normal distribution, i.e., a distribution that generates samples
xi ∈ Rd with independent components (xi)j ∼ N(0,1). With increasing dimension,
the probability mass contained in a sphere of ﬁxed radius around the origin decreases
rapidly (Figure 1.5a). In one dimension most points lie close to the origin, while in
higher dimensions almost no point does; in this sense, for high dimensions most of the
probability mass lies in the tails and not in the center of a normal distribution.
This behavior is due to the Lp norms deﬁnition in terms of absolute component values
|(xi)j|, with E(|(xi)j|) =
p
2/π causing kxikp to grow with each added dimension. Since
the distribution of kxikp is unimodal, the samples tend to lie on a hypersphere with radius
r = E(kxikp) (Figure 1.5b). The value of r depends on d and p: For the grid norm,
E(kxik1) = d
p






The concentration of norms is not limited to normally distributed samples; it also aﬀects
the distances between samples. In high dimensional spaces, under mild assumptions,
sample norms tend to concentrate. As a consequence, all distances are similar, samples
lie on a hypersphere, and each sample is nearest neighbor of all other samples.
For an intuitive explanation, consider independent samples x1,...,xn drawn uni-
formly from [0,1] ⊂ R. For n → ∞, E(xi) = 1
2 because the values average out over the
samples. Now consider a single sample x ∈ [0,1]d for d → ∞. Again, the values average
out, but this time over the components of x, so limd→∞
kxk1
d = 1
2. Note that Lp norms
increase with d. Figure 1.6 illustrates this for diﬀerent norm-induced distances.38 1 Ligand-based virtual screening


























Figure 1.6 Behavior of Lp norm-based distances. For n = 105 distances between points
sampled uniformly and independently from [0,1]d, the mean (solid line) ± its standard
deviation (dotted lines), and, the coeﬃcient of variation (dashed line) are shown.
The concentration of Lp norms and associated Minkowski metrics has been formally
studied (Beyer et al., 1999; Hinneburg et al., 2000; Aggarwal et al., 2001; Fran¸ cois et al.,
2007), often using the (absolute) contrast maxi kxik−mini kxik and the relative contrast
maxi kxik − mini kxik
mini kxik
(1.7)
as measures of concentration. However, these depend on extremal values, and therefore
on sample size, and are highly volatile. Instead, we use another measure of spread versus








where small values indicate concentration. Note that σ
µ can equivalently be deﬁned in
terms of norms by a change of domain (Fran¸ cois et al., 2007). Table 1.4 lists empirical
variation coeﬃcients computed on the COBRA data set.




























¢ = 0, (1.9)
where c and c0 are constants not depending on d (Fran¸ cois et al., 2007). This shows
that, under the strong assumption of independence and identical distribution of the
components, all Lp norms and Minkowski distances concentrate, and also gives the rates














where c and c0 depend on p.
Equation 1.9 stays valid for diﬀerently distributed components and dependences be-
tween them (Fran¸ cois et al., 2007). In the ﬁrst case, the equation still holds if the data
are standardized, i.e., if they have zero mean and unit variance (subtracting the mean
and dividing by the standard deviation achieves this). Standardization ensures that
the norm is not dominated by a few components. In the second case, concentration
takes place, but depends on the intrinsic dimensionality of the data, as opposed to the
dimensionality of the vector space itself.1.4 Retrospective evaluation 39
Table 1.4 Variation coeﬃcients for diﬀerent descriptors and (dis)similarity measures on
the COBRA data set. r = Pearsons correlation, d = Dice coeﬃcient, t = Tanimoto coeﬃcient,
c = Carb´ o index.
Minkowski metrics (p) (Dis)similarity coeﬃcients
Descriptor 1 2 3 5 ∞ 1 − r 1 − d 1 − t 1 − c
CATS2D 0.30 0.21 0.19 0.18 0.21 0.34 0.35 0.25 0.36
MOE 2D 0.42 0.38 0.37 0.40 0.49 0.29 0.30 0.17 0.33
Chemical descriptor spaces are, as a rule, normalized in some form or other, and
from Table 1.3a, as well as Figures 1.4, 1.5, and 1.6, it is evident that their dimension-
ality is high enough for distance concentration to occur. However, due to dependencies
between descriptors, various forms of bias (p. 39), and reasons given before (p. 36), the
intrinsic dimensionality of chemical data sets will be lower than the dimensionality of
the embedding descriptor space. For a more detailed treatment of these phenomena,
and their consequences for virtual screening, see Rupp et al. (2009).
1.4 Retrospective evaluation
The evaluation of virtual screening methods on known data, called retrospective evalua-
tion, serves two purposes: selection of the best model for a given target, and, estimation
of a given models hit rate on a target, with the focus usually on the former.
Although virtual screening has become an essential part of the drug discovery process,
still “there is no agreed upon theory as to how to conduct a retrospective evaluation”
(Nicholls, 2008). In the following, we discuss model validation issues with regard to
ligand-based virtual screening, based on literature recommendations (Gramatica, 2007;
Hawkins et al., 2008; Jain and Nicholls, 2008, and the references therein). Table 1.5
summarizes recommendations; Cornell (2006) compares existing retrospective studies.
1.4.1 Data selection
The data used in a retrospective virtual screening study are critical, and mistakes can
easily lead to overestimated performance. We discuss some important aspects.
Property bias
Diﬀerences in simple properties between actives and inactives can lead to good perfor-
mance of any method (artiﬁcial enrichment). The vast size of chemical space makes a
purely random selection of decoys both unlikely to be representative of inactivity space
and likely to be trivially separable from the actives. Good results due to property bias
can be detected by comparison with any simple baseline method. The maximum unbi-
ased validation data set (MUV; Rohrer and Baumann, 2008) was designed to eliminate
property (and analogue) bias by matching property distributions of actives and inactives.
Analogue bias and correlation
Virtual screening data sets often contain series of structurally related actives. This
violates the assumption of independence which underlies most statistical analyses. Con-
sider, e.g., a data set which contains a compound twice, or a trivial analog of it. Both
cases result in a lower estimate of the prediction error (due to increased sample size)
without actually reducing the error, leading to overestimation of performance.40 1 Ligand-based virtual screening
Table 1.5 Literature recommendations on the retrospective evaluation of virtual screen-
ing studies. ∗ Jain and Nicholls (2008), † Jorgensen (2006), ‡ Cleves and Jain (2008),
§ Good and Oprea (2008), ¶ Nicholls (2008), k OECD (2004), # Gramatica (2007),
♣ Tropsha et al. (2003), ♦ McGaughey et al. (2007), ♠ Hristozov et al. (2007). Refer-
ences ∗, †, ‡, §, ¶ directly deal with retrospective virtual screening evaluation, k, #, ♣
deal with validation of QSAR/QSPR models, and ♦,♠ are reference studies.
Ref. Recommendation
Data
∗,¶,♦,♠ Publish usable primary data.
∗†,♦ Use or provide public data, or prove necessity of proprietary data.
†,♠ Use at least one common (benchmark) data set.
¶,♠ Choose number of actives, inactives, and targets using statistical criteria.
∗ Ensure negatives are not active.
∗,¶ Ensure negatives are not trivially separable from positives.
∗ Quantify the diversity of the actives.
∗,§,¶,♦ Use only one representative per chemical class or weight them.
‡ Use old, new, and serendipitous ligands to control human inductive bias.
∗ Use the same protocol to prepare all compounds.
♣ Use an external test set.
Reporting
k,# Clearly state the measured/predicted endpoint, including the assay(s).
k,# Unambiguously describe the algorithm, including descriptors.
k,#,♣ State the domain of applicability, or provide conﬁdence estimates.
♣ Use cross-validation or bootstrapping.
#, ♣ Use Y -randomization.
k,# Report robustness of methods.
♦ Report performance of at least one baseline method.
†,♦,♠ Report performance of at least one commonly used method.
∗,♦ Report performance using default parameters as well.
∗,¶,♠ Report receiver operating characteristic area under curve.
∗,¶,♦ Report enrichment at 0.5%, 1%, 2%, 5%.
∗,¶ Use enrichment variant independent of active to inactive ratio.
∗,♠ Report Pearson’s correlation and Kendall’s tau.
∗ Provide error bars.
∗ Report accuracy of used experimental data.
k,# If possible, interpret the model in physico-chemical terms.1.4 Retrospective evaluation 41
Inductive bias
Known ligands are the result of (incremental) drug development processes, heavily inﬂu-
enced by human expertise. The demonstrated bias of human experts towards molecular
graph similarity has in turn led to an over-representation of topologically similar com-
pounds in ligand data sets. The high topological similarity of drugs that bind the same
target is therefore, at least in part, not a property of the target, but of the drug devel-
opment process. This has been investigated in detail by Cleves and Jain (2008).
Ratio and number of actives and inactives
The variance in performance estimates depends on the number of actives and inactives.
In evaluations of a single method on a single target, the number of actives dominates
error bars, with a low decoy to active ratio being acceptable (a ratio of 4:1 increases
ROCAUC 95% conﬁdence error bars by only 11% compared to the limiting case of
inﬁnitely many decoys). The actual number of actives can be as low as 10. In method
comparisons, target-to-target variance dominates, and a large number (on the order of
103) of targets is necessary for statistically signiﬁcant statements. See Nicholls (2008)
for details.
Data accuracy
It is meaningless to compare a property with greater precision than the accuracy of
the experiment that measures the property. Therefore, one can not in general expect
prediction accuracy to exceed the accuracy of the underlying experimental data, e.g., in
regression.16
Oral stories of laboratories — even within the same organization — unable to repro-
duce each others measurements to within an order of magnitude are frequent. Similar
observations have been reported in the literature.17 From these, it is clear that regression
requires a previous careful analysis of the error in target values. A data set of ligands
compiled from various sources will often not be suitable.
Data composition
The test data should reﬂect, in character and diﬃculty, the operational application,
especially if retrospective evaluation is done to assess potential prospective performance,
i.e., if an absolute instead of a relative performance estimation is done.
1.4.2 Performance measures
Comparing virtual screening methods and assessing their usefulness requires a measure
of performance. The latter evaluates a predictor on a data set, and is diﬀerent from, but
related to, the loss function, which evaluates a single prediction. A good performance
measure depends only on properties of the method (Nicholls, 2008). We focus on ranking
methods, as these are the most relevant to virtual screening (p. 24).
16Theoretically, this can happen if the measurement error is i.i.d. with zero mean — think of, e.g.,
points sampled from a line with independent and standard normally distributed measurement error.
Given enough samples, linear regression will recover the correct line parameters.
17R¨ ucker et al. (2006), for example, report a correlation coeﬃcient of r
2 = 0.48 between Ki values
(dissociation constants, p. 149) for the peroxisome proliferator-activated receptor γ of 61 compounds
using a scintillation proximity assay and a classical solution scintillation assay. Reported Ki values for
the drug rosiglitazone range from 47 to 230nM.42 1 Ligand-based virtual screening
Virtual screening-speciﬁc requirements
Virtual screening has special requirements on performance evaluation:
• Early recognition problem: In a general machine learning setting, performance on
the whole data set is of interest, whereas in virtual screening only the top-ranked
compounds are selected for assay tests. Performance on the ﬁrst part of the ranked
data set is therefore of higher interest than performance on the rest of the data.
• False positives versus false negatives: Inactive compounds predicted as active (type I
errors, false positives) waste money, time, and manpower, whereas active compounds
predicted as inactive (type II errors, false negatives) represent missed opportunities.
The relative importance of the two error types depends on the project; a good perfor-
mance measure will reveal the trade-oﬀ between the two.
Early enrichment is frequently thought to be important in virtual screening. This as-
sumption is implicitly based on an assumed cost structure, i.e., an assignment of costs to
true positives, false positives, true negatives, and false negatives. An example by Nicholls
(2008) demonstrates the sensitivity of both the resulting cost eﬀectiveness of a virtual
screening method and the importance of early recognition towards the assumed cost
structure. We are not aware of any study on this subject based on real cost estimates.
Enrichment factor
One of the simplest performance measures, the enrichment factor (Hawkins et al., 2008)








where n is the number of samples in the data set, n+ is the number of actives in the
data set, s = xn is the number of ranked samples considered, and s+ is the number
of actives in the ﬁrst s ranked samples. It measures how many times more actives are
found within the ﬁrst s ranked compounds as compared to chance alone. Typical values
for x are 0.005, 0.01, 0.02, 0.05 and 0.1. Other performance measures related to the
enrichment factor are (Cornell, 2006)
• The fraction s+/s of actives found in the s top-ranked compounds.
• The screened data fraction x necessary to recover a given fraction s+/s of actives.
• The maximum enrichment factor, maxx∈[0,1] x−1s+/n+.
• The fraction x of the data set where the maximum enrichment occurred.
Enrichment is computed easily and measures a quantity related to virtual screening
success, but has drawbacks:
• Dependence on number of actives: Increasing n+ for ﬁxed x and n lowers the range
of possible enrichment factors, making the statistic dependent on a data set property.
• Dependence on cut-oﬀ: The enrichment factor is a function of x, and evaluating it
at only a few locations gives an incomplete picture of virtual screening performance.
• No consideration of ties: Equally ranked samples are not considered. If, e.g., all
samples are ranked equal, s+ is arbitrary, and the enrichment could be chosen at will
between 0 and its maximum value n/n+ (or x−1 if n+ < s).1.4 Retrospective evaluation 43
























(a) ROC curve examples of a perfect (dashed
line, upper left), a random (solid line, diago-
nal), and a worst-case (dotted line, lower right)
ranker, as well as an instance of a learner who
can predict values in [0,1] within ±50% (dash-
dotted line, n = 103). Respective ROCAUCs
are 1, 1
2, 0, and 0.85.
























(b) ROC curves for rankings with the posi-
tive labels at the beginning and end (dashed
line), randomly distributed (solid line), and in
the middle (dotted line). All curves have a
ROCAUC of 1
2.
Figure 1.7 Examples of receiver operating characteristic curves.
• Order does not matter: If n+ < s, it does not matter if the actives are ranked at
the beginning or at the end of the ﬁrst s compounds.
The dependence on a data set property, the ratio of actives to inactives, prevents com-
parison of enrichment values between data sets. Nicholls (2008) suggests using ROC
enrichment, where the fraction of actives seen along with a fraction x of the inactives






+ is the number of actives in the ﬁrst s0 ranked samples and s0 is chosen to contain
xn− inactives, n− being the total number of inactives in the data set. Equation 1.12
does not depend on the ratio of actives to inactives, and, allows analytic error estimation
(Pepe, 2004), but still suﬀers from the other drawbacks.
Receiver operating characteristic
Originally from signal detection theory (Egan, 1975), the receiver operating character-
istic (ROC), together with the area under its curve (ROCAUC), are well established
performance measures for ranking methods. They are extensively used in several dis-
ciplines, including medicine and machine learning, and have been applied to evaluate
virtual screening methods (Triballeau et al., 2005; Jain and Nicholls, 2008).
A ROC curve plots the fraction of correctly classiﬁed positive samples (also true
positive rate, recall, sensitivity) on the ordinate over the fraction of incorrectly classiﬁed
negative samples (also false positive rate, 1 - speciﬁcity) on the abscissa. It visualizes
the performance of ranking algorithms by varying the decision threshold for positively
classiﬁed samples over the occurring ranks; in this way, each unique rank creates a
point in ROC space (Figure 1.7a; Algorithm 1.1a). The ROCAUC has advantages over
enrichment and some other performance measures:44 1 Ligand-based virtual screening
• Independence of data set properties: Although the number of samples inﬂuences
estimation accuracy of the ROCAUC (the positives more than the negatives; Hanley
and McNeil, 1982), its value itself is independent of the ratio of actives to inactives.
• Stochastic interpretation: The ROCAUC equals the probability of ranking a ran-
domly chosen positive sample above a randomly chosen negative sample.
• Analytical error estimation: Due to equivalence with the Wilcoxon-Mann-Whitney
test statistic, an error estimate of the ROCAUC can be computed analytically.
Still, the ROCAUC (Algorithm 1.1b) is a one-number summary of a ROC curve, which
necessarily loses part of the information: Consider three rankings, without ties, where
the ﬁrst one places the positive samples at the beginning and end of the list, the second
one places them randomly, and, the third one places them in the middle of the list.
All three lists have the same ROCAUC of 1
2 (Figure 1.7b), but only the ﬁrst ranking is
suitable for virtual screening, where only the ﬁrst ranks will be experimentally conﬁrmed.
As a global measure, the ROCAUC therefore does not reﬂect the possible im-
portance of early hits in virtual screening. Variants proposed to remedy this include
the Boltzmann-enhanced discrimination of receiver operating characteristic (BEDROC;
Truchon and Bayly, 2007) and usage of semi-logarithmic plots for AUC calculations
(pROCAUC; Clark and Webster-Clark, 2008). Both are based on the idea of an ex-
ponential weighting according to rank. Such approaches adapt the ROCAUC to early
recognition, but partially abandon its advantages; furthermore, data sets containing
more actives than the number of ranks considered early can cause saturation eﬀects
(Truchon and Bayly, 2007). In a study by Nicholls (2008), ROCAUC and BEDROC
scores were highly correlated (r2 = 0.901).
Performance measures for regression
Let yi denote the true label of the i-th sample and let ˆ yi denote its estimate. Performance






(yi − ˆ yi)2, (1.13)
and its root RMSE =
√






|yi − ˆ yi| (1.14)
(also mean absolute deviation, MAD), cumulative histograms, i.e., rank-frequency plots,



























Its square r2 equals the proportion of target value variance accounted for by the regres-
sion. As a performance measure for regression, it can be misleading (Figure 1.8).
Like the ROCAUC, these measures do not take the possible importance of early
recognition into account, but various modiﬁcations exist, e.g., weighting based on utility
(Torgo and Ribeiro, 2007).1.4 Retrospective evaluation 45
Algorithm 1.1 Receiver operating characteristic curve, and its area.
(a) Receiver operating characteristic curve. We assume that larger scores f(·) are better,
and that labels are either 0 (negatives) or 1 (positives). The idea is to deﬁne a function
hi(x) = 1 iﬀ f(x) > f(xi), and -1 otherwise, which classiﬁes all samples with score above
f(xi) as positive. The rates of true and false positives are then computed using hi, each
pair yielding a point in ROC space, not necessarily unique due to ties. The if-statement
addresses these. Linear interpolation of the points in P yields the ROC curve.
Input: input samples x1,...,xn, labels y1,...,yn ∈ {0,1}, scoring function f : X → R.
Output: set P of points on the ROC curve.
1 Set n+ ←
Pn
i=1 yi and n− ← n − n+.
2 Sort x1,...,xn, together with y1,...,yn, in descending order by f.
3 Set P ← ∅, tpi ←
Pi
j=1 yj and fpi ← i − tpi.
4 For each i ∈ [1,n),












(b) Area under receiver operating characteristic curve. The vectors a, b, and c cor-
respond to statistics 1, 2, and 3 in Hanley and McNeil (1982). Line 3 computes the
number u of unique ranks; ties are appropriately considered.
Input: input samples x1,...,xn, labels y1,...,yn ∈ {0,1}, scoring function f : X → R.
Output: area A under receiver operating characteristic curve.
1 Set n+ ←
Pn
i=1 yi and n− ← n − n+.
2 Sort x1,...,xn, together with y1,...,yn, in ascending order by f.
3 Set u ← |{f(xi) | 1 ≤ i ≤ n}|, r ← 1, and a ← c ← 0 ∈ Ru.
4 For each i ∈ [1,n],
5 If i > 1 ∧ f(xi) 6= f(xi−1) then r ← r + 1.
6 If yi 6= 1 then ar ← ar + 1 else cr ← cr + 1.










/(n− · n+).46 1 Ligand-based virtual screening
Other performance measures
Many other performance measures exist. Some metrics like robust initial enhancement
(RIE, Sheridan et al., 2001, Merck), cumulative probability (Bursulaya et al., 2003,
Molsoft), and average number of outranking decoys (Friesner et al., 2006, Schr¨ odinger)
have historically been used only by the groups that invented them (Hawkins et al., 2008).
They are not further treated here as they share some of the problems mentioned earlier,
and, due to insuﬃcient use, do not oﬀer comparability with the results of others.
Scalar performance measures do not provide insight into the conditions, e.g., misclas-
siﬁcation costs and class distributions, under which one predictor is superior to another.
ROC plots partially address this issue. Alternatives include cost curves (Drummond and
Holte, 2006) and precision-recall curves (Clark and Webster-Clark, 2008).
1.4.3 Statistical validation
The error of a model on the training data is a measure of how well the model ﬁts
these data. A high training error indicates the inability of a model to capture the
characteristics of a data set (Figure 1.9a), and a low training error is a prerequisite for
successful learning, indicating suﬃcient capacity of the model class (Figures 1.9b, 1.9c).
It is, however, not necessarily indicative of future performance, since a model class that
is too complex can lead to over-ﬁtting (rote learning, Figure 1.9c). Consequently, a good
model has to have low training and test errors (Figure 1.9b), and retrospective evaluation
requires performance measurements on both training and test data. For information on
statistical learning theory, see Vapnik (1998, 2001).
In virtual screening, the number of available samples is usually a limiting factor,
and generating new samples for testing purposes, or setting aside a substantial fraction
of samples as a test set, is not always an option. In such situations, resampling-based
statistical validation methods (Hjorth, 1994) can be used. Generalization performance
often depends on model parameters, e.g., the kernel width σ of the Gaussian kernel,
the parameter C in support vector machines, or, the number of principle components in
principle component analysis. Statistical validation can therefore also be used for model
selection, i.e., to guide the choice of model parameters.
Cross-validation
In k-fold cross-validation (also rotation estimation; Kohavi, 1995), the training data set
is partitioned into k ∈ {2,...,n} folds of approximately equal18 size. Each fold serves as
test data set once, with the other folds serving as training data. In this way, each sample
is used k−1 times for training and once for testing. Common choices of k are 5, 7, and 10;
the extreme cases are 2-fold cross-validation and leave-one-out cross-validation (LOOCV,
k = n − 1). Other variants of cross-validation exist; in Chapter 4, we use a leave-k-
clusters-out cross-validation strategy to counter over-estimation of performance due to
structural correlations in the training data. Note that model selection, e.g., parameter
optimization or feature selection, must be done separately for each fold. Cross-validation
is diﬀerent from, and on small data sets superior to, the hold-out (also split-sample)
method sometimes used for early stopping in neural networks (Goutte, 1997). It is also
diﬀerent from jackkniﬁng, a resampling scheme used to estimate the bias of a statistic.
18Let m = n − kbn/kc. There are k − m folds of size bn/kc, and m folds of size bn/kc + 1.1.4 Retrospective evaluation 47










(a) Predictor A has r = 0.82 (all points) and
r = 0.55 (only gray points).










(b) Predictor B has r = 0.90 (all points) and
r = 0.64 (only gray points). Removing the
three worst predictions (opaque disks) lowers r.
Figure 1.8 The correlation coeﬃcient and regression performance; example after
Sheiner and Beal (1981). Pairs (y, ˆ y) of measurements and corresponding predictions
are shown as gray disks for two predictors; the three points furthest from the diagonal
(black line) in (b) are shown as opaque disks. Although A is clearly the better predictor,
it’s correlation coeﬃcient is lower than that of B. This is due to the correlation coeﬃ-
cient measuring the best linear relationship between measurements and predictions (thin
dashed lines), whereas in regression, one is interested in association along the diagonal.









(a) Linear model y = 0.64 +
0.29x with RMSE of 0.124
(training data) and 0.443
(test data). The model class
is not complex enough to cap-
ture the pattern in the data,
resulting in high training and
test errors (underﬁtting).









(b) Quadratic model y =
0.03 + 1.92x − 0.90x2 with
RMSE of 0.044 (training
data) and 0.068 (test data).
The complexity of the model
class ﬁts the data, resulting in
low training and test error.









(c) Quartic model y = 1.15−
4.55x + 11.60x2 − 9.89x3 +
2.75x4 with RMSE of 0.036
(training data) and 0.939
(test data). The model class
is too complex, resulting in
the lowest training and high-
est test error (overﬁtting).
Figure 1.9 Model complexity and generalization error. On a training set of 10 points
(gray disks), three increasingly complex models — linear (left), quadratic (middle), and
quartic (right) — were ﬁtted to minimize the root mean square error. 5 test points from
the same distribution as the training data are shown as opaque disks.48 1 Ligand-based virtual screening









Figure 1.10 y-scrambling. Using the data and quadratic model from Figure 1.9b, per-
formance as measured by correlation coeﬃcient r (abscissa) and root mean square error
RMSE (ordinate) are shown for the original labels (green disk) and 15 permutations of
the labels (orange disks). Superpositioned are box-whisker plots showing range, median,
and 25% as well as 75% quantiles. Note that correlation coeﬃcient values for random
labels spread from 0.05 up to 0.62, whereas the RMSE is more consistent.
Bootstrapping
Another resampling scheme, bootstrapping (Efron and Tibshirani, 1993, 1997), can be
seen as a smoothed version of cross-validation. Repeated sampling with replacement
from the training set is used to create data sets of the same size as the training data set.
These are then used for training and performance estimation, averaging over all sets.
Stratiﬁcation
Stratiﬁcation is a sampling technique where one partitions the population (training data)
into homogeneous strata, and then samples from within each stratum, thereby increasing
representativeness of the overall sample. This can be used to reduce the high variance
encountered with stochastic methods like cross-validation and bootstrapping. Stratiﬁ-
cation requires partitioning criteria. In classiﬁcation, strata are naturally given by the
classes, resulting in equal class proportions in each training fold. In regression, the
distribution of the target labels should be similar in all folds.
y-scrambling
Good performance may be due to chance alone if the number of explanatory variables,
e.g., descriptor dimension, is large relative to the number of samples. To guard against
this, one can use y-scrambling (also y-randomization; Wold et al., 1995), where one
repeatedly conducts the learning experiment in question with randomly permuted la-
bels. The resulting performance measurements should be signiﬁcantly diﬀerent from the
performance based on the original labels (Figure 1.10).
1.4.4 Other aspects
Drug development is necessarily a complex process, depending on many factors. We
brieﬂy mention some aspects directly related to virtual screening.
Drug properties
Desired activity on a given target is a necessary but not a suﬃcient requirement for
a drug. Other important properties include absorption, distribution, metabolism, and1.5 Conclusions 49
excretion (ADME), as well as toxicity. Important examples are aqueous solubility, hu-
man intestinal absorption, and oral bioavailability. Late stage ADME/toxicity-related
failures are costly and frequent,19 and eﬀorts are being made to treat these issues earlier
on in the drug development process (Li, 2001). This necessitates predictions of these
properties (van de Waterbeemd and Giﬀord, 2003), as well as selection and optimization
of compounds according to multiple criteria.
Domain of applicability
A prediction is only useful if it can be trusted. Many machine learning methods and
bounds quantifying their generalization performance rely on the assumption that training
and test data are independent and identically distributed. As argued in this chapter, this
assumption is not valid in typical virtual screening scenarios, requiring ways to quantify
the trust in a prediction, or, equivalently, to determine the domain of applicability of a
model. Although there is consent on this necessity (Jaworska et al., 2003; OECD, 2004),
the methodological aspects are not settled.
Some methods provide implicit estimates of prediction conﬁdence, such as Gaussian
processes (Subsection 4.2.4); other methods require an external domain of applicability
model. These can be divided (Tetko et al., 2006) into those based on molecular similarity
(Jaworska et al., 2005) and those based on the predicted property. The former use
concepts like descriptor ranges, the presence of fragments, convex hull, or, probability
densities to determine whether a test compound is similar enough to the training data to
be reliably predicted by the model. The latter compute ensembles of models, using, e.g.,
diﬀerent representations, diﬀerent methods, or resampling schemes. They then analyze
the variance of the predictions, or consider the variation in the model residuals.
Scaﬀold hopping
Ligand-based virtual screening is per se well-suited for the retrieval of close structural
analogues. Scaﬀold hopping, the “identiﬁcation of isofunctional molecular structures with
signiﬁcantly diﬀerent molecular backbones” (Schneider et al., 1999), is more diﬃcult
for an approach based on the similarity principle. Strategies for ligand-based scaﬀold
hopping include inferring information about the target from the ligands, e.g., pseudo-
receptor models, and, using representations that suﬃciently abstract from the structure
graph, e.g., pharmacophore descriptors. The ability of ligand-based virtual screening
methods to retrieve new chemotypes was empirically conﬁrmed (Hristozov et al., 2007).
1.5 Conclusions
Ligand-based virtual screening, a problem relevant to drug development, is amenable to
machine learning approaches. In this chapter, we give an overview of the problem and
some of its aspects, in particular machine learning approaches and retrospective evalua-
tion, and, investigate the role of molecular representation and associated (dis)similarity
measures in detail.
19In a British study (Prentis et al., 1988), 39% of failures in clinical development were attributed to
inappropriate pharmacokinetics. After removal of a class of poorly bio-available anti-infectives, however,
this number reduced to 7% (Kennedy, 1997). Still, ADME/toxicity problems caused 24% of all failures.50 1 Ligand-based virtual screening
1.5.1 Summary
Virtual screening, the computational ranking of a compound data set with respect to a
predicted property, is a cheminformatics problem relevant to the hit generation phase
of drug development. Its ligand-based variant relies upon the similarity principle, which
states that (structurally) similar compounds tend to have similar properties. Many ma-
chine learning approaches are applicable, including clustering, novelty detection, classiﬁ-
cation, and regression. We focus on the role of molecular representations, and investigate
the eﬀect of the dimensionality of chemical descriptor spaces.
1.5.2 Ligand-based virtual screening
We discuss issues in ligand-based virtual screening based on our exposition of the subject.
Advanced machine learning methods may beneﬁt virtual screening
The applicability of machine learning methods to ligand-based virtual screening has been
demonstrated many times, and some algorithms have become standard tools in the ﬁeld,
e.g., neural networks, decision trees, and support vector machines. However, machine
learning, in particular kernel-based machine learning, is an area of intense research, and,
consequently, many new developments. The recent successful applications of advanced
kernel-based machine learning methods to ligand-based virtual screening, e.g., the stud-
ies by Schroeter et al. (2007) on aqueous solubility and by Schwaighofer et al. (2008) on
metabolic stability using Gaussian processes, hint at the potential improvements in this
direction. We back this claim in the following chapters.
Virtual screening lacks a standard protocol for retrospective evaluation
The development of virtual screening is hindered by the lack of a standard protocol
for retrospective performance evaluation. This complicates the comparison of studies, a
task further aggravated by the use of proprietary data sets. It also aﬀects neighboring
disciplines: In view of the increasing relevance of QSAR/QSPR models for regulatory
aﬀairs, in particular with regard to the European Union’s REACH regulation, there is a
growing need for reliable, accurate, and comparable evaluation and validation protocols.
Although the need for such protocols is clear, there is no consensus on the details so
far. Until then, we recommend reasonable adherence to the literature recommendations
(Table 1.5); a possible ligand-based virtual screening workﬂow facilitating this is shown
in Figure 1.11.
Performance measures
We recommend the use of the receiver operating characteristic, and the area under its
curve, on the grounds given in Subsection 1.4.2. From the discussion there, it is clear that
enrichment should be avoided, except for legacy comparisons to other studies. In situa-
tions where early enrichment is demonstrably relevant, weighted versions of ROCAUC
like BEDROC (Truchon and Bayly, 2007) and pROCAUC (Clark and Webster-Clark,
2008), may be given in addition; even better, the ROC curves themselves may be shown.
Statistical validation
We recommend cross-validation or bootstrapping for retrospective evaluation. Cross-






1.1 Create or select a training data set.
1.2 Assess activity value quality; for classiﬁcation, set activity cut-oﬀ.
1.3 Assess compound diversity; retain one compound per class or weight them.
1.4 Ensure inactives are not trivially separable from actives.
1.5 Preprocess compounds.
2 Retrospective evaluation:
2.1 Use cross-validation or bootstrapping to estimate performance.
Use an inner loop of cross-validation or bootstrapping to optimize parameters.
2.2 Create model for whole data set.
2.3 Determine domain of applicability.
3 Prospective application:
3.1 Create or select screening data set.
3.2 Preﬁlter by drug-likeness, assay and target-speciﬁc requirements.
3.3 Remove compounds not in domain of applicability.
3.4 Rank test data set using model from step 2.2.
3.5 Visually inspect and select (”cherry-pick“) top-ranked compounds.
3.6 Test selected compounds in a bioassay.
Figure 1.11 A ligand-based virtual screening workﬂow.
has high variance, whereas bootstrapping has lower variance but can be overly opti-
mistic. Other statistical criteria for model selection and performance estimation exist,
e.g., Akaike’s information criterion (AIC; Akaike, 1974; Bozdogan, 2000), Bayesian in-
formation criterion (BIC; Schwartz, 1978), minimum description length (Hansen and
Yu, 2003), and, likelihood-based cross-validation (van der Laan et al., 2004). If used,
additionally stating cross-validated results may facilitate study comparisons; 10-fold
cross-validation is a popular choice.
In cases where the assumption of independence and identical distribution is severely
violated, additional measures should be taken, e.g., modiﬁcation of the training set
by retaining only representatives from clusters, or, usage of a modiﬁed cross-validation
procedure as in Subsection 4.2.5.
Structure-based virtual screening
The computational alternative to ligand-based virtual screening is structure-based vir-
tual screening. With the advent of sophisticated structure elucidation methods, e.g.,
in-cell nuclear magnetic resonance spectroscopy (in-cell NMR; Sakakibara et al., 2009),
requiring the three-dimensional structure of the target might become less restrictive.
While structure-based approaches have attractive advantages like providing insight into
the mechanism of action, they also have problems, e.g., limitations of crystal structures
(Davis et al., 2008) and force ﬁelds (Kitchen et al., 2004). In a similar way, high-
throughput screening has neither replaced virtual screening, nor was it replaced by it;52 1 Ligand-based virtual screening
instead, synergistic uses have been put forward, like using virtual screening to suggest
compounds for re-testing to reduce error rates in high-throughput screening. We expect
ligand-based virtual screening to remain a valuable tool in drug development for the
foreseeable future.
1.5.3 High-dimensional descriptor spaces
We discuss consequences of high descriptor dimensionality based on our investigation in
Subsection 1.5.3.
Neighborhood computations
In neighborhood computations, the size of the neighborhood should depend on dimen-
sionality. For k-nearest neighbor methods, this is automatically achieved by ﬁxing the
number of neighbors. When using ²-balls as neighborhoods, ² should be computed based
on the data, e.g., by optimization as in the ad hoc-solution proposed by Tenenbaum et al.
in their rejoinder to Balasubramanian (2002).
Structure in chemical data sets
It is common knowledge that chemical data sets exhibit structure due to analogue bias
and inductive bias; we formalize this idea with a statistical test in our treatment of
the empty space phenomenon. For some representations like auto-correlation vectors,
descriptor space dimensions are always neither independent nor identically distributed.
Intrinsic dimensionality
Distance phenomena set in early and depend on the intrinsic dimensionality of the data
set in the non-i.i.d. case, which, as discussed above, is rule rather than exception in
chemical data sets. It is therefore important to determine the intrinsic dimensionality
of the data; we pursue this further in Chapter 3.
1.5.4 Outlook
Virtual screening is a complex problem, and many aspects were only hinted at in this
chapter, e.g., training compounds with activity on the same target but diﬀerent binding
mode, the problem of frequent hitters (also promiscuous binders; Roche et al., 2002), or,
the screening of virtual combinatorial libraries.
We propose ideas for future research, in increasing order of speculativity:
• Active learning for ligand-based virtual screening: By allowing the learning algorithm
to suggest compounds for intermediate assay testing, virtual screening can be turned
into an active learning problem. Sch¨ uller and Schneider (2008) demonstrate this idea
in virtual screening by experimentally testing the compounds in each generation of an
evolutionary strategy optimization scheme. Such approaches should be particularly
eﬀective in combination with virtual combinatorial libraries. An advanced example in
another area of science is given by King et al. (2009), who design a robot system that
generates functional genomics hypotheses about the yeast Saccharomyces cerevisiae
and experimentally tests them using microbial batch growth experiments.References 53
• Free-form learning for QSAR/QSPR models: Schmidt and Lipson (2009) developed
a learning system able to extract analytical expressions describing simple physical sys-
tems such as oscillators and pendulums from experimental data. Their approach is
based on symbolic regression,20 regularization, and partial derivatives for performance
measurements. In a similar approach, one could try to learn explicit laws, in analyti-
cally closed form, describing structure-activity or structure-property relationships.
• Structured output learning of conformations: Three-dimensional virtual screening
methods require knowledge about the conformational space inhabited by a compound.
Based on crystallographic data, kernel-based learning of structured outputs (Bakir
et al., 2007) could be used to predict biologically relevant ligand conformations. If
further data is available, e.g., from molecular dynamics simulations, conformation
distributions could be predicted.
• Learning electron densities: The single most important factor in virtual screening
is the molecular representation. Quantum mechanical descriptions of molecules, such
as electron densities of ground states, are well-founded, suﬃcient, and accurate, but
computationally costly. Various degrees of approximation are used, e.g., diﬀerent sets
of basis functions, semi-empirical parametrizations, restricted treatment of electron
correlation, and many others. An approximation based on semi-deﬁnite programming
(Vandenberghe and Boyd, 1996; Helmberg, 2000) could be used for a kernel-based
approach to ligand-based virtual screening founded in quantum mechanics.
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A molecular kernel based on
iterative graph similarity and
optimal assignments
The most important factor in virtual screening are the data and their representation.
While vector representations are popular with computational approaches, the molecular
structure graph is a universally used chemical representation. We introduce a kernel
deﬁned directly on the annotated molecular structure graph. The annotation allows for
the incorporation of domain- and problem-speciﬁc knowledge. The graph kernel itself
is based on iterative graph similarity and optimal assignments. We give an iterative
algorithm for its computation, prove convergence of the algorithm and the uniqueness
of the solution, provide an upper bound on the required number of iterations necessary
to achieve a desired precision, and discuss its positive semideﬁniteness. A retrospective
evaluation using support vector machine classiﬁcation and regression on pharmaceutical
and toxicological data sets shows encouraging results.
2.1 Introduction
Molecular representation and corresponding (dis)similarity measure are crucial choices
in a virtual screening study (Section 1.3). Many approaches focus on vector representa-
tions, e.g., descriptors and ﬁngerprints; consequently, popular molecular (dis)similarity
measures include metrics, similarity coeﬃcients, and kernels on vector spaces.
2.1.1 Structured molecular representations
Other approaches use more structured representations, e.g., strings and graphs (Ta-
ble 2.1). Often, these are not compared directly, but are ﬁrst converted into vectors,
e.g., using ﬁngerprints, hashing, or binning, and are then compared using vector-based
(dis)similarity measures. Such conversions are not always chemically motivated, and
information can be lost or noise added in the process.60 2 A kernel based on iterative graph similarity
Table 2.1 Examples of structured molecular representations and formats. See Engel
(2003) for further information on the representation of chemical compounds.
Structure Examples
Strings Simpliﬁed molecular input line entry speciﬁcation
(SMILES; Weininger, 1988).
Molecular query language (MQL, Proschak et al., 2007).
International chemical identiﬁer (InChi; Heller and McNaught, 2009).
Graphs Adjacency list, e.g., structured data format (SDF; Symyx, 2007).
Graph Laplacian (also admittance matrix, Kirchhoﬀ matrix).
Trees See Subsection 2.2.3.
Grammars RNA secondary structure (Searls, 2002).
Distributions Electron densities, e.g., based on quantum chemistry (McQuarrie, 2007).
Various Shape descriptors, e.g., shapelets (Proschak et al., 2008).
An alternative is to directly compare structured representations, avoiding the conver-
sion into vectors. In kernel-based learning, based on the work of Haussler (1999), kernels
on structured data like strings (Joachims, 2002; Vishwanathan and Smola, 2003), labeled
ordered trees (Collins and Duﬀy, 2002), or, probability distributions (Jebara et al., 2004),
have been developed. See G¨ artner (2009) for information on structured data kernels.
2.1.2 Graph theory and notation
We recapitulate basic terminology. See Diestel (2005) for a graph theory introduction.
Graphs
A graph1 G = (V,E) consists of a set of vertices (also nodes) V = {v1,...,v|V |} and a set
of edges E = {e1,...,e|E|}. The edges are either ordered vertex pairs (v,v0) if the graph is
directed, or, unordered vertex pairs {v,v0} if the graph is undirected. For our purposes, we
do not allow self-loops and multiple edges between two vertices. Note that for intuition’s
sake, we draw graph edges as in chemical structure graphs; see Figure 2.10 (p. 86) for an
example. In directed graphs, the number
¯ ¯©
v0 ∈ V
¯ ¯ (v0,v) ∈ E
ª¯ ¯ of incoming neighbors





¯ (v,v0) ∈ E
ª¯
¯ of outgoing neighbors is its










A labeled graph has labels (over some arbitrary but ﬁxed domain L) attached to its
vertices, edges, or both; the labels encode additional information. We denote with
label(v) ∈ L the label of a vertex v and with label(e) ∈ L the label of an edge e.
To measure similarity between labels, let kv and ke be positive deﬁnite kernels de-









. In the following, we as-
sume that these kernels have unit range, 0 ≤ kv,ke ≤ 1.
1Graph theory was started by Euler (1736, see Alexanderson, 2006). The word “graph” was introduced
by Sylvester (1878), based on the term “graphical notation”, as the chemical structure graph was called
then. See Rouvray (1991) for information on the origins of chemical graph theory.2.1 Introduction 61
Matrix representation
The adjacency matrix A ∈ R|V |×|V | of G is given by Ai,j = 1{{vi,vj}∈E}. The entries
¡
Ak¢
i,j of its k-th power, k ≥ 1, give the number of walks of length k from vertex vi
to vertex vj. For directed graphs, Ai,j = 1{(vi,vj)∈E}. Let l1,...,ll denote the possible
vertex labels. The label vertex matrix L ∈ R|L|×|V | of G is given by Li,j = 1{li=label(vj)}.




ij gives the number of edges between vertices labeled with li and lj.
Properties
A walk of edge-length k is a sequence v1e1v2e2 ...ekvk+1 of vertices and edges in G with
ei = {vi,vi+1}. The vertex-length of a walk is one more than its edge length. A path









is a cycle. A graph is connected
iﬀ there is a path between each pair of its vertices. A graph G0 = (V 0,E0) is a subgraph
of G iﬀ V 0 ⊆ V and E0 ⊆ E. A graph G is isomorphic to another graph G0 iﬀ there
is an isomorphism between V and V 0 which preserves edge structure, i.e., if there is a




A connected graph without cycles is a tree; those of its vertices with degree 1 are called
leaves. In a rooted tree, one of the leaves is called the trees root. For directed graphs, all
vertices have in-degree 1, except the root; the vertices with out-degree 0 are leaves. The
depth of a tree node is the length of a path from the root to the node. A perfectly depth-
balanced tree of order h is a tree where each leaf has depth h. The branching cardinality
of a tree is one less than its number of leaf nodes. A graph whose components are trees
is a forest.
Treewidth
Treewidth (Robertson and Seymour, 1986) is a measure of the tree-likeness of a graph.
A tree-decomposition maps the vertices of a graph to subtrees of a tree such that the
subtrees of adjacent vertices intersect. Let G = (V,E) be a graph, let T denote the






∀{u,v} ∈ E : ∃t ∈ T : u,v ∈ Vt, (2.2)
∀t,t0,t00 ∈ T with t0 on the path from t to t00 : Vt ∩ Vt00 ⊆ Vt0. (2.3)
Equations 2.1 and 2.2 state that G is the union of the subgraphs induced by the parts Vi,
and Equation 2.3 enforces a tree-like organization of the parts. The width of a tree





¯ t ∈ T
ª
, (2.4)
and the treewidth of G is the smallest width of any tree decomposition of G.62 2 A kernel based on iterative graph similarity
Product graphs
Let G = (V,E) and G0 = (V 0,E0) denote two graphs. In the direct product graph, vertices
correspond to pairs of vertices from G and G0, and edges are present only if edges exist
for both corresponding vertex pairs. Formally, G× = (V×,E×) with
V× = V × V 0 =
©
(v,v0)






¯ ¯ {u,v} ∈ E ∧ {u0,v0} ∈ E0
o
. (2.6)
A walk in G× corresponds to two walks, one in G and one in G0.
Spectral graph theory




is the largest magnitude of the eigenvalues of M. If M is real and component-wise non-
negative, e.g., the adjacency matrix of an undirected graph, then ρ(M) is an eigenvalue
of M, called the Perron root.
2.1.3 Characteristics of molecular graphs
In molecular graphs (also structure graphs), vertices correspond to atoms, and edges
correspond to covalent bonds. Such graphs possess distinct characteristics that can be
exploited in the design of specialized graph kernels.
Graph type
Molecular graphs are simple graphs, i.e., they are undirected,2 and have neither self-loops
nor multiple edges. They are connected (for salts and ions, only the largest fragment
is kept). Vertices and edges are annotated with element and bond type information.
Often, there are additional annotations in the form of descriptors, e.g., E-state indices
(Kier and Hall, 1999).
Many organic compounds are planar (R¨ ucker and Meringer, 2002), i.e., they can be
embedded in the plane without two edges crossing. Some graph theoretical problems
are computationally easier on planar graphs (Nishizeki and Chiba, 1988).
Size
Molecular graphs can in general be very large, e.g., the muscle protein titin has approxi-
mately 4.23·105 atoms. In ligand-based virtual screening, however, only small molecules
are considered.3 Hydrogen atoms can often be treated implicitly and therefore do not
have to be represented as vertices. In, e.g., the COBRA data set (p. 88), the median
molecular graph size is 28, and no graph has more than 98 vertices (Table 2.2a, Fig-
ure 2.1a). The small size of molecular graphs admits otherwise infeasible algorithms,
e.g., algorithms with cubic runtime in the limit and a small constant factor.
2It is valid to model molecular graphs as directed graphs, e.g., as in Mah´ e and Vert (2009); for our
purposes, there is no advantage to this.
3Biopharmaceuticals (also biologicals), i.e., medicinal products containing biotechnology-derived pro-
teins as active substances (European Medicines Agency, 2005), such as erythropoietin, insulin, and
growth hormone, are an exception. They diﬀer from conventional small-molecule drugs, among other
aspects, in size and complexity of the active substance (Roger and Mikhail, 2007).2.1 Introduction 63
Table 2.2 Statistics of molecular graph properties of the COBRA data set (p. 88; 10848
molecules, 590778 atoms). std. dev. = standard deviation, H = with explicit hydrogens,
no H = with implicit hydrogens.
(a) Molecule size (number of atoms).
Molecule size H no H
Mean 54.46 29.19




(b) Vertex degree (number of covalent bonds).
Vertex degree H no H
Mean 2.09 2.16











(a) Molecule size (number of atoms).








(b) Vertex degree (number of covalent bonds).
Figure 2.1 Histograms of molecular graph properties for the COBRA data set (p. 88;
10848 molecules, 590778 atoms). Shown are histograms with implicit hydrogens (white)
and with explicit hydrogens (gray).
Maximum vertex degree
In molecular graphs, the vertex degree is limited by a small constant, the maximum
valency number, which is 7 for non-metals such as, e.g., Iodine. The coordination num-
ber, the number of neighboring atoms linked to a central atom, can be up to 12 for
solid-phase metals.4 Since we are interested mainly in covalent binding, we neglect such
higher coordination numbers. Indeed, the maximum valency number found in the COBRA
data set (p. 88) was 4 (Table 2.2b, Figure 2.1b), and the maximum valency number
observed in several large vendor libraries was 5 (Rupp et al., 2007). Moreover, the aver-
age vertex degree was consistently slightly above 2, both with and without hydrogens,
which we attribute to the dominance of carbon ring systems in such data sets. Note that
most metal-based therapeutics (Hambley, 2007) can be modeled with graphs of vertex
degree 7 or less. The small vertex degrees of molecular graphs admit algorithms which
would otherwise be infeasible, e.g., algorithms with runtime exponential in the vertex
degree and a small constant factor.
4Highest possible coordination numbers are related to the generalized Gregory-Newton problem of
kissing spheres. Excluding fullerenes and similar structures, coordination numbers up to 12 can be
realized in solid phases. For liquid and gas phases, higher coordination numbers are possible. See
Hermann et al. (2007) for further information and an example (PbHe
2+
15 in gas phase).64 2 A kernel based on iterative graph similarity
2.2 Graph kernels
The molecular graph is an established and intuitive structured representation of mole-
cules. Several graph kernels, i.e., positive deﬁnite measures of similarity between graphs,
were introduced for direct comparison of (molecular) graphs for kernel-based learning.
A complete graph kernel is injective modulo graph isomorphism, i.e., it separates all
non-isomorphic graphs. The computation of inner products in the feature space indexed
by all subgraphs, which would allow such kernels, is NP-hard5 (G¨ artner et al., 2003).
Graph kernels therefore trade in separation capability for computational eﬃciency. For
further information on graph kernels, see Borgwardt (2007); Vishwanathan et al. (2009).
Note that graph kernels are diﬀerent from, but related to, kernels with graph-
structured input spaces, i.e., kernels between vertices of a graph, such as diﬀusion kernels
(Kondor and Vert, 2004), the regularized Laplacian kernel (Smola and Kondor, 2003),
or, the von Neumann kernel (Kandola et al., 2003).
2.2.1 Convolution kernels
Many kernels for structured data, including graph kernels, are based on the idea of
convolution kernels (Haussler, 1999). Assume that a sample x ∈ X can be decomposed
into parts x1,...,xd ∈ X1,...,Xd, e.g., a decomposition of a graph into subgraphs. The
relation R indicates possible decompositions, where R(x,x1,...,xd) means that x can be
decomposed into x1,...,xd. Given positive deﬁnite kernels ki : Xi × Xi → R, 1 ≤ i ≤ d,
the convolution kernel







is positive deﬁnite for ﬁnite R (Haussler, 1999). The sum runs over all decompositions
indicated by R; if a sample can not be decomposed, the sum is zero. Convolution kernels
can be generalized to mapping kernels (Shin and Kuboyama, 2008), where the sum in
Equation 2.8 is over transitive subsets of the cross product. Random walk-based graph
kernels, tree-based graph kernels, and cyclic pattern kernels are convolution kernels.
2.2.2 Random walk kernels
Label sequence kernels (G¨ artner et al., 2003; Kashima et al., 2004) are based on the
similarity of random walks on graphs. They can be seen as kernels on label sequences
marginalized with respect to these random walks, and are also called marginalized graph
kernels. Speciﬁc kernels diﬀer in the employed random walk model and the kernels used
to compare the vertex and edge labels.
Random walks
A random walk on a graph G = (V,E) can be constructed by ﬁrst choosing a start ver-
tex x1 ∈ V according to an initial probability distribution ps; subsequent vertices xi are
chosen from the neighbors of xi−1 according to a transitional probability distribution pt
conditional on xi−1, or, the random walk ends with probability pq(xi−1). Note that
5Even approximating a complete graph kernel is as hard as the graph isomorphism problem (Ramon
and G¨ artner, 2003), whose complexity is unknown but believed to be between P and NP (Johnson, 2005).
In general, one can not expect graph kernels to eﬃciently learn concepts that are hard to compute.2.2 Graph kernels 65
label sequences of inﬁnite length can occur. The probability of a random walk instance







A default choice for ps, pt, and pq is to set ps(vi) = |V |
−1, pq(vi) = c for a small constant
0 < c ≤ 1, and, pt(vi|xi−1) = 1−c
d(xi−1), where d(v) is the (out-)degree of v.
Label sequences
The label sequence hx = label(x1)label({x1,x2})label(x2)···label(xl) is the sequence
of alternating vertex and edge labels generated by traversing the random walk x (Fig-
ure 2.2). The probability of a label sequence is the sum of the probabilities of all random















For diﬀerent lengths, kz(hx,h0
x) = 0. A label sequence kernel for graphs is given by the









Kashima et al. (2004) show that for non-negative kv and ke, Equation 2.11, and therefore
Equation 2.12, is positive deﬁnite. The latter is an example of a marginalized kernel
(Tsuda et al., 2002), i.e., a kernel between visible and hidden variables — here, graphs
and random walks — computed by taking the expectation over the hidden variables.
An alternative formulation using matrix power series and the product graph is given
by Borgwardt et al. (2007), based on the observation that a walk in the product graph G×
















denote the weight matrix of G×, and deﬁne start and stop distributions on G× by letting





×W ip× = qT
×(I − λW)−1p×, (2.14)
where λ > 0 is a constant small enough to ensure convergence. Note that vertex labels
can be encoded into edge labels, e.g., by using edge labels from ΣV × ΣE × ΣV , where





































(b) Benzodioxole (structure graph,
left, and annotated graph, right).
Figure 2.2 Random walks on molecular graphs. Considering only element type vertex
labels, the random walks 12131456 (a) and 53124689 (b) both produce the same label
sequence COCOCCCC. Taking bond type edge labels into account (s = single, d =
double) leads to diﬀerent label sequences CdOdCsOsCsCsCsC and CsOsCsOsCsCdCsC
of the same random walks. The tottering walks 13131414 and 42424646 reproduce the
ﬁrst label sequence, but use only three vertices.
Computation
For acyclic graphs, e.g., reduced molecular graphs (Xu and Johnson, 2001, 2002), Equa-
tion 2.12 can be computed using topological sorting and dynamic programming in time
O
¡
cc0 |V ||V 0|
¢
, where c, c0 are the maximum vertex degrees in G and G0.
Molecular graphs themselves are cyclic due to, e.g., carbon ring structures. For
cyclic graphs, Equation 2.12 can be computed by solving a system of linear equations,
or, equivalently, by inverting a sparse |V ||V 0|×|V ||V 0| matrix. In both cases, the number
of non-zero coeﬃcients is upper-bounded by cc0 |V ||V 0|. For molecular graphs, cc0 ≤ 49,
and, in almost all scenarios, even cc0 ≤ 25. The solution exists if a convergence condition
on the involved probabilities and kernels is met. For random walk models with constant
termination probabilities pq(·) = γ, the requirement is
kv(·,·)ke(·,·) <
1
(1 − γ)2, (2.15)
which is met by vertex and edge label kernels with 0 ≤ kv,ke ≤ 1. The solution can
be computed using matrix power series (G¨ artner, 2003), an iterative method (Kashima
et al., 2004), the Sylvester or Lyapunov equation, or, conjugate gradient methods (Borg-
wardt et al., 2007).
Tottering
A random walk x = x1 ···xl can immediately revisit a vertex, i.e., xi = xi+2 for some i ∈
[1,l − 2], a behavior called tottering (Mah´ e et al., 2004, Figure 2.2). Such excursions
are likely to be uninformative and to add noise to the model, especially because the
ratio of tottering to non-tottering walks increases rapidly. Tottering can be prevented
by switching to second-order Markov random walks, i.e., by conditioning the transition







As a default, one can choose ps, pq, and pt(xi|xi−1) as before, set pt(vi|xi−2,xi−1) =
1−c
d(xi−1)−1 for vi 6= xi−2, and 0 otherwise. The corresponding label sequence kernel can be
computed using the algorithms for Equation 2.12 on a transformed graph G00 = (V 00,E00).2.2 Graph kernels 67
The latter is constructed by inserting an additional vertex for each (directed) edge in
the original graph G = (V,E),





















label(v00) if v00 ∈ V









for u00 ∈ V ∪ E ∧ v00 ∈ E. (2.20)
Mah´ e et al. (2004) show that there is a bijection between the non-tottering walks on G
and the tottering walks on G00. The graph transformation increases the complexity of
computing the label sequence kernel by a factor of
¡
|V | + |E|
¢¡




with G = (V,E) and G0 = (V 0,E0) the original input graphs (Mah´ e and Vert, 2009).
Variants
An early variant of random walk-based graph kernels, where only walks of equal length
with matching ﬁrst and last vertex label were counted, was introduced by G¨ artner (2003).
Later, extensions to transition graphs were introduced by G¨ artner et al. (2003), e.g., to
Markov chains (Diaconis, 2009), where edges are labeled with transition probabilities,
and, to non-contiguous label sequences, where gaps are allowed (but penalized) when
matching label sequences. Random walk-based graph kernels can also be extended to
graphs with multiple edges (Kashima et al., 2004). Contextual information can be
embedded into the labels using the Morgan index, which improves computation time by
decreasing the number of common paths while still giving comparable performance on
test data sets (Mah´ e et al., 2004).
2.2.3 Tree pattern kernels
Tree-based graph kernels (Mah´ e and Vert, 2009) are based on the idea of comparing
subtrees of the graphs.
Tree patterns
Let G = (V,E) be a graph and let T = (W,F), W = {w1,...,wt} be a rooted directed
tree. A tree pattern of G with respect to T consists of vertices v1,...,vt ∈ G such that
label(vi) = label(wi) for 1 ≤ i ≤ t








for (wi,wj) ∈ W
and j 6= k ⇔ vj 6= vk for (wi,wj),(wi,wk) ∈ W
(2.22)
Each vertex in tree T is assigned a vertex from graph G such that edges and labels match.
The v1,...,vt need not be distinct, as long as vertices assigned to sibling vertices in T
are distinct (Figure 2.3). The tree pattern counting function ψ(G,T) returns the number
of times the tree pattern T occurs in the graph G, i.e., the number of distinct tuples


























Figure 2.3 Tree patterns. Shown are the structure graph of acetic acid (a), a corre-
sponding annotated graph (b), and, a tree pattern contained in it (c). The numbers in
(c) indicate the assigned vertices from (b). Note that vertices 1 and 4 appear twice.
Graph kernel
Let G = (V,E), G0 = (V 0,E0) be graphs, let T be a set of trees, and, let w : T → R+





is positive deﬁnite as it corresponds to a weighted inner product in the feature space
indexed by the trees in T .
Balanced trees
Let Bh denote the set of balanced trees of order h. By weighting tree patterns according
to their size or their branching cardinality, two diﬀerent kernels are derived, the size-






where |T| denotes the number of vertices in T, and, the branching-based balanced tree-






where branch(T) denotes the branching cardinality of T. The parameter λ controls the
weight put on complex tree patterns: more weight is put on them for λ > 1, and less for
λ < 1. Since |T| − h ≥ branch(T), the weighting is more pronounced in Equation 2.24
than in Equation 2.25.
In the limit of λ → 0, only linear trees have non-zero weight, and the two kernels






where Wh−1(G) denotes the set of all walks of length h − 1 in G.2.2 Graph kernels 69
General trees
The branching-based kernel of Equation 2.25 can be extended to arbitrary trees of depth







where T≤h denotes the set of all trees with depth h or less. The feature space of this
kernel is indexed by all trees in T≤h. Although Equation 2.24 can be generalized in the
same manner, this loses the proper weighting scheme.
Computation
Mah´ e and Vert (2009) show how to compute Equations 2.24, 2.25 and 2.27 using dynamic




where d denotes the maximum vertex degree.
Tottering
Recall that graph vertices may be used more than once when matching tree patterns
(Equation 2.22). This causes the equivalent of tottering in random walk-based graph
kernels. In the computation of Equations 2.24, 2.25 and 2.27, all trees up to a given depth
are enumerated by recursively extending depth 2 trees. In this process, it is possible that
a vertex appears both as a parent and as a child of another vertex.
Mah´ e and Vert (2009) modify the tree pattern counting function ψ to prevent tot-
tering by introducing additional constraints. In order to retain the algorithms for the
computation of Equations 2.24, 2.25 and 2.27, they transform the input graphs, replac-
ing edges with additional vertices. Their transformation does not change the maximum
vertex out-degree, but increases the size of the graphs, leading to an increase in runtime
by a factor of
(|V | + |E|)(|V 0| + |E0|)
|V ||V 0|
. (2.28)
2.2.4 Cyclic pattern kernels
Introduced by Horv´ ath et al. (2004), cyclic pattern graph kernels are based on the idea
of mapping graphs to sets of cyclic and tree pattern strings that are compared using the
intersection kernel.
Intersection kernel
Let U be a set, and let 2U denote the set of all subsets of U. The intersection kernel
k∩ : 2U × 2U → R, k∩(S,S0) =
¯ ¯S ∩ S0¯ ¯ (2.29)
is positive deﬁnite since for all ci, cj ∈ R
X
i,j
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Figure 2.4 Cyclic and
tree patterns of indegli-
tazar (Compound 44,
p. 153). Shown are ver-
tices belonging to simple






















































Cyclic and tree patterns
A subgraph is a simple cycle if it is connected and each vertex has degree 2. Let S(G)
denote the set of simple cycles in a graph G. An edge not belonging to a simple cycle
is a bridge. We denote the subgraph of all bridges in G, which is a forest, by B(G)
(Figure 2.4). Let π be a mapping, computable in polynomial time, from the set of
labeled simple cycles and trees to label strings that is injective modulo isomorphism.
Note that such a mapping can always be constructed (Horv´ ath et al., 2004; Zaki, 2005).












¯ T is a connected component of B(G)
ª
. (2.32)










Computing Equation 2.33 is at least as hard as counting simple cycles in a graph, which
is computationally not tractable if P 6= NP (Flum and Grohe, 2004). For graphs with
a small number of simple cycles, Equation 2.33 can be computed via enumeration of
B,T ,S,C (Horv´ ath et al., 2004).
Bounded tree width
The number of cyclic and tree patterns in a graph can be exponential in |V | (Horv´ ath
et al., 2004), leading to computational infeasibility of the cyclic pattern kernel for general
graphs. The restriction of inputs to graphs with few simple cycles can be relaxed to
graphs of bounded treewidth, for which many NP-complete problems become tractable
(Bodlaender, 1993). For graphs of constant bounded treewidth, Equation 2.33 can be






An alternative relaxation is to consider a diﬀerent class of cycles. Horv´ ath (2005) uses
algebraic graph theory to compute the cyclic pattern kernel on monotone increasing
subsets of simple cycles generated by relevant cycles (Plotkin, 1971), with a runtime
bound similar to the one in the previous paragraph, but with diﬀerent cyclic patterns.
While the number of relevant cycles is typically cubic in |V | for molecular graphs (Gleiss
and Stadler, 1999), it is still exponential in the worst case.2.2 Graph kernels 71
2.2.5 Optimal assignment kernels
Optimal assignment graph kernels (Fr¨ ohlich et al., 2005a) are based on the idea of an
optimal assignment of vertices between graphs.
Optimal assignments
Let G = (V,E) and G0 = (V 0,E0) be two undirected labeled graphs. Based upon a
measure kG,G0 of similarity6 between the (labels of) vertices of G and G0, the optimal
assignment kernel injectively assigns the vertices of the smaller graph to vertices of the
larger graph such that the total similarity between the assigned vertices is maximized:
koa(G,G0) =

   














The maximum in the ﬁrst case is over all possible assignments π of the vertices in V to
vertices in V 0, i.e., all preﬁxes of length |V | of permutations of size |V 0|; in the second
case, the roles of V and V 0 are exchanged. Since koa(G,G0) = koa(G0,G), we assume







To prevent the value of the kernel depending on the size |V | of the smaller graph, the







Optimal assignment kernels were proposed by Fr¨ ohlich et al. (2005a,b) in the context of
machine learning and cheminformatics. However, their proof that koa is positive deﬁnite
is wrong, as the inequality at the end of their proof is bounded into the wrong direction.
Furthermore, their proof idea (induction over matrix size based on properties of 2 × 2
matrices) fails, as there are 3 × 3 matrices which are not positive deﬁnite, although all
their 2 × 2 submatrices are; consider, e.g., the following matrices and their smallest








































1 1 1 1 0
.
The 3 × 3 matrix is not positive deﬁnite, as its smallest eigenvalue is negative, but all
submatrices of size 2 × 2 are.
In general, whether an optimal assignment is positive deﬁnite or not depends on the
underlying vertex similarity kG,G0. Vert (2008) shows that koa is positive deﬁnite for
kG,G0(v,v0) = 1, and gives an example of kG,G0 for which koa is not positive deﬁnite.
6Note that we allow kG,G0 : V × V
0 → R+ to depend on G and G
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Computation










is calculated. Then, an optimal assignment (one column assigned unambiguously to each
row) is computed, e.g., using the Kuhn-Munkres assignment algorithm (also Hungarian
algorithm; Kuhn, 1955; Munkres, 1957; Bourgeois and Lassalle, 1971) in time O(|V 0|3).
Similarity matrix
Let kv and ke be non-negative bounded kernels deﬁned on the labels of vertices and
edges, respectively. Default choices for kv and ke are the Dirac kernel
k(x,y) = 1{x=y} (2.38)
for discrete labels and the Gaussian kernel (p. 30) for continuous labels.
Fr¨ ohlich et al. (2005b) start by deﬁning kG,G0(v,v0) using the mean similarity k0(vi,v0
j)
























where n(v) denotes the set of all neighbors of vertex v. They extend this deﬁnition to



















Since vertex degrees are bounded in molecular graphs, Equations 2.40, 2.41 and 2.42
can be computed in constant time for ﬁnite topological distances L. For γ(r) = γr with
0 < γ < 1, the sum in Equation 2.42 converges for L → ∞. In another publication, they
replace the mean with an optimal assignment of the neighbors (Fr¨ ohlich et al., 2005a).
2.2.6 Other graph kernels
Several other approaches to graph kernels have been proposed.2.2 Graph kernels 73
Complement graph
Let k(G,G0) denote the random walk kernel from Equation 2.14. Borgwardt et al. (2007)
propose to use the composite graph kernel
kc(G,G0) = k(G,G0) + k( ¯ G, ¯ G0), (2.43)
where ¯ G =
¡
V,V × V \ E
¢
denotes the complement graph of G. This kernel also takes
the absence of an edge in both graphs into consideration, which is useful for modeling
protein-protein interaction networks.
Fingerprint kernels
Ralaivola et al. (2005) propose kernels based on common walks of bounded length, which
they compute explicitly using depth-ﬁrst search, molecular ﬁngerprinting (Raymond and
Willett, 2002), and suﬃx trees (Ukkonen, 1995). Let P denote the set of all labeled walks
of bond-length up to d, let φw(G) indicate either the presence of the walk w in G (if
binary features are used) or the number of times w occurs in G (if counting features




w∈P denote the mapping into the feature space indexed
by such walks, and let k(G,G0) = hφ(G),φ(G0)i denote the inner product in this space.
The authors use the derived Tanimoto kernel
kt(G,G0) =
k(G,G0)
k(G,G) + k(G0,G0) − k(G,G0)
(2.44)












Enumeration by depth-ﬁrst search of all walks of length up to d, starting from each






















The all-paths kernel (Borgwardt and Kriegel, 2005) is related to random walk kernels
(Subsection 2.2.2), but uses paths instead of walks, i.e., walks without repetition of
vertices. Let P,P0 denote the set of all paths on the graphs G,G0, and let kp denote a






is positive deﬁnite, but its computation is NP-hard. Restriction to shortest paths renders
Equation 2.46 computationally feasible, and can be achieved by considering transformed
graphs ˜ G = (V, ˜ E), ˜ G0 = (V 0, ˜ E0), with edges between all vertices connected by a path.
The edges are labeled with shortest path distances, which are computable in polyno-
mial time (all-pairs shortest-path problem; Cormen et al., 2001), resulting in an overall
runtime of O
¡
|V |2 |V 0|2¢
.74 2 A kernel based on iterative graph similarity
Edit distance kernels
The edit distance (Levenshtein, 1966; Gusﬁeld, 1997) between two graphs is the minimum
number of vertex and edge insertions, deletions, and substitutions required to transform
one graph into another. Graph edit distance computation requires time exponential
in the number of vertices, but can be eﬃciently approximated (Neuhaus and Bunke,
2004). Let d(G,G0) denote the non-negative and symmetric edit distance between the





d2(G,G0) + d2(G0,G0) − d2(G,G0)
¢
, (2.47)
where the graph G0 is called zero graph because it has the role of origin. Equation 2.47
relates the direct distance between G and G0 to the distance between G and G0 via the










improves performance in practice. Equations 2.47 and 2.48 are positive deﬁnite if −d2
is conditionally positive deﬁnite, which is not the case for edit distances in general. An
advantage of edit distances is their robustness against noise in the input graphs.
2.2.7 Applications in cheminformatics
Kernels on structured data, and graphs in particular, have been successfully applied to
various problems in cheminformatics, including ligand-based virtual screening.
Structured data
An example of an application in cheminformatics using kernels on non-graph structured
data is given by G¨ artner et al. (2004), who use structured data kernels and a 1-nearest
neighbor classiﬁer to improve classiﬁcation accuracy to 95% in diterpene structure eluci-
dation from 13C nuclear magnetic resonance spectra, an improvement of 10% compared
to the state of the art at that time.
Graphs
Examples of applications in bio- and cheminformatics using kernels on graphs:
• Borgwardt et al. (2005) use a modiﬁed random walk kernel, hyperkernels (Ong et al.,
2005), and support vector machines for protein function prediction. Classiﬁcation
accuracy for enzymes versus non-enzymes was 84.04%, a signiﬁcant improvement over
previous vector-based approaches.
• Menchetti et al. (2005) propose weighted decomposition kernels for molecules, using
local topology and graph complements. They achieve performance similar to other
graph-based approaches in the predictive toxicology challenge (Toivonen et al., 2003),
and, discriminating active versus moderately active compounds in a screen for activity
against human immunodeﬁciency virus. Ceroni et al. (2007) later incorporate spatial
information into weighted decomposition kernels for molecules.
• Borgwardt et al. (2006) employ graph representations of proteins, random walk kernels,
and kernel mean discrepancy to statistically test whether two protein samples are from2.3 Iterative similarity optimal assignment graph kernel 75
the same distribution, with excellent results (no errors on a signiﬁcance level of 0.05).
Gretton et al. (2007) improve the test, and apply it to protein homology detection on
a KDD cup (Caruana and Joachims, 2004) data set, with state of the art performance.
• Airola et al. (2008) introduce the all-dependency-paths graph kernel for the automated
extraction of protein-protein interactions from scientiﬁc literature (text mining), with
state of the art results (ROCAUC between 0.80 and 0.85 on ﬁve public text corpora).
For further examples, see Jain et al. (2005).
2.3 Iterative similarity optimal assignment graph kernel
Quantitative measures of graph similarity, including, but not limited to, the graph ker-
nels of the previous section, are required in many contexts. Consequently, the graph
isomorphism problem (K¨ obler et al., 1993; Johnson, 2005), as well as its generalizations,
edit distance and maximum common subgraph/minimum common supergraph, have
been intensively investigated (Conte et al., 2004). Starting from iterative methods for
the similarity of general graphs, we develop a vertex scoring scheme tailored to molec-
ular graphs. Combining this scheme with optimal assignment kernels, we introduce the
iterative similarity optimal assignment graph kernel.
2.3.1 Iterative graph similarity
In one particular approach to graph similarity, vertices (and edges) in two graphs are
considered similar if their respective neighborhoods are similar. This recursive deﬁnition
naturally leads to iterative computation schemes for pairwise vertex (and edge) similar-
ity scores, where initial similarities are repeatedly updated, propagating information
according to the graph structures, until convergence occurs.
Several methods based on this approach have been developed, e.g., Kleinberg (1999);
Melnik et al. (2002); Jeh and Widom (2002); Heymans and Singh (2003); Leicht et al.
(2006); Zager and Verghese (2008). We essentially follow Zager and Verghese (2008) in
our exposition.
Hub and authority scores in a single graph
The hypertext induced topic selection algorithm (HITS; Kleinberg, 1999) for scoring
internet search queries is an iterative scheme for scoring the vertices of a single directed
graph G = (V,E). Each vertex v is associated with a hub score h(k)(v) and an authority
score a(k)(v), where k is the iteration number. In each iteration, the hub score of a
vertex is the sum of the authority scores of the vertices it points to, and its authority








constituting a mutually reinforcing relation between hubs and authorities. In each iter-
ation, a normalization step is necessary to keep the scores from unlimited growth,
h(k)(v) =
˜ h(k)(v)
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The convergence behavior of Equation 2.52 depends on spectral properties of M (Blondel










where Π is the orthogonal projector on the invariant subspace associated with the Perron















In both cases, convergence limits depend on the initial value x(0). Kleinberg (1999)
assumes the case of Equation 2.53, an assumption not necessarily valid in practice,
and sets x(0) = 1|V |, ensuring convergence to the solution with largest possible sum
norm k·k1.
Generalization to two graphs









, where h(k)(v) and a(k)(v) are interpreted
as the similarity of v to h and a, respectively.
They generalize this to a similarity measure between two arbitrary directed graphs
G = (V,E) and G0 = (V 0,E0) by introducing a similarity score xv,v0 for each pair of
















which adds the similarities of all pairs of incoming and outgoing neighbors, respectively.
Note that, as in Equation 2.54, a normalization step x(k) = ˜ x(k)/k˜ x(k)k2 is required.
Equation 2.55 can be written in matrix form as
˜ X
(k)
= ATX(k−1)A0 + AX(k−1)A0T, (2.56)
where A and A0 are the adjacency matrices of G and G0. Concatenating the columns
of X into vec(X) and using vec(CXD) = (DT ⊗C)vec(X) (Horn and Johnson, 1991,
p.254), where ⊗ denotes the Kronecker matrix product (also tensor or direct product),
one gets
˜ x(k) = (A0T ⊗ AT + A0 ⊗ A)x(k−1) = Mx(k−1). (2.57)
The convergence of this equation is subject to the same conditions as Equation 2.52.
Blondel et al. (2004) set x(0) = 1|V ||V 0| and use the limit of the even iterations.2.3 Iterative similarity optimal assignment graph kernel 77
Coupled vertex-edge scoring
Zager and Verghese (2008) extend this approach by introducing similarity scores for
edges. They deﬁne two edges to be similar if their respective source and terminal vertices
are similar, i.e., they couple edge similarity to vertex similarity. Let S,T ∈ {0,1}|V |×|E|
denote the source-edge and terminus-edge matrices,
Sv,e = 1{∃u∈V :e=(v,u)}, T v,e = 1{∃u∈V :e=(u,v)}. (2.58)
Note that DS = SST and DT = TT T are diagonal, with the out- and in-degrees of the
vertices on the diagonal, respectively. Let ye,e0 denote the edge score between e ∈ E and























updates the edge scores using the vertex scores and vice versa. Again, a normalization
step is required in each iteration. The update can be given in matrix form,
˜ Y
(k)
= STX(k−1)S0 + T TX(k−1)T 0,
˜ X
(k)
= SY (k−1)S0T + TY (k−1)T 0T,
(2.60)
and, using column concatenation, as a matrix-vector product
˜ y(k) =
¡
S0T ⊗ ST + T 0T ⊗ T T¢
x(k−1) = Nx(k−1), (2.61a)
˜ x(k) =
¡
S0 ⊗ S + T 0 ⊗ T
¢
y(k−1) = NTy(k−1). (2.61b)




, Equation 2.59 can be expressed as






z(k−1) = Mz(k−1). (2.62)
Zager and Verghese (2008) show that for arbitrary x(0) and y(0) = αNx(0) with α > 0,
Equation 2.62 converges to a unique non-negative solution. Inserting Equation 2.61a







A0 ⊗ A + A0T ⊗ AT + D0




the ﬁrst part of which is identical to Equation 2.57. Coupled vertex-edge similarity
therefore diﬀers from the update of Blondel et al. (2004) in additional diagonal terms
that amplify the scores of highly connected vertices.
2.3.2 Iterative similarity for molecular graphs
The coupled vertex-edge update (Equation 2.63) has several desirable properties: It
converges to a unique limit, independent of the initialization value, and, it has a succinct
matrix notation, making it amenable to analysis and enabling a simple implementation
via iterated matrix multiplication.
With regard to the comparison of molecular graphs, however, it has several short-
comings: It is based exclusively on graph topology and does not take any labeling of
vertices or bonds into account, which is indispensable for chemical similarity measures
as the graph topology alone does not provide enough information. Molecular graph
properties (Part 2.1.3), in particular bounded vertex degrees, are not exploited.78 2 A kernel based on iterative graph similarity
Update equation
We propose the following update equation that has the desirable properties of Equa-
tion 2.63, but is tailored towards the requirements of ligand-based virtual screening,
i.e., the comparison of small labeled undirected graphs with bounded vertex degree:
X
(n)













for |v| < |v0| and
X
(n)













for |v| ≥ |v0|. The maximum in Equation 2.64a is over all possible assignments of neigh-
bors of v to neighbors of v0, i.e., over all length |v| preﬁxes of length |v0| permutations;
in Equation 2.64b, the roles of v and v0 are exchanged. In other words, Equation 2.64
optimally assigns the neighbors of the vertex with smaller degree to the neighbors of the
vertex with larger degree, based on the similarity values of the previous iteration. The
parameter α ∈ (0,1) weights the constant and the recursive parts of the equation. A
normalization step is not necessary.
Equation 2.64 obviously takes vertex and edge labels into account. In the following,
we introduce a succinct matrix notation, prove that the corresponding iteration converges
to a unique limit independent of the initialization value X(0), and, show that it exploits
the bounded degree of molecular graphs.
Matrix notation
To obtain Equation 2.64 in matrix form, note that the graph neighborhood structures








¯ {v0,u0} ∈ E0ª
, and ke({u,v},{u0,v0}) constants depending only on u, v, u0, v0,















denote the corresponding vectorization of kv. We encode the neighbor assignments
of a single iteration into a |V ||V 0| × |V ||V 0| square matrix P as follows: Each row
corresponds to a speciﬁc neighbor assignment in Equation 2.64, e.g., row (j −1)|V |+i,
which corresponds to entry X
(n)
i,j , contains one possible assignment of neighbors of vi to
neighbors of v0
j, or, vice versa, depending on |vi| and |v0
j|. The non-zero entries of P are
the corresponding products of ke and |v0
j|−1 or |vi|−1, respectively. Equation 2.64 can
be written as
x(n) = (1 − α)kv + αmax
P
Px(n−1). (2.66)
The maximum is over all matrices P compliant with the graph neighborhood structure.
For the formal determination of the maximum, we compare two vectors a and b using
a < b ⇔ ∀i : ai ≤ bi ∧ ∃i : ai < bi. (2.67)
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Figure 2.5 The two cases of Equation 2.69. In case (a), replacing P 00
i y by P 0
iy can
only result in a lower value, since P 00
i maximizes P 00
i y. Consequently, |P 0
ix − P 00
i y| ≤
|P 0
ix − P 0
iy|. In case (b), the roles of P 0
ix and P 00
i y are exchanged. In both cases,
|P 0
ix − P 00
i y| ≤ |P ix − P iy|.
Convergence
We can now state the main theorem of this chapter.
Theorem. For any x(0) ≥ 0, the iteration given by Equation 2.64 converges to the
unique solution of x = (1 − α)kv + αmax
P
Px.
Proof. Let M =
©
x ∈ R|V ||V 0| ¯ ¯ xi ≥ 0
ª
denote the non-negative orthant, and let
f : M → M, x 7→ (1 − α)kv + αmaxP Px. We show that f is a contraction mapping
on M, that is kf(x) − f(y)k ≤ λkx − yk for some positive λ < 1 and some norm k·k.
Let
P 0 = argmax
P
Px, P 00 = argmax
P
Py, (2.68)





i if P 0
ix ≥ P 00
i y
P 00
i if P 0
ix < P 00
i y
, (2.69)
where P i denotes the i-th row of P. Note that |P 0
ix−P 00
i y| ≤ |P ix−P iy| (Figure 2.5),
giving
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, so the i-th component of Px can be at most maxi |xi|.
Since f is a contraction mapping deﬁned on the complete metric space M, the
proposition follows from Banach’s ﬁxed point theorem (Granas and Dugundji, 2003).80 2 A kernel based on iterative graph similarity
Number of iterations
The following lemma states a number of iterations k suﬃcient for the computation of
x(k) to a desired precision ². Due to several inequalities used, the number of necessary
iterations will, in general, be lower than k.
Lemma. For given ² > 0,
°





≤ ² after at most k =
&
logα




Proof. We want to ﬁnd k ≥ 0 such that
°
°x(k) − x(k+m)°
° < ² for all m ≥ 0. By repeated
application of the triangle inequality we get




° °x(k+l) − x(k+l+1)° °
∞. (2.71)




















































∞ ≤ ² ⇐⇒ k ≥ logα




Since k is integer, the proposition follows.
2.3.3 A kernel for molecular graphs
Combining the ideas of optimal assignment kernels (Subsection 2.2.5) and iterative sim-















Note that we assume |V | ≤ |V 0| (as for Equations 2.34 and 2.35).2.3 Iterative similarity optimal assignment graph kernel 81
Computation
The vertex similarity scores kx can be computed iteratively to a given precision ² using
Equation 2.66 and Lemma 2.3.2. In each iteration and for each pair of vertices (v,v0) ∈
V ×V 0, an optimal assignment π of the neighbors of v to the neighbors of v0 (or vice versa)
is computed, based on the similarity values of the previous iteration (Algorithm 2.1).
The ﬁnal optimal vertex assignment can be done using the Kuhn-Munkres assignment
algorithm (Kuhn, 1955; Munkres, 1957); Bourgeois and Lassalle (1971) give an extension
of the algorithm to non-quadratic matrices (Algorithm 2.2).
Figures 2.10 and 2.11 show examples of ISOAK similarity and assignments.
Algorithm 2.1 Iterative similarity optimal assignment kernel. A Java (version 1.5, Sun
microsystems, www.sun.com) implementation is available at www.mrupp.info.
(a) Normalization uses (b) to compute k(G,G0)/
p
k(G,G)k(G0,G0) (Equation 2.36).
If kv(v,v) = ke(e,e) = 1 for all v ∈ V , e ∈ E, then k(G,G) = |V | by Equation 2.64.
Input: graphs G=(V,E),G0=(V 0,E0), vertex and edge kernels kv,ke, parameters α,².
Output: ISOAK k(G,G0) normalized to [0,1].




(b) ISOAK computation. For implementation purposes, one can use column-wise lin-
earized indices, where Xi,j corresponds to entry (j −1)|V |+i in vec(X). The neighbor-
hood assignments (preﬁxes of length |vi| of permutations of {1,...,|v0
j|}, or vice versa;
see Sedgewick (1977) for a survey and analysis of permutation generation algorithms),
as well as kv and ke can be precomputed.
Input: graphs G=(V,E),G0=(V 0,E0), vertex and edge kernels kv,ke, parameters α,².
Output: ISOAK k(G,G0), similarity matrix X(k), optimal assignment (j1,...,jn).
1 Set X(0) ← 1|V |×|V 0|, k ← 0.
2 Do
3 Set k ← k + 1.




6 If |vi| < |v0















7 If |vi| ≥ |v0































10 Use Algorithm 2.2 to compute an optimal assignment of −X(k).82 2 A kernel based on iterative graph similarity
Algorithm 2.2 Optimal assignment algorithm (also Hungarian algorithm; Kuhn, 1955,
1956; Munkres, 1957), in an extended version for rectangular matrices (Bourgeois and
Lassalle, 1971). A Java (version 1.5, Sun microsystems, www.sun.com) implementation
is available at www.mrupp.info. The algorithm distinguishes zero entries of the matrix
as primed 00 and starred 0?; rows can be covered.
Input: matrix A ∈ Rn×n0
, n ≤ n0.
Output: assignment (j1,...,jn) minimizing
Pn
i=1 Ai,ji.
Initially, no lines are covered, no zeros are starred or primed.
1 From each row, subtract its minimum.
2 For all Ai,j: If Ai,j = 0 and there is no 0? in row i or column j, then set Ai,j ← 0?.
3 Cover each column with a 0? in it.
If n columns are covered, return their indices (j1,...,jn) as the optimal assignment.
4 If all zeros are covered, go to 6, else prime a non-covered Ai,j = 0.
If there is no Ai,k = 0? in row i, go to step 5,
else cover row i, un-cover column k, and go to step 4.
5 Construct a series of alternating 00 and 0?:
Set z0 ← (i,j). z0 is the 00 found in step 4.
Set z1 to the 0? in z0’s column (if any), set z2 to the 00 in z1’s row, and so on.
Un-star each 0? and star each 00 in the sequence.
Erase all 00 in A, un-cover every row, and go to step 3.
6 Set h to the smallest non-covered element in A. h was un-covered in step 4.
Add h to all covered rows, then subtract h from all non-covered columns.
Go to step 4.
















(a) Dependence on ² for α = 1
4 (solid line),
α = 1
2 (dashed line), and α = 3
4 (dotted line).


















(b) Dependence on α for ² = 1
2 (solid line),
² = 1
10 (dashed line), and ² = 1
100 (dotted line).
Figure 2.6 ISOAK runtime dependence on parameters ² and α.2.3 Iterative similarity optimal assignment graph kernel 83
Runtime
















This leads to a factorial worst-case runtime complexity for general graphs. In molecular
graphs, the vertex degree is bounded by a small constant (p. 63), up to which the cor-
responding assignments can be precomputed, allowing the determination of each vertex
assignment π in constant time. In this way, update Equation 2.66 exploits the bounded
degree of molecular graphs.









(1 − α)²/kx(0) − x(1)k∞
¢¨
iterations are necessary. From kx(0) − x(1)k∞ ≤ 1 and α ∈ (0,1), it follows that
logα(kx(0) − x(1)k∞) ≥ 0, and the computation of the similarity matrix X takes time in
O
¡





Computing the ﬁnal optimal assignment (Algorithm 2.2) has cubic runtime, resulting in
a total runtime complexity of
O
¡





With the convention |V | < |V 0|, this simpliﬁes to
O
¡





Runtime depends polynomially on the size of the input graphs, and increases exponen-
tially for ² → 0 (Figure 2.6a) and α → 1 (Figure 2.6b) as the approximation approaches
the exact solution and the complete topology of the graphs is considered. Empirical
runtimes agree with Equation 2.79 (r2 = 1, RMSE = 0.016, Figure 2.7).
Positive deﬁniteness
Optimal assignments are not positive deﬁnite in general (p. 71), and whether Equa-
tion 2.75 constitutes a proper kernel or not depends on the measure of pairwise vertex
similarity kx. We do not know if the ISOAK update rule (Equation 2.64) always leads
to positive deﬁnite optimal assignments.
We have checked all kernel matrices computed with Algorithm 2.1 in several exper-
iments for positive deﬁniteness with the eigenvalue criterion (p. 30). Slightly negative
eigenvalues were encountered, but might be partly or entirely numerical artifacts. Fig-
ure 2.8 shows the distribution of the smallest eigenvalues over the parameter α. Most
of the negative smallest eigenvalues are close to zero; for α → 1 all eigenvalues are non-
negative, indicating that the recursive similarity part of Equation 2.75 might be positive
deﬁnite in general.
In practice, matrices with negative smallest eigenvalue λn can be corrected by adding
a constant σ to their diagonal. This shifts their eigenspectrum,
(M + σI)x = Mx + σx = (λ + σ)x, (2.80)
and adding σ = |λn| to their diagonal renders them positive deﬁnite. A disadvantage
of this correction is that adding to the diagonal can worsen the performance of kernel
algorithms due to diagonal dominance (Greene and Cunningham, 2006).84 2 A kernel based on iterative graph similarity
Expressiveness
According to Equation 2.77, the runtime of Algorithm 2.1 increases with α and 1/².
Such an increase in computation time should lead to an improvement in discriminative
power. To quantify this, we introduce the expressiveness χ(k,D) of a normalized graph










On all the data sets investigated in Section 2.4 and for all the used vertex and edge
kernels, expressivity increased monotonically with α (Figure 2.9). Since runtime also
increases with α, this parameter directly controls the trade-oﬀ between separation power
and computational complexity. For the used data sets, note that expressivity saturates
already for small values of α ≈ 0.2.
2.4 Retrospective evaluation
We retrospectively evaluate (Section 1.4) the performance of ISOAK in multiple virtual
screening experiments using support vector machines (Shawe-Taylor and Cristianini,
2004) for binary classiﬁcation and regression on public, proprietary, and benchmark data
sets. We analyze the results and compare them to those of optimal assignment kernels
(Subsection 2.2.5) from the literature. For a prospective application, see Chapter 4.
2.4.1 Data sets
We tested our graph kernel on 12 diﬀerent data sets (Table 2.3). These included public
(drug-nondrug, ptcfm, ptcmm, ptcfr, ptcmr) as well as proprietary data (cobra:ache,
cobra:cox2, cobra:dhfr, cobra:fxa, cobra:ppar, cobra:thrombin, bbb) coming from
four diﬀerent sources. 11 data sets are binary classiﬁcation problems and one (bbb) is a
regression problem. In all data sets, duplicate molecules and molecules that could not
be processed by some of the used software were removed.
Drugs versus non-drugs
Drug-likeness, i.e., the similarity of a compound to known drugs in terms of physico-
chemical properties like solubility and lipophilicity, is an important concept in drug
discovery (Leeson and Springthorpe, 2007). It has been characterized in various ways;
a prominent example is the rule of ﬁve (Lipinski et al., 1997), which states that for
small molecules, notwithstanding substrates of biological transporters, “poor absorption
or permeation are more likely when there are more than 5 hydrogen-bond donors, more
than 10 hydrogen-bond acceptors, the molecular weight is over 500, or, the [computed]
LogP (MLogP) is over 5 (4.15)”.
We compiled the drug-nondrug data set using the DrugBank repository (Wishart
et al., 2008, www.drugbank.ca, n+ = 809 drugs) and randomly sampled compounds from
the Sigma-Aldrich catalog (www.sigmaaldrich.com; n− = 734 assumed non-drugs).2.4 Retrospective evaluation 85








Figure 2.7 Empirical ISOAK runtimes
(gray disks) and a ﬁt to Equation 2.79
(solid line). Runtimes are in units of 10−2 s
for a Java (version 1.5, Sun microsystems,
www.sun.com) implementation running on a
Xeon processor (2.2 GHz, 3 GB RAM, In-
tel, www.intel.com). Runtime values for
each α are averages over several data sets
and choices of kv and ke, with ² = 1
100.
The average runtime over all computed ker-
nel values was 1.88 ± 0.17s−2. The ﬁt
0.1042 + 0.0157logα(1 − α) 1
100 has r2 = 1
and RMSE = 0.016.
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Figure 2.8 Smallest eigenvalues of ISOAK
matrices, plotted against parameter α.
Shown are the mean (solid line), mean ±
standard deviation of negative and positive
values, respectively (dotted lines), and, the
minimum (dashed line), computed at a pre-
cision of ² = 10−3 over all parametrizations
and all data sets used in Section 2.4 (n =
















c Figure 2.9 Expressiveness of ISOAK, plot-
ted against parameter α. Shown are the
mean (solid line), mean ± standard devi-
ation of negative and positive values, re-
spectively (dotted lines), and, the mini-
mum and maximum values (dashed lines),
computed to a precision of ² = 10−3 over
all data sets and parametrizations used


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(c) Assignment strength, color-coded from red (highest similarity) to black (lowest similarity).
Figure 2.11 ISOAK on tesaglitazar (a, Compound 38, p. 152) and muraglitazar (b,
Compound 37, p. 152), with Dirac kernels on vertex element type and edge bond type
annotation, α = 0.875, ² = 0.01. Colors indicate assigned components, with gray in-
dicating unassigned vertices. Assignment strength is shown separately (c). The overall
normalized similarity is 0.57.88 2 A kernel based on iterative graph similarity
COBRA subsets
The COBRA database (version 6.1; Schneider and Schneider, 2003) is a commercial data set
containing compounds collected from the literature, annotated with activity on biolog-
ical targets and interaction mode. Subsets cobra:ache (n−=58, n+=92), cobra:cox2
(n−=136, n+=126), cobra:dhfr (n−=60, n+=60), cobra:fxa (n−=228, n+=221),
cobra:ppar (n−=94, n+=92), and cobra:thrombin(n−=185, n+=186) were used.
For each data set, all compounds belonging to the respective class were taken as
positive samples, and an identical number of molecules was randomly selected from the
database as negative samples. In this, the negative samples problem (p. 28) was accepted
as a concession to conventional procedure and the ability to directly compare results with
those in the literature.
Predictive toxicology challenge
The predictive toxicology challenge 2000–2001 (Helma and Kramer, 2003) dealt with
prediction of carcinogenicity in rodents, based on data from the national toxicology
program (NTP) of the United States department of health and human services. We
used the training data sets ptcfm (female mice, n− = 202, n+ = 135), ptcmm (male
mice, n− = 204, n+ = 118), ptcfr (female rats, n− = 224, n+ = 118), and ptcmr (male
rats, n− = 186, n+ = 146); all are binary classiﬁcation problems.
Blood-brain barrier permeability
The blood-brain barrier (BBB; Edwards, 2001; Cecchelli et al., 2007) is one of several
mechanisms regulating the exchange of substances between blood and the central ner-
vous system (CNS). The BBB is formed by the endothelial cells of cerebral capillaries,
regulating access to the CNS to protect it against changes in the hematic environment.
Predicting a compounds ability to permeate the BBB is important in drug development,
as drugs targeted at the CNS have to cross the BBB, whereas peripherally acting drugs
should not do so in order to prevent CNS-mediated side eﬀects. We use the bbb (n=115)
data set published by Hou and Xu (2003), a regression problem.
2.4.2 Representation
All data sets were treated identically. Molecular graphs did not include hydrogen atoms.
ISOAK parametrizations
In total, 8 diﬀerent combinations of vertex and edge annotations, and thus of vertex
and edge kernels, were used (Table 2.4). For discrete labels, we used the Dirac ker-
nel (Equation 2.38). For continuous labels, we used the Gaussian kernel (p. 30) with
the kernel width σ set to the standard deviation of the labels in a data set. Phar-
macophore types were computed using the molecular query language (MQL; Proschak
et al., 2007, Table 2.5). Gasteiger-Marsili partial charges (Gasteiger and Marsili, 1980)
were computed using the PETRA software (version 3.11, Molecular networks, www.
molecular-networks.com).
Baseline representations
Besides the diﬀerent ISOAK parametrizations, we used two established vectorial descrip-
tors as baseline representations, the CATS2D descriptor (p. 154) and Ghose-Crippen
fragment descriptors (p. 156). With vectorial descriptors, we used two standard kernels,
the homogeneous polynomial kernel (p. 30) and the Gaussian kernel (p. 30).2.4 Retrospective evaluation 89
Table 2.3 ISOAK retrospective evaluation data sets.
Samples
Name neg. pos. Description
drug-nondrug 734 809 Known and desirable bioactivity
cobra:ache 58 92 Acetylcholinesterase inhibitors
cobra:cox2 136 126 Cyclooxygenase-2 inhibitors
cobra:dhfr 60 60 Dihydrofolate reductase inhibitors
cobra:fxa 228 221 Factor Xa inhibitors
cobra:ppar 94 92 Peroxisome proliferator-activated receptor agonists
cobra:thrombin 185 186 Thrombin inhibitors
ptcfm 202 135 Predictive toxicology challenge, female mice subset
ptcmm 204 118 Predictive toxicology challenge, male mice subset
ptcfr 224 118 Predictive toxicology challenge, female rats subset
ptcmr 186 146 Predictive toxicology challenge, male rats subset
bbb 115 Blood-brain barrier
Table 2.4 ISOAK parametrizations. All possible eight combinations of the listed vertex
and edge kernels were used.
Abbrev. Description
Vertex kernel
none kv(v,v0) = 1. No vertex kernel.
delement Dirac kernel (Equation 2.38) with element types as labels.
dppp Dirac kernel with potential pharmacophore points (Table 2.5) as labels.
echarge Gaussian kernel (p. 30) with Gasteiger-Marsili partial charges as labels.
Edge kernel
none ke(e,e0) = 1. No edge kernel.
dbond Dirac kernel using covalent bond type (single, double, triple) as label.
Table 2.5 Molecular query language (MQL; Proschak et al., 2007) deﬁnitions of the
used potential pharmacophore points (PPP).
PPP MQL deﬁnition
lipophilic C[!bound(∼Hetero)], Cl, Br, I
positive *[charge>0], N[allHydrogens>1]
negative *[charge<0], O=P’∼O’, O=S’∼O’, O=C’∼O’[allHydrogens=1|charge<0],
O[allHydrogens=1|charge<0]∼C’=O
acceptor O, N[allHydrogens=0]
donor O[allHydrogens=1&!bound(-C=O)], N[allHydrogens>0]90 2 A kernel based on iterative graph similarity
2.4.3 Support vector machines
Many good introductions to support vector machines (SVMs) exist, and we limit our ex-
position to the basic ideas. Bennett and Campbell (2000) provide an intuitive, geometric
introduction to SVMs; for details, see the text books by Cristianini and Shawe-Taylor
(2000); Steinwart and Christmann (2008). For reviews of SVMs in chemistry and com-
putational biology, see Ivanciuc (2007) and Ben-Hur et al. (2008), respectively.
Separating hyperplanes
Consider a binary classiﬁcation problem with training samples x1,...,xn ∈ Rd and
associated labels y1,...,yn ∈ {−1,1}. The decision function
f(x) = sgng(x), g(x) = hw,xi + b, (2.82)
depends on a vector w ∈ Rd and a bias b ∈ R that determine orientation and oﬀset of
a discriminant (hyper)plane (Figure 2.12a). The hyperplane is orthogonal to w and the
bias b translates it along w. New samples x0 will be classiﬁed as negative or positive
depending on which side of the hyperplane they lie, i.e., whether g(x0) < 0 or g(x0) > 0.
Maximum margin
A ﬁnite number of linearly separable training samples can be separated by inﬁnitely many
hyperplanes, i.e., w and b such that f(xi) = yi. Intuitively, the one that generalizes best
to new samples7 is the one farthest from all training samples, i.e., the one with maximum
margin d−+d+, where d− and d+ are the shortest distances between the hyperplane and
the negative and positive samples, respectively. Since the decision function f is invariant
under positive rescalings of g, we can require
g(xi) = hw,xii + b ≥ +1 if yi = 1 (2.83a)
g(xi) = hw,xii + b ≤ −1 if yi = −1
,
(2.83b)
with equality for at least one training sample x+ and x−, respectively. Equation 2.83
deﬁnes two hyperplanes, parallel to the separating hyperplane, with no training samples
between them. The distance between the projections (Meyer, 2001) of x+ and x− onto





























where hw,x+ − x−i = 2 follows from subtracting Equation 2.83b from Equation 2.83a.
Maximizing the margin is equivalent to minimizing its inverse 1
2 kwk
2, resulting in the










≥ 1 for i ∈ {1,...,n}. (2.85)
7Drawn from the same distribution as the training samples. Relaxation of this assumption leads to
the problem of covariate shift (Shimodaira, 2000; Zadrozny, 2004; Sugiyama et al., 2007, 2008). The
latter is relevant to ligand-based virtual screening because training and (prospective) test samples are







(a) Linear separable case. Two times 13 sam-










port vectors; w = (0.97,0.98), b = −1.85.







(b) Linear inseparable case. Two times 13










support vectors; w = (0.53,0.77), b = 0. For
the 2 misclassiﬁed samples, the distance to the
separating hyperplane is shown (dotted lines).









(c) Non-linear case. 25 i.i.d. samples from





samples spaced evenly on a circle of radius 5





SVM with degree 2 homogeneous polynomial
kernel k(x,x0) = hx,x0i
2; 4 support vectors.







(d) Regression. 25 equidistant samples of
f(x) = 1
x sinx. SVM with C = 1, ² = 0.1,
and a Gaussian kernel with σ = 1; 13 support
vectors.
Figure 2.12 Support vector machine classiﬁcation (a, b, c) and regression (d) exam-
ples. In (a), (b), (c), samples from two classes (orange and blue disks), the separating
hyperplane (solid line), the margins (gray dashed lines), and the support vectors (encir-
cled in light blue) are shown. In (d), samples from a function (orange disks), the ²-tube
around the regressand (gray dashed lines), the regressor (solid line), and support vectors
(encircled in light blue) are shown.92 2 A kernel based on iterative graph similarity
Soft margins
In practice, data sets are often not linearly separable due to noise and non-linear patterns
in the data. The latter can be addressed with the kernel trick (p. 28); the former
is handled by introducing slack variables ξi ≥ 0 that measure the extent to which a
















+ ξi ≥ 1, ξi ≥ 0, (2.86)
where p is either 1 (hinge loss) or 2 (quadratic loss), and 0 < C < ∞ is a parameter
controlling the trade-oﬀ between margin size and tolerated error.
Non-linear case
The linear SVM described so far uses only inner products of the training samples and
the weight vector w. Applying the kernel trick (p. 28) requires a diﬀerent representation
of the decision function f, since w is now a vector in feature space and can not be
explicitly computed. The representer theorem (Kimeldorf and Wahba, 1971; Sch¨ olkopf
and Smola, 2002) guarantees the existence of a representation of f as a kernel expansion
over the training samples,




The αi ∈ [0,C] are the solution coeﬃcients. A training sample xi is called a support vec-
tor8 iﬀ αi > 0. The Karush-Kuhn-Tucker conditions (Karush, 1939; Kuhn and Tucker,
1951; Boser et al., 1992; Cortes and Vapnik, 1995) state that αi > 0 iﬀ yi g(xi) ≤ 1, i.e.,
support vectors are training samples that lie on the hyperplane or violate it (Figure 2.12).
Computation
Usually, Equation 2.86 is solved for the αi by applying Lagrange multipliers to its dual
formulation, but the solution can also be computed eﬃciently in the primal using gradient
descent (Chapelle, 2007).
Regression
Support vector regression (Vapnik, 1995; Smola and Sch¨ olkopf, 2004) directly extends
soft margin SVMs (Equation 2.86) by dropping the sgn in the decision function and









max{0,|yi − g(xi)| − ²}. (2.88)
The used ²-insensitive loss function does not penalize the predictor as long as it stays
within ±² around the known function values.
8Note that after the switch to kernels, x ∈ X need not be an element of a vector space.2.4 Retrospective evaluation 93
2.4.4 Evaluation
We retrospectively evaluated the performance of SVM classiﬁcation and regression with
ISOAK. Data sets, machine learning algorithms, statistical validation procedures, and
performance measures were chosen to allow comparison with the literature, in particular
with the study by Fr¨ ohlich et al. (2005a).
Data sets
We used the bbb data set and the drug-nondrug, cobra:ache, cobra:cox2, cobra:dhfr,
cobra:fxa, cobra:ppar, cobra:thrombin data sets to assess ISOAK performance on a
public data set and subsets of a high-quality pharmacological data set, respectively.
We used the predictive toxicology challenge subsets ptcfm, ptcmm, ptcfr, and ptcmr,
as well as the bbb data set to compare ISOAK to a related graph-based approach from
the literature, the optimal assignment kernel (Fr¨ ohlich et al., 2005a, 2006).
Algorithms
We employed a soft margin, C-parameter variant of SVMs for binary classiﬁcation, and
a C-parameter variant of SVMs with ²-insensitive loss function for regression. In both
cases, a modiﬁed version of the SVMlight package (Joachims, 1999) was used.
Statistical validation
Performance estimation was done using 10 runs of stratiﬁed 10-fold cross-validation.
Model selection
The SVM parameter C was optimized on the training folds of each cross-validation run
using a uniform grid search in log parameter space, C ∈
©
2k ¯
¯ k ∈ N,−10 ≤ k ≤ 11
ª
.
For SVM regression, we set ² = 3σ
p
lnn/n, as proposed by Cherkassky and Ma (2004).
Kernel parameters were optimized by grid search (Table 2.6).
















¯ k ∈ N,−10 ≤ k ≤ 3
ª
Performance measures
We used the average (over all runs and cross-validation folds) percentage of correctly
classiﬁed samples, and the correlation coeﬃcient (Matthews, 1975; Baldi et al., 2000)
r =
tp · tn − fp · fn
p
(tp + fn)(tp + fp)(tn + fp)(tn + fn)
, (2.89)
where tp, tn, fp, fn are the numbers of true positives, true negatives, false positives and










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.7 shows, for each data set, the best performing parametrization of each method.
On 10 out of 12 data sets, ISOAK outperforms standard kernel/descriptor combinations
as well as the optimal assignment kernel. On the two remaining data sets, our method
performs about as good as its competitors. In Table 2.7a, the correlation coeﬃcients of
the baseline methods were within a standard deviation of ISOAK results, except on the
cobra:ppar data set. In Table 2.7b, performance diﬀerences were within one standard
deviation for two data sets, ptcmr and bbb, and above that for the remaining three data
sets ptcfm, ptcmm, and ptcfr. The results for the latter were consistent with those of
other studies (Byvatov et al., 2003; M¨ uller et al., 2005).
2.5 Conclusions
Graph kernels provide a direct way to compare the topological structure of two com-
pounds without resorting to vectorial descriptors. In this chapter, we gave an overview
of graph kernels, and, introduced and retrospectively evaluated the iterative similarity
optimal assignment graph kernel.
2.5.1 Summary
Graph kernels are formal similarity measures deﬁned directly on graphs such as the an-
notated molecular structure graph. They correspond to inner products, and are suitable
for kernel-based machine learning approaches to virtual screening. Three major types
of graph kernels have been proposed in the literature so far, based on random walks,
subgraphs, and optimal vertex assignments. By combining the latter with an iterative
graph similarity scheme, we develop the iterative graph similarity optimal assignment
kernel. We give an iterative algorithm for its computation, prove the convergence of
the algorithm and the uniqueness of the solution, and provide an upper bound on the
required number of iterations necessary to achieve a desired precision. In a retrospec-
tive virtual screening study using several pharmaceutical and toxicological data sets, our
kernel consistently improved performance over chemical descriptors and other optimal
assignment type graph kernels.
2.5.2 Graph kernels and virtual screening
Graph kernels (Section 2.2), i.e., positive deﬁnite measures of graph similarity for use
with kernel-based machine learning, are a recent9 and active10 area of research.
Relevance
Graph kernels were retrospectively evaluated for use in virtual screening, ADME/tox-
icity prediction, and various bioinformatics tasks, with considerable success (Subsec-
tion 2.2.7). Prospective virtual screening studies using graph kernels are still rare; in
the end, it is such studies that will prove whether graph kernels are indeed useful for
ligand-based virtual screening. The prospective study conducted in Chapter 4 for novel
inhibitors of the peroxisome proliferator-activated receptor γ using the ISOAK graph
kernel developed in this chapter provides ﬁrst positive hints in this direction.
9Starting perhaps with convolution kernels on structured data (Haussler, 1999), with early contribu-
tions by Tsuda et al. (2002) and G¨ artner et al. (2003).
10See, e.g., Borgwardt (2007); Mah´ e and Vert (2009); Demco (2009); Vishwanathan et al. (2009).96 2 A kernel based on iterative graph similarity
Adaptation to molecular graphs
Graph kernels are a compromise between expressivity and computational complexity,
i.e., they trade in separation capability for runtime eﬃciency (p. 64). Molecular graphs
have speciﬁc characteristics (Subsection 2.1.3), such as small size and bounded vertex
degree. Graph kernels designed for molecular graphs can exploit these properties, attain-
ing higher expressivity than general-purpose graph kernels at acceptable computational
cost. Consequently, eﬀorts are being made to develop graph kernels specialized to molec-
ular graphs (Ralaivola et al., 2005; Fr¨ ohlich et al., 2006; Rupp et al., 2007; Smalter et al.,
2008; Demco, 2009). This work contributes to such eﬀorts.
2.5.3 Iterative similarity optimal assignment kernel
The ISOAK graph kernel (Section 2.3) was designed to take advantage of the charac-
teristics of molecular structure graphs. We discuss some of its properties, the obtained
results, and compare it with other graph kernels.
Positive deﬁniteness
It is currently not known whether ISOAK is positive deﬁnite (p. 71), but empirical evi-
dence suggests that this is the case for α → ∞. Although positive deﬁniteness is desirable
for use with kernel-based machine learning because it allows globally optimal solutions,
useful indeﬁnite kernels exist, e.g., the sigmoidal kernel k(x,x0) = tanh(κhx,x0i − ϑ),
with κ,ϑ > 0 (Sch¨ olkopf, 1997). See Haasdonk (2005) for SVMs with indeﬁnite kernels.
Parameter settings
We do not provide a single set of default parameter values because a good choice of
parameters depends on the problem at hand (Table 2.7), in particular the choice of
vertex and edge kernel. In the absence of any other information, a value of α = 7
8 seems
a reasonable choice from practical experience.
Results
From Table 2.7, ISOAK seems to perform as good as CATS2D and Ghose-Crippen frag-
ment descriptors, with reduced variance, and slightly better than the optimal assignment
kernels of Fr¨ ohlich et al. (2005a, 2006), at the cost of higher variance. In Chapter 4,
we apply ISOAK together with vectorial descriptors, leading to signiﬁcantly improved
results. This suggests that graph kernels might complement traditional chemical de-
scriptors.
Comparison with other graph kernels
ISOAK combines global and local graph similarity in a unique way, setting it apart from
other graph kernels.
Random walk kernels (Subsection 2.2.2) implicitly represent molecular graphs by
weighted sequences, whereas subgraphs are often believed to be more relevant for chem-
ical problems. The random walk model requires a choice of start, transition and ter-
mination probabilities, which on the one hand increases the number of free parameters,
but on the other hand provides the possibility to adapt the kernel to problem-speciﬁc
requirements, e.g., up-weighting of local reactivity centers.2.5 Conclusions 97
Tree and cyclic pattern graph kernels (Subsections 2.2.3 and 2.2.4) rely on predeﬁned
subgraphs. These may be relevant for an application, but do not have to be so in general.
Tree kernels have runtime super-exponential in the maximum vertex degree; even for the
low degrees of molecular graphs, this constant is quite high, i.e., 72·7 ≈ 1011.8.
The optimal assignment kernels of Fr¨ ohlich et al. (2005a, 2006) are most similar to
ISOAK, with the diﬀerence lying in the deﬁnition of pairwise vertex similarity: Where
the former employ a ﬁxed topological distance, ISOAK uses a recursive deﬁnition that
is conceptually more related to the equilibrium states of Markov chains.
ISOAK shares one advantage with optimal assignment kernels in that it provides
additional, interpretable information in the form of the pairwise vertex similarity matrix
and the computed optimal assignment (Figures 2.10, 2.11).
2.5.4 Outlook
We propose ideas for further research on ISOAK, as well as graph kernels and graph
models for ligand-based virtual screening.
Iterative similarity optimal assignment kernel
We propose ideas for further development of ISOAK:
• Vertex and edge annotation: Other vertex and bond annotations exist, and might be
useful for ligand-based virtual screening with ISOAK, e.g., quantum chemical atom
and bond properties, and, E-state indices (Kier and Hall, 1990, 1999).
• Completeness of ISOAK: In the limit of maximum recursive similarity α → 1 and
inﬁnite precision ² → 0, every vertex inﬂuences the similarity of all other vertices,
and ISOAK might be complete, i.e., able to separate all non-isomorphic graphs (Fig-
ure 2.13). Note that this is in accordance with the complexity results of G¨ artner et al.
(2003, p. 64) due to the increase in runtime (p. 83).
• Neighborhood contiguity: A disadvantage of ISOAK seems to be that vertices are
assigned individually, i.e., no attention is paid to preserve neighborhoods in the as-
signment (Figure 2.13a). Consider matching the structure graph of benzene, where
all vertices and edges are identical, against itself. The similarity matrix is the all-ones
matrix, and all assignments are optimal. However, assignments that map neighbors of
vertices to neighbors of the assigned vertices are preferable. In non-isomorphic graphs,
preserving neighborhood contiguity might well be worth small losses in assignment
strength. The optimal assignment algorithm (Algorithm 2.2) could be modiﬁed by
including neighborhood contiguity in the optimality criterion.
• Multiple alignment: ISOAK can be used to rigidly align two compounds by ﬁnd-
ing a transformation matrix (translation and rotation) that minimizes the root mean
squared error of the diﬀerences in the three-dimensional coordinates of assigned ver-
tices; ﬂexible alignments can be achieved by incorporating conformational ﬂexibility.
To align multiple compounds, the ﬁnal assignment in Algorithm 2.1 needs to be opti-
mal with regard to multiple similarity matrices, requiring the assignment to consider
the similarity matrices between all pairs of graphs simultaneously. Alternatively, a
stochastic approach in the spirit of simulated annealing (Salamon et al., 2002) might
be possible, where the pairwise similarities between vertices of diﬀerent graphs play


























































(a) ISOAK assignments for α = 10−4 and
² = 10−1; overall normalized similarity is 1.
Since there is essentially no recursive simi-
larity, pairwise vertex similarity reduces to
element type identity and carbon atoms are


























































(b) ISOAK assignments for α = 9
10 and ² = 10−1;
overall normalized similarity is 0.78. The high
impact of recursive similarity assures that each
vertex is unique with respect to its neighborhood,
as the compounds are not symmetric, and vertices
are assigned correctly, with the mismatch in the






(c) Decenoic acid (top) and
9-decenoic acid (caproleic
acid, bottom).
Figure 2.13 Completeness and neighborhood contiguity
of ISOAK. Shown are assignments of decenoic and capro-
leic acid (c) for α close to 0 (a) and α close to 1 (b). Com-
putations are with Dirac kernels on element and bond type
annotations. In (a) and (b), colors indicate assigned con-
tiguous neighborhoods in decenoic acid (top) and capro-
leic acid (middle), with red indicating lone vertices. As-
signment strength (bottom) is shown color-coded from red
(highest similarity) to black (lowest similarity).
Graph kernels
The basic idea of graph kernels for ligand-based virtual screening is to exploit properties
of molecular structure graphs (Subsection 2.1.3) to increase expressivity while retaining
eﬃcient computability. We propose research ideas for graph kernels on molecular graphs:
• Eﬃcacy of complete graph kernels: Complete graph kernels (p. 64) are thought to be
desirable due to maximum expressivity, but are hard to compute (Ramon and G¨ artner,
2003). Molecular graphs have bounded degree (p. 63); for such graphs, the graph
isomorphism problem is in P (Luks, 1982), rendering the complete binary isomorphism
graph kernel k(G,G0) = 1{G isomorphic to G0} eﬃciently computable. While this kernel
is complete, it is unlikely to be useful. We propose to investigate the conditions under
which a complete graph kernel is useful for ligand-based virtual screening.
• Eﬃciency considerations: The worst-case runtime of an algorithm is of obvious
practical importance, but is not the only relevant measure of eﬃciency. Graph ker-
nels eﬃcient in the average-case, with empirical underlying input distributions, or,
randomized graph kernels might provide valuable alternatives. An example of the
latter is given by Shervashidze et al. (2009) who introduce graphlets (small subgraph
sampling) to compare large graphs.References 99
• Characteristic subgraphs kernel: Consider the feature space indexed by all subgraphs.
Computing the inner product in this space is NP-hard (G¨ artner et al., 2003) due to
the large number of subgraphs. However, not all subgraphs will be equally relevant
for a given data set. Similar to the determination of scoring matrices for sequence
alignments (Eddy, 2004), one could enumerate all subgraphs (up to a given size) in
a data set and a reference background data set, compute their log-odds scores, and
retain only those subgraphs which are frequent in the training set, but rare in the
background set. Although the initial computational requirements are high, compu-
tation of the background and training data set subgraphs has to be done only once,
while restricting the feature space to the characteristic (or relevant) subgraphs allows
eﬃcient computation of the inner product, and might also retain eﬃcacy in chemin-
formatics learning tasks. Another advantage of this approach is the interpretability of
the discovered subgraphs; it also provides a measure of similarity between data sets.
Graph models
We propose an idea for generative use of graph models in ligand-based virtual screening:
• Generative models: Instead of using graph models to compare existing molecular
graphs, one could use them as generative models to create new structure graphs, e.g.,
to suggest new compounds in de novo design. One approach, similar to modeling RNA
secondary structure with stochastic context-free grammars (Nebel, 2004; Dowell and
Eddy, 2004; Metzler and Nebel, 2008), is to create a stochastic grammar generating
molecular graphs, learn its probabilities from a set of ligands, and use it to generate
new compounds with similar structure and thus properties. Ideally, the grammar
would use fragments as terminal symbols and known chemical reactions as rules to
ensure synthetic feasibility.
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Spectral dimensionality reduction methods like principle components analysis are tools
for determining the intrinsic dimensionality and structure of data, and for their visual-
ization. In this chapter, we demonstrate how graph kernels can improve chemical data
visualization using kernel versions of spectral dimensionality reduction methods, and,
provide proof of principle for novelty detection by kernel principle components analysis.
The latter opens up a new way to address the negative samples problem, i.e., virtual
screening using only experimentally conﬁrmed positive samples.
3.1 Introduction
Classiﬁcation algorithms like support vector machines (Subsection 2.4.3) are discrimina-
tive models in the sense that they discriminate between two or more classes of samples.
Like Gaussian process regression (Subsection 4.2.4), they are supervised techniques that
exploit given structural information in the form of labels. In contrast, dimensionality
reduction methods are descriptive in nature, and, as unsupervised techniques, aim to
discover structure in data.
The intrinsic dimensionality of chemical data sets is, as a rule, considerably lower
than the dimensionality of the containing chemical descriptor space (p. 35). Dimension-
ality reduction methods aim at the identiﬁcation of the internal structure of such data,
enabling visualization (by reducing to two or three dimensions), feature selection (by
determining the most relevant descriptors, e.g., sparse principle components analysis),
chemical interpretation (by clustering), and novelty detection (by measuring how well
new samples ﬁt into the established low-dimensional model of the training data). In the
following, we demonstrate how kernel-based versions of established spectral dimensional-
ity reduction algorithms, more recent algorithms, and graph kernels can improve results
for these tasks, and how the projection error of kernel principle component analysis can
be used for novelty detection.106 3 Dimensionality reduction and novelty detection
3.2 Spectral dimensionality reduction
Spectral dimensionality reduction methods rely on the spectrum of a data set, e.g., the
eigenvalues of a matrix constructed from the training samples. We provide details for
the perhaps best-known algorithm, (linear) principle component analysis, together with
its kernel variant, and brieﬂy mention other spectrum-based methods.
3.2.1 Principle component analysis
Principle component analysis (PCA) is a linear dimensionality reduction technique dat-
ing back to Pearson (1901) and made popular by Hotelling (1933a,b). It determines
orthogonal directions (uncorrelated variables) of maximum variance in a data set, based
on an eigendecomposition of the empirical covariance matrix. These directions are called
principle components (PC). In the following, we brieﬂy describe PCA; for further infor-
mation, see the book by Jolliﬀe (2004). Since we are interested in statistical inference,
we restrict ourselves to the sample PCA scenario (as opposed to the population PCA
scenario, where covariances are known a priori).
Computation
Consider an unsupervised learning setting (p. 27) with i.i.d. vectorial training data
x1,...,xn ⊂ Rd. PCA determines a new coordinate system based on the variance-
covariance structure of the training data. If the latter occupy a linear subspace of lower
dimensionality than the embedding space Rd, the ﬁrst PCs can be used to approximate
this subspace. Whether this approach is appropriate or not depends on the structure of
the data (Figure 3.1).
The covariance covar(A,B) = E
¡
(A − E(A))(B − E(B))
¢
of two random variables A
and B measures how much A and B vary together.1 In the case of centered data, where




the centered training data. Let ˜ X = (˜ x1,..., ˜ xn)




















T ˜ X (3.1)
the empirical covariance matrix of the centered samples.2 It is symmetric (due to symme-
try of covariance) and positive semi-deﬁnite.3 Let λ1,...,λd ∈ R≥0 and v1,...,vd ∈ Rd
denote the non-negative eigenvalues (in descending order) and corresponding orthonor-





h˜ xk,vi ˜ xk = λv, (3.2)
1If covar(A,B) is positive (negative), A and B tend to increase (decrease) together. Independence
of A and B implies covar(A,B) = 0, but not vice versa. An example for the latter is A ∈ {1,2,3} with
probability
1
3 each, and B = 1{A=2}.
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 ˜ Xv, ˜ Xv










(a) Linear data set pca1. n = 60 samples
of ¯ x + (x,x) + (n1,n2) with ¯ x = (1
4, 1
2), x ∼
U(−1,1) and n1,n2 ∼ N(0, 1
20). The eigen-





are λ1 = 0.627
and λ2 = 0.002; the corresponding PCA coor-
dinate system axes (black arrows) are unique
up to sign. The ﬁrst PC carries 99.6% of the
total variance. Here, linear PCA successfully











(b) Non-linear circular data set pca2. n = 60
samples of ¯ x+(sinx,cosx)+(n1,n2) with ¯ x =
(1
4, 1
2), x ∼ U(0,2π) and n1,n2 ∼ N(0, 1
20).





λ1 = 0.522 and λ2 = 0.504. The similar
eigenvalues indicate that the PCA coordinate
system axes (black arrows) are arbitrary and
mainly determined by noise. Here, linear PCA
fails to capture the structure of the data.
-0.5 0.0 0.5 1.0 1.5
PC 1
(c) Projection of pca1 data on the ﬁrst PC.
-0.5 0.0 0.5 1.0 1.5
PC 1
(d) Projection of pca2 data onto the ﬁrst PC.
Figure 3.1 Two synthetic data sets for PCA. Data set pca1 is suitable for linear PCA,
whereas capturing the structure of data set pca2 requires a non-linear form of PCA
(Subsection 3.2.2).
Since the left hand side is a projection onto the subspace spanned by ˜ x1,..., ˜ xn, all
eigenvectors v with λ 6= 0 (and only these) lie in this subspace.
The projection of a sample ˜ xi onto the k-th sample principle component hvk,·i is
hvk, ˜ xii. Let V ∈ Rq×d denote the matrix with rows v1,...,vq. The projection of
˜ x1,..., ˜ xn onto the subspace spanned by the ﬁrst q PCs is given by the rows of ˜ XV T.
These vectors use PC coordinates; the global coordinates of these points are given by
hvk,·ivk and ˜ XV TV , respectively.4
The projection error (also reconstruction error) pq(˜ x0) measures the Euclidean dis-
tance between a sample ˜ x0 and its representation using the ﬁrst q PCs,
pq(˜ x0) =
°
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The second equality follows from Pythagoras theorem.5 For several test samples















Figure 3.2 illustrates projection coordinates and reconstruction error. Algorithm 3.1
summarizes the computations.
Properties
It can be shown (Jolliﬀe, 2004) that v1 maximizes the sample variance of hv1, ˜ xii subject
to the constraint kv1k = 1, that v2 maximizes the sample variance of hv2, ˜ xii subject to
kv2k = 1 and the additional constraint of zero correlation between hv1, ˜ xii and hv2, ˜ xji,
and so on. In general, vk maximizes the variance of the training data projected onto it
under the constraints of unit length and orthogonality to the previous v1,...,vk−1. The
sample PCs have the following properties (Jolliﬀe, 2004; Sch¨ olkopf and Smola, 2002):
• The ﬁrst q PCs carry more variance than any other q orthogonal directions. Con-
versely, the last q PCs carry less variance than any other q orthogonal directions.
• Sample representations using the ﬁrst q PCs minimize the squared reconstruction error
with regard to all other sets of q directions.









Further properties can be established under assumptions about the distribution of the
samples. For pairwise diﬀerent eigenvalues, the subspace deﬁned by the PCs is unique up
to sign; for equal eigenvalues, the subspace is unique up to sign and order (Figure 3.1b).
See Subsection 3.2.6 on how to choose the number of eigenvalues q. Section 3.3 provides
an in-depth example of using PCA to learn the concept of fatty acids.
In summary, PCA is a linear dimensionality reduction method based on an eigende-
composition of the empirical covariance matrix of the data. Eigenvectors correspond to
the principal axes of the maximum variance subspace, whereas eigenvalues correspond
to the projected variance of the input data along the eigenvectors. PCA is deterministic,
parameter-free (given q), and globally optimal, but limited to second-order statistics.
3.2.2 Kernel principle component analysis
PCA can be expressed in terms of inner products (Equation 3.2); therefore, the kernel
trick (p. 28) can be applied, resulting in implicit PCA in feature space, or kernel PCA.
Since kernel PCA is linear PCA in feature space, it retains the properties of the latter.
Although other non-linear generalizations of PCA such as principal curves (Hastie and
Stuetzle, 1989) exist, kernel PCA has become widely popular since its introduction
by Sch¨ olkopf et al. (1998). It is prototypical in the sense that many other spectral
dimensionality reduction algorithms can be reduced to it.




















. This is due to the orthonormality of the PCs, and global
coordinates being conﬁned to PCA subspace. Technically, it follows from V V





for a matrix M and vectors x, y of compatible dimensions.

























Figure 3.2 Projection coordinates and re-
construction error. When projected onto the
ﬁrst PC v1 = (0.7046,0.7096), the sample





= 1.334 and global coordinates ­
v1, ˜ x
®
v1 = (0.7986,0.8042). Its projection
error is k˜ x − (0.7986,0.8042)k = 0.5617.
The projection error can also be computed
using Pythagoras theorem as p =
p
h2 − g2.
Algorithm 3.1 Principal component analysis training, projection, and projection error.
Samples do not have to be centered.
(a) Principal component analysis training.
Input: sample matrix X ∈ Rn×d, number of PCs q ∈ R
Output: eigenvalues λ1,...,λq, eigenvector matrix V = (v1,...,vq)
T ∈ Rq×d






2 Compute eigenvalues λ1,...,λq and corresponding eigenvectors v1,...,vq of C.
3 Normalize eigenvectors vi by scaling with kvik
−1.
4 Return λ1,...,λq and V = (v1,...,vq)
T.
(b) Principal component analysis projection.
Input: test sample matrix X0 ∈ Rm×d, eigenvector matrix V ∈ Rq×d
Output: matrix of projected samples in PC or global coordinates as row vectors
1 For principle component coordinates, compute XV T.
For global coordinates, compute XV TV .
(c) Principle component analysis projection error.
Input: test sample matrix X0 ∈ Rm×d, eigenvector matrix V ∈ Rq×d





X0(Id×d − V TV )X0T´
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Computation
Let ˜ Φ : X → H denote a map from input space to feature space with
Pn
i=1 ˜ Φ(xi) = 0,






®˜ Φ(xk) = λv. (3.5)
Since eigenvectors v with λ 6= 0 lie in the span of ˜ Φ(x1),..., ˜ Φ(xn), we can replace






for all k, 1 ≤ k ≤ n. (3.6)





where α = (α1,...,αn)






























­˜ Φ(xj), ˜ Φ(xi)















­˜ Φ(xj), ˜ Φ(xi)











α = nλ ˜ Kα, (3.8)
where ˜ K =
³­˜ Φ(xi), ˜ Φ(xj)
®´
i,j=1,...,n
is the kernel matrix corresponding to ˜ Φ. The
following Lemma shows that for our purpose, it is suﬃcient to instead solve
˜ Kα = nλα. (3.9)
Lemma (Sch¨ olkopf et al., 1999). Solving ˜ Kα = nλα and ˜ K
2
α = nλ ˜ Kα yields the
same solutions of e Cv = λv in feature space with respect to span
¡˜ Φ(x1),..., ˜ Φ(xn)
¢
.
Proof. Let µ1,...,µn ∈ R≥0 and b1,...,bn ∈ Rn denote the eigenvalues (in descending
order) and corresponding orthonormal eigenvectors of ˜ K. Assume that λ, α satisfy


















i = nλνiµi for all i ⇐⇒ µi = nλ ∨ µi = 0 ∨ νi = 0 for all i,
(3.10)
where the second line follows from the orthogonality of the bi. Applying the same














⇐⇒ νiµi = nλνi for all i ⇐⇒ µi = nλ ∨ νi = 0 for all i.
(3.11)
7See the following page for a way to deal with non-centered samples.3.2 Spectral dimensionality reduction 111
All solutions of Equation 3.11 satisfy Equation 3.10. Conversely, solutions satisfying
(3.10) but not (3.11) have some µi = 0, and therefore diﬀer only by multiples of eigenvec-
tors bi of ˜ K with eigenvalue 0. While such solutions lead to diﬀerent coeﬃcients α, they
do not lead to diﬀerent solution eigenvectors v with respect to span
¡˜ Φ(x1),..., ˜ Φ(xn)
¢

















We derive a normalization condition on α by normalizing in feature space:
























­˜ Φ(xi), ˜ Φ(x0)
®
. Global coordinate representations are not meaningful in a
kernel PCA context, since they require explicit representations of feature space vectors.
Non-centered kernels
To deal with the restriction of samples being centered in feature space, we express ˜ K in
terms of the original kernel matrix K:
˜ K =

























































































































where αk,i ∈ R are coeﬃcients of the k-th non-zero eigenvalue solution to Equation 3.9.112 3 Dimensionality reduction and novelty detection
Algorithm 3.2 Kernel principle component analysis and projection of test samples.
(a) Kernel principle component analysis training.




Output: eigenvalues nλ1,...,nλq, coeﬃcient matrix A = (α1,...,αq)
T ∈ Rq×n
1 Compute centered kernel matrix ˜ K ← (In×n − 1
n1n×n)K(In×n − 1
n1n×n).
2 Compute non-zero eigenvalues nλ1,...,nλq and eigenvectors α1,...,αq of ˜ K.
3 Normalize eigenvectors αi by scaling with 1/
p
nλi hαi,αii.
4 Return nλ1,...,nλq and A = (α1,...,αq)
T.
(b) Kernel principle component analysis projection.
Input: kernel matrices K ∈ Rn×n, L ∈ Rn×m, coeﬃcient matrix A ∈ Rq×n










Let A = (α1,...,αq)
T ∈ Rq×n denote the coeﬃcient matrix of the ﬁrst q PCs and
let L ∈ Rn×m with Li,j = k(xi,x0
j) denote the kernel matrix between training and test
samples. The projection of the test samples x0
1,...,x0
m onto the ﬁrst q PCs is then given

























Algorithm 3.2 summarizes kernel PCA training and projection computations.
Remarks
We conclude with some remarks on kernel PCA (Sch¨ olkopf and Smola, 2002):




PCs with non-zero eigenvalues,





• Both linear and kernel PCA allow the reconstruction of the training samples based on
all PCs. Linear PCA, if successful, also allows good reconstruction of the samples using
only the ﬁrst PCs. For kernel PCA, however, a pre-image in X of the approximate
reconstruction in H does not necessarily exist.
• Since centering the training data renders kernel PCA translation invariant, condition-
ally positive deﬁnite kernels can be used.
3.2.3 Isometric feature mapping
The isometric feature mapping (Isomap) algorithm (Tenenbaum et al., 2000) assumes
that the data lie on a Riemannian manifold, i.e., in a locally Euclidean subspace. It ﬁrst
approximates geodesic distances (shortest paths along the manifold) between the train-
ing data and then uses classic multidimensional scaling (Cox and Cox, 2001; Borg and3.2 Spectral dimensionality reduction 113
Groenen, 2005) to ﬁnd an embedding preserving these distances. It can be formulated
as kernel PCA with a special kernel (Ham et al., 2004).
Computation
For geodesic distance approximation, a symmetric neighborhood graph G = (V,E) is
computed, e.g., using k-nearest-neighbors. Then, the all-pairs-shortest-paths problem
(Cormen et al., 2001) is solved on G, e.g., with the Floyd-Warshall (Floyd, 1962) algo-
rithm.8 The length of a shortest path in G between two vertices is an approximation
of the distance along the underlying manifold between the corresponding samples. Let


















yields the Isomap solution up to a factor of
√
λi (Ham et al., 2004). Note that this centers
the kernel matrix (removing the need for this step in Algorithm 3.2). Algorithm 3.3
summarizes the procedure.
Positive deﬁniteness
It depends on S whether the kernel matrix in Equation 3.16 is positive deﬁnite. If S
contains Euclidean distances, e.g., if the geodesic distances are proportional to Euclidean
distances in the parameter space of the manifold, K is positive deﬁnite. This is due to
negative quadratic distance kernels k(xi,xj) = −kxi − xjk
β being conditionally positive
deﬁnite for 0 ≤ β ≤ 2 and Equation 3.16 being positive deﬁnite if and only if −S is
conditionally positive deﬁnite (Sch¨ olkopf and Smola, 2002, pp.49–51).
Out-of-sample extension
There are several ways to extend Isomap to samples not available during training. We
follow Bengio et al. (2004a) by using the precomputed neighborhood graph for geodesic















































where S0 ∈ Rn×m denotes the matrix of squared geodesic distances between training and
test samples. For details see Algorithm 3.3.




. Faster algorithms are available, e.g.,





. For sparse graphs, |V | applications of Dijkstra’s single-source-











since |E| is upper-bounded by k |V | in k-
nearest-neighbor graphs. This can be improved using more complicated techniques, e.g., Pettie and




, where α(·,·) is the inverse Ackermann function (a
constant for all practical purposes). The advantage of the Floyd-Warshall algorithm lies in its simplicity.114 3 Dimensionality reduction and novelty detection
Algorithm 3.3 Isometric feature mapping (Isomap). Training and projection of test
samples are done using kernel PCA (Algorithm 3.2), with projections scaled by
√
λi.
The necessary matrices K, L, and M are computed by this algorithm.
(a) Isomap training. If distance matrices are given, step 1 can be omitted. Note that
due to the symmetry in the construction procedure, vertices of G can have degree greater
than k. G may be disconnected, which can be tested after step 3.
Input: input kernel matrix ˜ K ∈ Rn×n, number of nearest neighbors k ∈ N
Output: Isomap kernel matrix K ∈ Rn×n, eigenvalues nλ1,...,nλq, coeﬃcient matrix
A = (α1,...,αq)
T ∈ Rq×n, squared geodesic distances S ∈ Rn×n




T − 2K + 1ndiag(K)
T ∈ Rn×n (p. 29).
2 Construct k-nearest neighbor graph G = (V,E) by setting V ← {1,...,n} and for
each vi ∈ V inserting an undirected edge to its k nearest neighbors as given by D.
3 Compute matrix S ∈ Rn×n of squared shortest path lengths between all vertices,
using, e.g., the Floyd-Warshall algorithm (Footnote 8 on p. 113).
4 Do kernel PCA (Algorithm 3.2) with K ← −1
2S.
To deﬁne G using ²-balls instead of k-nearest neighbors, replace step 2 by
2 Construct neighborhood graph G = (V,E) by setting V ← {1,...,n} and for each
vi ∈ V inserting an undirected edge to all neighbors vj with Di,j < ².
(b) Isomap projection. In case of ties in step 2, shortest path length should be computed
using all closest training samples.
Input: input kernel matrices ˜ K ∈ Rn×n, ˜ L ∈ Rn×m, and ˜ M ∈ Rm, Isomap kernel ma-
trix K ∈ Rn×n, coeﬃcient matrix A = (α1,...,αq)
T ∈ Rq×n, squared geodesic
distances between training samples S ∈ Rn×n
Output: matrix of projected samples (rows)




T − 2L + 1nMT ∈ Rn×m between training and test samples.
2 For each test sample x0
i0, 1 ≤ i0 ≤ m, determine the closest training sample xi
with i ← argmin1≤i≤n Dii0.




4 Set L ← −1
2S0.
5 Do kernel PCA projection (Algorithm 3.2) with K, L, and A.




To reduce computational load, the Isomap authors proposed (de Silva and Tenenbaum,
2003) to use only a (randomly selected) subset of the training samples, called landmark
points, together with a formula for the embedding of the remaining samples. The latter
has been shown (Bengio et al., 2004b) to be equivalent to the Nystr¨ om formula and
therefore to the computation given by Algorithm 3.3.3.2 Spectral dimensionality reduction 115
3.2.4 Other spectral methods
Many other spectral dimensionality reduction methods exist. We give a brief and non-
comprehensive overview.
Laplacian eigenmaps
Laplacian eigenmaps (Belkin and Niyogi, 2002) start with a neighborhood graph G =








|vi| if i = j
−1 if i 6= j ∧ {vi,vj} ∈ E
0 otherwise
, (3.20)
with D the diagonal matrix of vertex degrees, and A the adjacency matrix (p. 61).
Under certain conditions, the graph Laplacian is an approximation of the Laplace-
Beltrami operator, whose eigenfunctions are mappings that optimally preserve the lo-
cality of the data. Laplacian eigenmaps can be formulated as kernel PCA with the
pseudo-inverse of the graph Laplacian as kernel (Ham et al., 2004).
Diﬀusion maps
In diﬀusion maps (Coifman and Lafon, 2006), a normalized kernel matrix derived from
a neighborhood graph, e.g., the normalized graph Laplacian, is interpreted as deﬁning
a random walk on this graph. This correspondence relates geometric properties of the
manifold to properties of the corresponding ergodic Markov chain, with structure given
by the neighborhood graph and transition probabilities proportional to the edge weights
given by the kernel. Depending on parametrization, the normalized graph Laplacian,
the Fokker-Planck operator, and the Laplace-Beltrami operator can be retrieved.
Locally linear embedding
Locally linear embedding (LLE; Roweis and Saul, 2000) uses linear interpolation to
locally approximate the underlying manifold. A neighborhood graph deﬁnes the size of
these locally linear patches; the linear approximations are computed by solving a least
squares problem. Locally linear embedding can be formulated as kernel PCA (Ham
et al., 2004). It can be seen as an empirical version of Laplacian eigenmaps (Donoho
and Grimes, 2003).
Hessian locally linear embedding
Hessian locally linear embedding (also Hessian eigenmaps; Donoho and Grimes, 2003)
is a variant of locally linear embedding related to Laplacian eigenmaps. It replaces the
Laplacian with an operator based on the Hesse matrix of second derivatives deﬁned using
local tangent spaces. For this algorithm, the manifold does not have to be convex.
Local tangent space alignment
Local tangent space alignment (Zhang and Zha, 2004; Wang, 2008), like Hessian locally
linear embedding, starts from a neighborhood graph and constructs local linear approx-
imations of the underlying manifold in the form of tangent spaces. These are aligned to
obtain a global parametrization of the manifold.116 3 Dimensionality reduction and novelty detection
Maximum variance unfolding
Maximum variance unfolding (MVU; also semideﬁnite embedding, SDE; Weinberger
et al., 2004) uses kernel PCA with a data-dependent kernel obtained by solving the
semideﬁnite programming problem maxK Tr(K) subject to
1 K positive semi-deﬁnite,
2
Pn
i,j=1 Ki,j = 0 (samples are centered in feature space),
3 Ki,i − 2Ki,j + Kj,j = kxi − xjk
2 iﬀ {vi,vj} ∈ E or ∃v ∈ V : {vi,v},{v,vj} ∈ E,
where G = (V,E) is the underlying neighborhood graph. The last condition ensures lo-
cal distance preservation; it can be relaxed by the introduction of slack variables (Wein-
berger and Saul, 2006). Similar to landmark Isomap, computation time can be reduced
by approximating K ≈ QK0QT as a product of the kernel matrix between landmark
samples K0 and a matrix Q obtained by solving a sparse system of linear equations
(Weinberger et al., 2005). Unlike in the previously mentioned algorithms, projection of
test samples is not immediately possible as it requires the kernel matrix between training
and test samples.
Minimum volume embedding
Minimum volume embedding (Shaw and Jebara, 2007) is a variant of maximum vari-
ance unfolding that additionally optimizes the eigengap, i.e., the diﬀerence between the










with the same constraints on K as in maximum variance unfolding. A local optimum of
Equation 3.21 guaranteed to improve over initial PCA or MVU solutions can be obtained
by solving a sequence of semi-deﬁnite programs.
For further information on spectral dimensionality reduction, see Bengio et al. (2006);
Saul et al. (2006); Lee and Verleysen (2007).
3.2.5 Projection error-based novelty detection
Novelty detection (p. 27) is the problem of deciding whether new samples come from the
same distribution as the training data. It can be used to address the negative samples
problem (p. 28), i.e., for ligand-based virtual screening using only positive samples.
Idea
Spectral dimensionality reduction methods that allow the projection of new samples onto
the learned manifold can be used for novelty detection by utilizing the projection error
(also reconstruction error). The latter measures the error introduced by representing a
sample using the learned manifold, or, in other words, the distance between a sample
and its projection onto the manifold. If the learned manifold successfully captures the
structure of the training data, the projection error will be low for these and similar test
data. For data that do not lie on the manifold, i.e., data diﬀerent from the training data,
it will be high. Conceptually, this approach is related to multivariate outlier detection,
where samples that are ordinary in the original variables individually may still be outliers
if they do not conform to the covariance structure of the training data.3.2 Spectral dimensionality reduction 117
Kernel PCA projection error
Many spectral dimensionality reduction methods are eﬀectively variants of kernel PCA
with diﬀerent kernels; we therefore focus on the kernel PCA projection error (Hoﬀmann,































is an evaluation of the centered (with respect to the
training samples) kernel ˜ k.9 The second summand can be evaluated using Equation 3.14.

















































































i,j ∈ Rm×m is the kernel matrix of test samples (centered with
respect to the training samples). This is the equivalent of Equation 3.4 in feature
space. Algorithm 3.4 summarizes the procedure. Figures 3.3 and 3.4 show examples
of projection error-based novelty detection.
Decision threshold
Using the projection error for novelty detection requires a threshold τ ∈ R≥0: Test
samples x0 with projection error pq(x0) ≤ τ are considered to belong to the training
samples’ distribution, whereas samples with pq(x0) > τ are considered novel.
The choice of τ controls the trade-oﬀ between false negatives and false positives, i.e.,
between sensitivity and speciﬁcity. It can be based on statistical considerations, e.g.,
the distribution of the projection error over the training samples. This approach allows
statistical bounds on misclassiﬁcation rates.
Choices of τ include the maximum projection error on the training samples and
quantiles, e.g., the 75% or 90% quantiles. The maximum is a poor choice, as it is an
extremal value and highly volatile. Figures 3.3 and 3.4 show projection error decision
surfaces for the maximum and 75% quantile in two example data sets, as well as box
plots of the projection errors.











































































(b) Isolines of second principle component.
Shown are isolines (lines of equal height; black lines) of both principle components; the
isolines run orthogonal to the principle components themselves.
q min µ σ max
1 0.356 · 10−3 0.0445 0.0374 0.161
2 0 0 0 0
q Q0.25 Q0.5 Q0.75
1 0.0139 0.0330 0.0666
2 0 0 0
(c) Projection error statistics of training sam-
ples. q = number of principle components,
min = minimum, µ = mean, σ = standard de-
viation, max = maximum, Q0.25 = 25% quan-




1 0.276 · 10−3 0.529
2 0 0








(e) Decision surface of novelty detection for
thresholds 0.161 (max, solid red line) and
0.0666 (Q0.75, dashed black line) with q = 1.
0.0 0.1 0.2 0.3 0.4 0.5
(f) Projection error box plot (q = 1).
Figure 3.3 Projection error and novelty detection, linear example. 60 training samples
(orange disks) generated as
¡
¯ x + (x,x) + (n1,n2)
¢T with ¯ x = (1
4, 1
2), x ∼ U(−1,1) and
n1,n2 ∼ N(0, 1









The ﬁrst eigenvalue carries 99.5% of the total variance.3.2 Spectral dimensionality reduction 119







(a) Isolines of ﬁrst principle
component.







(b) Isolines of second princi-
ple component.







(c) Isolines of third principle
component.
Shown are isolines (lines of equal height; black lines) of all three principle components;
the isolines run orthogonal to the principle components themselves. The eigenvalues
cover 0.52%, 0.47%, and 0.01% of the total variance. The last eigenvector captures
almost no variance, but encodes the constant-norm invariant of the training data.
q min µ σ max
1 0.0429 0.443 0.219 0.800
2 0.884 · 10−3 0.0496 0.0378 0.166
3 0 0 0 0
q Q0.25 Q0.5 Q0.75
1 0.248 0.447 0.639
2 0.0171 0.0450 0.0705
3 0 0 0
(d) Projection error statistics of training sam-
ples. q = number of principle components,
min = minimum, µ = mean, σ = standard de-
viation, max = maximum, Q0.25 = 25% quan-





1 0.717 0.0206 0.880
2 0.716 0.697 · 10−2 0.880
3 0 0 0
(e) Projection error statistics of test samples.







(f) Decision surface of novelty detection for
thresholds 0.161 (max, solid red line) and
0.0666 (Q0.75, dashed black line) with q = 2.
0.0 0.2 0.4 0.6 0.8
(g) Projection error box plot (q = 2).
Figure 3.4 Projection error and novelty detection, non-linear example. 60 training




T with x ∼ U(−1,1)
and n1,n2 ∼ N(0, 1









2.120 3 Dimensionality reduction and novelty detection
Algorithm 3.4 Kernel principle component analysis projection error. The formula
for centering a kernel matrix of training versus test samples in step 2 follows from a
calculation similar to those of Equation 3.13 and Footnote 9.
Input: kernel matrices K ∈ Rn×n, L ∈ Rn×m, M ∈ Rm×m, coeﬃcient matrix A ∈ Rq×n
Output: vector of projection errors
1 Center M with respect to the training samples,




2 Center L with respect to the training samples,











3.2.6 Choice of eigenvalues
PCA models come with a free parameter, the number q ∈ N of principle components to
use. Aside from statistical validation techniques (Subsection 1.4.3) like cross-validation,
several eigenspectrum-based heuristics for the choice of q exist. In the following, p =
min{dimH,n} denotes the number of available kernel PCs. See Jackson (1993) for an
empirical comparison and further heuristics.
Fraction of total variance







A common choice is x = 0.9.
Largest eigengap
An eigengap (also spectral gap) is the diﬀerence between two eigenvalues (that are neigh-
bors when sorted in descending order), |λi−λi+1|. Choose the q with maximal eigengap,
q = argmax
1≤q≤p−1
|λq − λq+1|. (3.27)
This criterion is theoretically motivated by the Davis-Kahan theorem (Stewart and Sun,
1990) and related to the stability of the PCs under perturbation (von Luxburg, 2007).
Kaiser-Guttman criterion
Guttman (1954) and Kaiser and Dickman (1959) suggest to retain all PCs with eigen-
vectors greater than unity,
q = argmax
1≤q≤p
λq > 1. (3.28)
The motivation for this heuristic is that a PC is not of interest if it explains less variance
than one of the original variables. Note that this reasoning assumes standardization of
the input data in the space that PCA is carried out in.3.3 Learning fatty acids 121
Scree plot
The Scree criterion (Cattell, 1966) chooses q to be the number where the most prominent
bend in the eigenspectrum plot occurs. This subjective (and manual) criterion can be
made more precise by the use of the ﬁrst derivative, at the risk of numerical problems.
The motivation for this heuristic is that eigenvalues of (homoscedastic) random data
tend to be of equal size, resulting in the ﬂattened out terminal part of the eigenvalue
plot.
In empirical tests of projection error-based novelty detection on several artiﬁcial
data sets, none of the above criteria seemed suitable for the determination of q. This is
exacerbated further by the fact that the decision threshold τ and the number of PCs q
are not independent.
3.3 Learning fatty acids
We apply the ideas developed so far to the recognition of fatty acids as a simple but
illustrative example, thereby providing proof of principle for their applicability to vir-
tual screening using only positive samples. The advantage of this example is that the
target concept is simple enough to be completely understood; this extends to observed
phenomena like outliers and the obtained models.
3.3.1 Fatty acids
Fatty acids are the building blocks of lipids, and therefore play an important role in
human health and biochemistry in general.
Deﬁnition
The international union of pure and applied chemistry (IUPAC) deﬁnes fatty acids as
aliphatic monocarboxylic acids derived from or contained in esteriﬁed form
in an animal or vegetable fat, oil or wax. Natural fatty acids commonly have
a chain of 4 to 28 carbons (usually unbranched and even-numbered), which
may be saturated or unsaturated. By extension, the term is sometimes used
to embrace all acyclic aliphatic carboxylic acids. (Moss et al., 1995)
There are over 1000 known natural fatty acids, of which about 20–50 are of common
concern; most of these are straight-chained with an even number of carbon atoms be-
tween 12 and 22. (Gunstone, 1996) Fatty acids are either saturated, having only single
bonds in the hydrocarbon chain, or unsaturated, having at least one double bond be-
tween two carbon atoms. Such a double bond is either in cis or in trans isomeric form
(Scheme 3.1).
For the purposes of this section, we deﬁne fatty acids as single-carbon-chain mono-
carboxylic acids. This excludes branched and cyclic variations, and includes methanoic
acid (COOH), ethanoic acid (C-COOH), and, propanoic acid (CC-COOH). The resulting
concept is simple enough to be expressed as a regular expression (Sipser, 2005):
{C,\C=C/C,\C=C\C}
∗ -COOH,
where the star denotes zero or more selections from the bracketed terms and SMILES
(Weininger, 1988) syntax has been used to denote cis (\C=C/C) and trans (\C=C\C)









Scheme 3.1 cis,trans-5,12-octadecadienoic acid. In fatty acid nomenclature, carbon
atoms are counted starting from and including the carboxylic group COOH carbon,
with numbers specifying the ﬁrst atom of a double bond. The name of Compound 7
consists of the isomeric forms of the double bonds (cis, trans), the positions of the double
bonds (5, 12), the number of carbon atoms (octadeca) and the number of double bonds
(dienoic), giving cis,trans-5,12-octadecadienoic acid. The position of the last double
bond can be indicated by counting from the last carbon, named ω, as, e.g., ω-6. The
butene isomers 8 and 9 exemplify cis and trans isomerism.
Data sets
The fattyacids training data set (Scheme 3.2) contains 85 fatty acids in four series of
structurally similar compounds. In this respect, it mimics the composition of real-world
virtual screening data sets. The nonfattyacids test data set (Scheme 3.3) contains
85 compounds, arranged in 11 series. Two series consist of compounds very diﬀerent
from fatty acids, while the other series consist of decoys structurally similar to fatty
acids in diﬀerent ways.
3.3.2 A linear model
The concept of fatty acids (one carboxylic group attached to the end of a straight carbon
chain) is simple enough to be captured by a linear model, here PCA. The choice of
molecular descriptors is of capital importance, as the model is limited to the information
contained in the descriptors.
The model
For the linear model linfa, we used six simple topological descriptors (Table 3.1),
standardized by subtraction of mean and division by standard deviation (on the fatty-
acids training data set). Constant descriptors were only centered. The descriptors of
the nonfattyacids test data set were standardized using means and standard deviations
computed on the training data set. A PCA resulted in two non-zero eigenvalues λ1 = 2.98
and λ2 = 0.98, with corresponding eigenvectors a1 = (0.316,0,0.317,0.052,0.316,0) and
a2 = (0.071,0,0.001,0.858,0.070,0).
The number of eigenvalues coincides with the two degrees of freedom in fatty acids,
the length of the carbon chain, and the degree of its saturation. The ﬁrst PC weights the
descriptors dc, db, di equally, puts little weight on dd and ignores the other descriptors.
This reﬂects the fact that in the carbon chain, the number of carbon atoms, the number
of bonds and the diameter are proportional to each other. The small weight on dd is
due to the variance in saturation being lower than the variance in chain length in the
training data. With the addition of highly unsaturated fatty acids to the training data,
the weight on dd would increase. The second PC puts weight only on the number of
double bonds dd, reﬂecting the degree of saturation of the carbon chain.3.3 Learning fatty acids 123
Id Structure/name Series
sn











of ω-3 fatty acids
odn







1 ≤ n ≤ 20
4-pentenoic acid (allylacetic acid)
9-decenoic acid (caproleic acid)
11-dodecenoic acid (11-lauroleic acid)
9-tetradecenoic acid (myristoleic acid)
9-hexadecenoic acid (palmitoleic acid)
cis,trans-9,11-octadecadienoic acid (rumenic acid)
9,12-octadecadienoic acid (linoleic acid)
5,9,12-octadecatrienoic acid (pinolenic acid)
6,9,12-octadecatrienoic acid (γ-linolenic acid)
cis,trans,cis-8,10,12-octadecatrienoic acid (jacaric acid)
cis,trans,cis-9,11,13-octadecatrienoic acid (punicic acid)
9,12,15-octadecatrienoic acid (α-linolenic acid)
6,9,12,15-octadecatrienoic acid (stearidonic acid)
11-eicosenoic acid (gondoic acid)
5,8,11-eicosatrienoic acid (mead acid)
5,8,11,14-eicosatetraenoic acid (arachidonic acid)
5,8,11,14,17-eicosapentaenoic acid (timnodonic acid)
13-docosenoic acid (erucic acid)
7,10,13,16-docosatetraenoic acid (adrenic acid)
15-tetracosenoic acid (nervonic acid)
unsaturated
fatty acids
Scheme 3.2 The fattyacids training data set, containing 85 fatty acids in four series
of 40, 10, 15 and 20 molecules each. If not speciﬁed otherwise, all double bonds are in
cis isomeric form. The unsaturated fatty acids of the v series occur naturally, except for
4-pentenoic acid.124 3 Dimensionality reduction and novelty detection
Id Structure/name Series
zan
1 ≤ n ≤ 5 H2O, O2, CO2, N2, HCl tiny molecules
zbn
1 ≤ n ≤ 5










1 ≤ n ≤ 10










1 ≤ n ≤ 5 n-1
alkenes
zfn





1 ≤ n ≤ 10
[2+2n]annulene
³












zh2 R1: OH, R2: OC, R4: CC=C
zh3 R1: C(=O)O, R3–5: O













R1: C, R2: CC
R1–2: benzene
R1: O, R2: CC(=O)C
R1: O, R2: CC(O)C
ketones
Continued on next page...
aInternational non-proprietary names (INN; World Health Organization, 1997); corresponding IU-





Scheme 3.3 The nonfattyacids test data set, containing 85 non-fatty acids in 11 series
of 5, 5, 10, 15, 5, 5, 10, 5, 5, 5 and 15 molecules each. The za and zb series contain
molecules highly diﬀerent from fatty acids, while the other series contain compounds
structurally similar to fatty acids in diﬀerent aspects. If not speciﬁed otherwise, all
double bonds are in cis isomeric form.3.3 Learning fatty acids 125
...continued from previous page.
Id Structure/name Series
zkn






























Table 3.1 Descriptors used for the linfa model. The ﬁrst four descriptors have similar
means, but higher standard deviations on the test data. Descriptors do and dr are
constant on the training data. µ = mean, σ = standard deviation.
fattyacids data set nonfattyacids data set
Id Description min max µ σ min max µ σ
dc number of carbon atoms 1 40 18.0 9.0 0 57 14.7 16.3
do number of oxygen atoms 2 2 2.0 0.0 0 6 2.0 2.1
db number of bonds 3 120 52.4 27.2 1 172 41.3 47.5
dd number of double bondsa 1 6 1.8 1.1 0 11 2.8 3.2
di diameter of structure graph 2 40 18.1 8.9 0 41 10.9 11.3
dr number of rings 0 0 0.0 0.0 0 4 0.4 0.8
aFor the purposes of this computation, aromatic bonds were counted as double bonds.126 3 Dimensionality reduction and novelty detection
Visualization
Projection of training and test data onto the two PCs (Figure 3.5) shows the two types
of variance in the training data (variance of carbohydrate chain length and variance in
saturation). The projection coordinates alone, however, are not suﬃcient to separate
fatty acids from non-fatty acids.
Novelty detection
The projection error allows almost perfect separation of training and test samples: With
the exception of s1 (methanoic acid), all training samples have projection error less than
0.0056, whereas the lowest projection error of the test samples is 0.0748 (Figure 3.6).
Outliers
Training sample s1 (methanoic acid) has projection error 0.0853 and is more than nine
standard deviations away from the mean training sample projection error (more than
60 standard deviations if mean and standard deviation are computed without s1). The
second largest projection error is 0.0056. The fattyacids data set therefore contains
methanoic acid as the only outlier.
This is caused by methanoic acid being diﬀerent from the other fatty acids with regard
to the proportionality between the descriptors dc, db and di that determine the ﬁrst PC.
Normally, a reduction in dc and db is accompanied by a corresponding reduction in di;
going from ethanoic acid (s2) to methanoic acid (s1), however, reduces dc and db, but
leaves di unchanged (the longest shortest path is now between the two oxygen atoms).
Setting the projection error threshold to the largest non-outlier projection error in
the training data allows perfect recognition of fatty acids. Alternatively, training without
the outlier results in a maximum projection error of 0.001 on the training data and a
minimum projection error of 0.0794 on the test data, again allowing perfect recognition.
Invariants
Descriptors constant on the training data can encode invariants of the target concept,
e.g., in the linfa model the descriptors do and dr encode the containment of two oxygen
atoms and no ring structures, respectively. Such descriptors do not vary, and therefore
do not contribute to the PCs. They do, however, increase the projection error because
they are orthogonal to the PC subspace.10 Indeed, the average projection error on the
nonfattyacids test data set decreases by 80.91% from 1.97 down to 0.38 when excluding
descriptors do and dr.
Stability
10 runs of 10-fold stratiﬁed cross-validation11 were used to test the stability of the linfa
model with regard to the composition of the training set, resulting in a ROCAUC of
0.998 ± 0.004 (mean ± standard deviation). The second eigenvalue and the PCs showed
comparably little variation, with ﬁrst eigenvalue variation slightly elevated (Table 3.2).
10Assume that the p-th descriptor is constant, i.e., zero for centered data. Then by deﬁnition the p-th
row and column of the covariance matrix C are zero. Let e = (0,...,0,1,...,0) denote the vector with
p-th entry 1 and let v denote an eigenvector of C with non-zero eigenvalue λ. Then he,vi = vp = 0 due
to (Cv)p = (λv)p ⇔
Pn
i=1 Cp,ivi = λvp ⇔ 0 = λvp.








PC2 (a) Training data set fattyacids.
Chain length increases along the x-
axis, saturation decreases with the y-
axis. The lowest row of points con-
sists of saturated fatty acids (sn se-
ries), the next row contains all fatty
acids with one double bond, and so on,
until the topmost row, which contains
v17, the only pentaenoic fatty acid in
the data set. Note that fatty acids
with equal chain length and number
of double bonds, e.g., ω36 and v2, are
projected onto the same coordinates.









(b) Test data set nonfattyacids.
The embedding follows the rules given
in (a) for the training data, e.g., the
zg series stretches from (−2.8,−0.14)
to (−1.1,8), staying on the left due
to short overall carbon “chain” length
and extending upward due to the large









(c) Training and test data set. The
projection coordinates alone are not
enough to separate fatty acids from
non-fatty acids. Some test data lie
outside of the shown range.
Figure 3.5 Projection of data sets fattyacids (n = 85, blue disks) and nonfattyacids
(n = 85, red disks) onto the two principle components of the linfa model.128 3 Dimensionality reduction and novelty detection
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p.e.
(a) Training data set fatty-
acids.
0.000 0.001 0.002 0.003 0.004 0.005
p.e.
(b) Training data set fatty-
acids without the outlier s1.
æ æ
0 1 2 3 4 5
p.e.
(c) Test data set nonfatty-
acids.
Figure 3.6 Projection error box plots of the linfa model. p.e. = projection error.
Table 3.2 Stability of the linfa model under 10 runs of 10-fold stratiﬁed cross-
validation. Albeit lower in absolute terms, relative to their means the second eigen-
value λ2 shows more variation than the ﬁrst eigenvalue λ1 (9% versus 5%). Variation of
the second PC, albeit low, is about an order of magnitude higher than variation of the
ﬁrst PC. We attribute this to carbon chain length varying more strongly than saturation,
and the latters smaller range of values.
Quantity Mean ± standard deviation
ROC AUC 0.998 ± 0.004
λ1 2.896 ± 0.138
λ2 0.971 ± 0.084
a1 (0.572, 0, 0.575, −0.114, 0.573, 0)± (0.002, 0, 0.000, 0.018, 0.002, 0)
a2 (0.093, 0, 0.010, 0.991, 0.093, 0)± (0.010, 0, 0.011, 0.002, 0.011, 0)
Noise
We investigated the inﬂuence of noise in the form of additional random dimensions
(Figure 3.7). These represent descriptors not related to the target concept. The ﬁrst
added random descriptor leads to a sharp drop in performance, whereas further noise
dimensions have little eﬀect. The number of non-zero eigenvalues increases linearly
with the number of noise dimensions, since each of these constitutes an independent
(orthogonal) attribute of the data.
3.4 Conclusions
Novelty detection based on the projection error of spectral dimensionality reduction
methods can be used for ligand-based virtual screening using only positive samples.
In this chapter, we provided an overview of kernel principle component analysis, an
algorithm underlying many spectral dimensionality reduction methods, and gave proof
of principle of how the projection error can be used in a novelty detection approach to
virtual screening.
3.4.1 Summary
Chemical data sets often lie in subspaces or manifolds of lower dimensionality than the
embedding chemical descriptor space. Dimensionality reduction methods allow the iden-
tiﬁcation of these manifolds, eﬀectively providing descriptive models of the data. For
spectral dimensionality reduction methods based on kernel principle component analy-
sis, the projection error provides a quantitative measure of how well new samples are
described by such models. This can be used for novelty detection, i.e., the identiﬁcation
of compounds structurally dissimilar to the training samples, and thereby for ligand-
based virtual screening using only known ligands. As proof of principle, we show how
the concept of fatty acids can be learned using principle component analysis.3.4 Conclusions 129



























(c) Eigenvalue spectra for Gaussian noise
(gray area). The eigenspectra for 0, 7, 15,
25, 37 and 50 additional noise dimensions are
highlighted (black lines).
Figure 3.7 Inﬂuence of added noise di-
mensions. Random noise descriptors with
zero mean and unit standard deviation
were added. Shown are mean (solid lines)
± standard deviation (dashed lines) of 10
runs of 10-fold cross-validation for each
added noise dimension d, 0 ≤ d ≤ 50.
The eigenvalue spectra for uniform noise
are similar to those of Gaussian noise.
3.4.2 Dimensionality reduction and novelty detection
We discuss aspects related to virtual screening based on novelty detection and dimen-
sionality reduction.
Previous work
Dimensionality reduction methods, including kernel-based spectral dimensionality re-
duction methods, have been intensively researched. In contrast, the application of such
methods to novelty detection in general, and ligand-based virtual screening using only
positive samples in particular, have so far been scarcely investigated. Hoﬀmann (2007)
explores the use of kernel principle component analysis with the Gaussian kernel for
novelty detection on artiﬁcial data and an optical character recognition benchmark data
set. Hristozov et al. (2007) apply self-organizing maps to novelty detection for virtual
screening. To the best of our knowledge, projection error-based novelty detection has
not been applied to ligand-based virtual screening before.
Assessment
Our proposed approach — ligand-based virtual screening via projection error-based nov-
elty detection — is new, and, although backed up by a detailed example in this chapter,
needs further investigation, in particular a prospective study.130 3 Dimensionality reduction and novelty detection
The underlying principle component analysis is deterministic, well understood, opti-
mal with regard to a least squares-criterion, and allows formulation of a kernel version.
Projection error-based novelty detection is a straight-forward and natural extension, de-
terministic, interpretable, and applicable to all spectral dimensionality reduction meth-
ods that allow projection of new test samples onto the learned model.
Drawbacks and unresolved aspects include the potential susceptibility of principle
component analysis to outliers in the data (robustness), and the introduction of two free
parameters (the number of principle components q and the novelty detection cut-oﬀ τ).
It is not clear how our approach performs compared to other methods, most notably
the one-class support vector machine (Sch¨ olkopf et al., 2001) and its variants like the
quarter-sphere support vector machine (Laskov et al., 2004).
3.4.3 Visualization
A classic application of dimensionality reduction methods is visualization of high-di-
mensional data. In anticipation of Chapter 4, we use kernel PCA with diﬀerent kernels
to visualize a data set of 176 agonists of the peroxisome proliferator-activated receptor
(both target and data set are described in detail in Chapter 4, Subsection 4.1 and p. 149).
Figures 3.8 and 3.9 show two-dimensional projections of this data set using linear PCA
and kernel PCA with two chemical descriptors, as well as kernel PCA with the iterative
similarity optimal assignment graph kernel of Chapter 2.
Linear PCA (Figures 3.8a, 3.8b) is not able to resolve the diﬀerent chemical classes in
the data set, the only exception being fatty acids, the class structurally most dissimilar
to the other classes, and the related thiazolidinedione-fatty acid hybrids. We attribute
this to the non-linearity of the relationships between the compound representations.
Kernel PCA with the Gaussian kernel12 did not improve results. This was expected,
as the Gaussian kernel on the one hand is a universal approximator (p. 30), and therefore
suited to novelty detection, but on the other hand requires many dimensions, and is
therefore not suited to visualization.
The iterative similarity optimal assignment kernel (Figure 3.9) clearly improves re-
sults, and the parametrization with atom pharmacophore types retrieves almost all chem-
ical classes of the data set (when considering the tyrosine classes A, B, and C as one
class). Details include the adjoint placement of thiazolidinediones and thiazolidinedione-
fatty acid hybrids, where the hybrids are closer to the thiazolidinediones than to the fatty
acids, closely reﬂecting the structural relationships of the classes.
In summary, visualization using kernel PCA in conjunction with the iterative simi-
larity optimal assignment kernel projected most of the chemically motivated classes of
the data set into separate clusters. This shows that for these data, our approach is
able to reproduce human chemical classiﬁcation in an unsupervised setting, i.e., without
explicit guidance.
3.4.4 Outlook
The introduction of projection error-based novelty detection opens up a new and promis-
ing approach to ligand-based virtual screening. We propose ideas for future research:
• Model selection for q and τ: In this chapter, we chose the number q of model PCs and
the novelty detection cut-oﬀ τ based on visual inspection and retrospective novelty
12The kernel width σ was optimized using a grid search and a cluster separation criterion together
with visual inspection.3.4 Conclusions 131
detection performance, which requires negative samples. This is clearly unsatisfactory
in a prospective setting. We tested several commonly used criteria for the automatic
choice of q (p. 120) without success. A number of model selection approaches in
PCA and novelty detection have been proposed, e.g., the Bayesian approach by Hoyle
(2008), or, the consistency-based approach by Tax and M¨ uller (2004). Some of these
might be suitable for this purpose.
• Incorporation of training sample distribution along the PCs: Consider Figure 3.3.
The point
¡
¯ x + 106(1,1)
¢T has zero projection error, but is far away from all training
samples. This is because the training samples cover only a ﬁnite fraction of the
unbounded PCA model subspace. A possible solution is to incorporate into the novelty
score the likelihood of the test samples with respect to the empirical distribution given
by the projection of the training samples onto each model PC. Alternatively, one could
conduct outlier tests on the same projections. In both cases, restriction to the PCs
avoids the curse of dimensionality.
• Robustness and sparsity: Two drawbacks of PCA are its susceptibility to outliers,
due to the large variance introduced by them, and the density of its solution. Robust
(de la Torre and Black, 2003; Deng et al., 2006; Nguyen and De la Torre, 2009; Huang
et al., 2009) and sparse (Tipping, 2001; Zou et al., 2006; d’Aspremont et al., 2007;
Witten et al., 2009) variants of kernel PCA exist, and could beneﬁt our approach.
• Domain of applicability: The idea of using the projection error to measure distance
to the training sample manifold is not limited to novelty detection. In (kernel) partial
least squares (PLS; also projection to latent structures; Wold et al., 2001), a com-
bination of PCA (Subsection 3.2.1) and multiple linear regression (Rice, 2006), the
projection error is a natural measure of the domain of applicability (p. 49).
• Projection of new samples for minimum volume embedding: A ﬁrst study (Lasitschka,
2009) indicates that minimum volume embedding (p. 116), a spectral dimensionality
reduction method specialized to subspaces of low preset dimensionality, can improve
visualization of chemical data sets even further. Unfortunately, it does not allow for
the projection (error) of new samples (out-of-sample data), as it uses a data dependent
kernel, i.e., it provides no explicit kernel function. Chin and Suter (2008) approxi-
mate the maximum variance unfolding (p. 116) kernel function by a series expansion
of Gaussian basis functions, similar to the approach by Schwaighofer et al. (2005).
Alternatively, one could solve the original optimization problem again for each test
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(a) Linear PCA, MOE 2D descriptors. The
ﬁrst two PCs explain 51.8% of the total vari-
ance; 15 PCs cover 90% of it. While fatty
acids (∗) and thiazolidinedione-fatty acid hy-
brids (H) form distinguishable clusters, other





















à à à à
à
à








ò ò ò ò ò ò
ò ò òò
òò

















ò ò ò ò ò ò ò
+ +














ç ç ç ç
ç çç
ç









ì ì ì ì
ì ì
ô ô ô ô ô ô ô ô ô ô ô ô ô ô ô ô
à









(b) Linear PCA, CATS2D descriptor. The
ﬁrst two PCs explain 46.6% of the total vari-
ance; 14 PCs cover 90% of it. Only fatty acids
(∗, all projected into a single point) form a dis-
tinguishable cluster, while other classes form
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(c) Kernel PCA with Gaussian kernel (σ =
13) on MOE 2D descriptors. The ﬁrst two
PCs explain 34.6% of the total variance; 39
PCs cover 90% of it. Clustering behavior is
marginally better than in (a). Parameter σ
optimized using a grid search and the aver-
age receiver operating characteristic area un-
der curve (p. 43) when ranking against each
compound as performance criterion.
Figure 3.8 Principle component anal-
ysis visualization of the ppar data set.
• = tyrosines A (1–23), ¥ = tyrosines B
(24–52, 176), N = tyrosines C (53–94), +
= thiazolidinediones (95–100), × = indoles
(101–110), ◦ = oxadiazoles (111-133), ∗ =
fatty acids (134–142), ‡ = tertiary amides
(143–148), ¨ = tyrosines N (149–159), H
= thiazolidinedione-fatty acid hybrids (160–
175). Numbers in brackets refer to compound
numbers in R¨ ucker et al. (2006), whose clas-
siﬁcation is similar to, but diﬀerent from the
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(a) Kernel PCA with ISOAK (no vertex ker-
nel, no edge kernel). The ﬁrst two PCs explain
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(b) Kernel PCA with ISOAK (Dirac kernel on
element type as vertex annotation, Dirac kernel
on bond type as edge annotation). The ﬁrst
two PCs explain 32.2% of the total variance;
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(c) Kernel PCA with ISOAK (Dirac kernel on
pharmacophore type as vertex annotation, no
edge kernel). The ﬁrst two PCs explain 31.1%
of the total variance; 48 PCs cover 90% of it.
Figure 3.9 Kernel principle component
analysis visualization of the ppar data set
using the iterative graph similarity opti-
mal assignment kernel. • = tyrosines A
(1–23), ¥ = tyrosines B (24–52, 176), N = ty-
rosines C (53–94), + = thiazolidinediones (95–
100), × = indoles (101–110), ◦ = oxadiazoles
(111-133), ∗ = fatty acids (134–142), ‡ = ter-
tiary amides (143–148), ¨ = tyrosines N (149–
159), H = thiazolidinedione-fatty acid hybrids
(160–175). Numbers in brackets refer to com-
pound numbers in R¨ ucker et al. (2006), whose
classiﬁcation is similar to, but diﬀerent from
the one in Scheme 4.7.134 3 Dimensionality reduction and novelty detection
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The peroxisome proliferator-activated receptor is a nuclear transcription factor involved
in the regulation of lipid and glucose metabolism that plays a crucial role in the devel-
opment of diseases like type 2 diabetes and dyslipidemia. We carry out a prospective
virtual screening study for novel agonists of subtype γ of this receptor, based on Gaus-
sian process regression using molecular descriptors and the iterative similarity optimal
assignment graph kernel developed in Chapter 2. The most potent selective hit (EC50
= 10±0.2µM) is a derivative of truxillic acid, a substance that occurs naturally in plant
cell walls. Our study delivered a novel agonist, de-orphanized a natural bioactive prod-
uct, and, hints at the natural product origins of pharmacophore patterns in synthetic
ligands.
4.1 Target
We describe the peroxisome proliferator-activated receptor (PPAR) as a drug target,
with particular emphasis on the PPARγ subtype (Table 4.1). For further information
on PPARs, see Willson et al. (2000); Mudaliar and Henry (2002); Michalik et al. (2006);
for PPARγ in particular, see Rosen and Spiegelman (2001); Henke (2004).
4.1.1 Overview
PPAR research started when Issemann and Green (1990) cloned the ﬁrst member of
this receptor group.1 Since then, PPARs and their ligands have been intensively inves-
tigated,2 establishing the receptor as a validated drug target (Rau et al., 2006).
1The name PPAR is a misnomer, based upon the early identiﬁcation of the receptor as a target for
substances that cause a proliferation of liver peroxisomes in rodents. See p. 144 for regulatory functions.
2As of 2009-04-03, a search for publications using the keyword PPAR yielded 9869 hits in PubMed
(www.ncbi.nlm.nih.gov/pubmed), and 13151 hits in Web of Science (www.isiknowledge.com).138 4 Peroxisome proliferator-activated receptor
Table 4.1 PPARγ summary, based on Michalik et al. (2006). HRE = hormone response
element, Hs = Homo sapiens, Mm = Mus musculus, Rn = Rattus norvegicus, NR1C3 = nuclear
receptor subfamily 1, group C, member 3 (see Table 4.2).
Property Description
Receptor




structure Hetero-dimer, RXR partner (physical, functional)
HRE core sequ. AACTAGGNCA A AGGTCA (DR-1)
activated genes FATP, acyl CoA-synthetase, aP2 adipocyte lipid-binding protein,
Lpl, UCP-1, PEPCK, Apoa2 (all Mm)
co-repressors NRIP1, SAF-B, TAZ, NCOR1, NCOR2, SMRT
co-activators PGC-2, ARA-70, PGC-1α, PPARGC1B, CREBBP, p300,
CITED2, ERAP140, PPARBP, PRMT-2, PIMT, NCOA1,
NCOA2, NCOA3, NCOA6, SWI/SNF, PDIP
Tissue distribution Adipose tissues, lymphoid tissues, colon, liver, heart (Hs, Mm, Rn)
Important isoforms • PPARγ1 (Hs, Mm): encoded by 8 exons (2 of them γ1-speciﬁc)
• PPARγ2 (Hs, Mm, Rn): 28 additional N-terminal amino acids
• PPARγ3 (Hs): protein indistinguishable from PPARγ1, diﬀer-
ent promoter, only expressed in colon and adipose tissue
Human disease • Obesity, insulin resistance: associated with a mutation in the
ligand-independent activation domain of PPARγ2
• Insulin resistance, type II diabetes mellitus, hypertension: as-
sociated with a mutation of the ligand binding domain
• Syndrome X, metabolic syndrome: associated with dominant-
negative PPARγ mutations
• Atherosclerosis: increased receptor expression in atheroscle-
rotic lesions, macrophages, monocytic cell lines
• Colon cancer: associated with loss-of-function mutations in
PPARγ ligand binding domain
• Prostate cancer: PPARγ expressed in human prostate adeno-
carcinomas and cell lines derived from human prostate tumors
• Thyroid tumors: the PAX8-PPARγ fusion protein promotes
diﬀerentiated follicular thyroid neoplasia4.1 Target 139
Classiﬁcation
PPARs belong to the frequently targeted3 superfamily of nuclear receptors (Table 4.2;
Ottow and Weinmann, 2008), which act as transcription factors regulating gene ex-
pression. There are 3 PPAR subtypes, PPARα (NR1C1), PPARβ/δ (NR1C2),4 and
PPARγ (NR1C3). Each subtype is the product of a distinct gene. The human gene for
PPARα is located on chromosome locus 22q12–q13.1 (Sher et al., 1993), PPARβ/δ on
6p21.1–p21.2 (Yoshikawa et al., 1996), and PPARγ on 3p25 (Beamer et al., 1997). Of
PPARγ, three messenger RNA isoforms are known in humans, PPARγ1, PPARγ2, and
PPARγ3, arising through diﬀerent promoter usage and alternative splicing (Fajas et al.,
1997). PPARγ1 and PPARγ3 encode the same protein, while the PPARγ2 protein has
28 additional amino acids at the N-terminus.
Mechanism of action
PPARs form hetero-dimers with the retinoid X receptor (RXR; NR2B)5 and bind to
PPAR-speciﬁc response elements (PPRE) within the promoter regions of their target
genes. In their inactive (ligand-free) state, these hetero-dimers form complexes with
nuclear receptor co-repressors, which prevent DNA transcription, e.g., via histone de-
acetylation (Mudaliar and Henry, 2002). After binding by an agonist, the induced confor-
mational change into the active form of the protein causes the co-repressor complexes to
dissociate and allows the recruitment of co-activators; the resulting complexes acetylize
histones near the promoter, leading to gene transcription (Figure 4.1). This activation
depends on the agonist to stabilize the active conformation6 of the PPAR (Figure 4.3).
Transcriptional activity is further modulated via phosphorylation of PPAR by various
kinases (Burns and Vanden Heuvel, 2007). See Gampe et al. (2000) for structural details
of hetero-dimerization and agonist binding.
PPREs have mainly been found in the control regions of genes related to lipid
metabolism and transport (Duval et al., 2007), e.g., acyl-CoA synthetase (Schoon-
jans et al., 1995), and lipoprotein lipase (Schoonjans et al., 1996), as well as genes
related to glucose neogenesis and metabolism, e.g., phosphoenolpyruvate carboxykinase
(Tontonoz et al., 1995) and pyruvate dehydrogenase kinase (Degenhardt et al., 2007).
See Hein¨ aniemi et al. (2007) for an analysis and prediction of PPREs in the human
genome.
From the three PPAR subtypes, PPARγ binds PPREs with the highest aﬃnity,
while PPARα and PPARβ/δ show similar but lower aﬃnities. Juge-Aubry et al. (1997)
propose to classify PPREs into strong (all 3 subtypes bind with equal aﬃnity), interme-
diate (PPARγ binds with twice the aﬃnity of PPARα and PPARβ/δ), and weak (only
bound by PPARγ) elements. PPREs can also inﬂuence the preferred RXR subtype for
dimerization.
313% of the drugs approved by the United States food and drug administration are targeted at
nuclear receptors (Overington et al., 2006).
4PPARβ was ﬁrst discovered in Xenopus laevis by Dreyer et al. (1992). When subsequently identiﬁed
in mice (Kliewer et al., 1994), rats, and humans, it was called PPARδ. Only later were the two recognized
as orthologues.
5In contrast to other RXR hetero-dimers, only the ligand binding domain contributes to the dimer-
ization, but not the DNA binding domain. This is due to the PPAR D-box having only 3 instead of
the usual 5 amino acids between the cysteins of the ﬁrst pair (Hsu et al., 1998). Note that PPAR/RXR
hetero-dimers can be activated by both PPAR and RXR ligands (Kliewer et al., 1992).
6See Gani and Sylte (2008) for a molecular dynamics study of PPARγ stabilization and activation
by two glitazones and docosahexenoic acid.140 4 Peroxisome proliferator-activated receptor
Table 4.2 Human nuclear receptors, based on Gronemeyer et al. (2004). For details on
nuclear receptor nomenclature, see Nuclear Receptors Nomenclature Committee (1999);
Germain et al. (2006). F = subfamily, G = group, # = member. The code for a
subfamily x, group y, member z receptor is NRxyz, e.g., NR1C3 for PPARγ. COUP-
TF = chicken ovalbumin upstream promoter-transcription factor, NGF = nerve growth factor,
DSS-AHC = dosage-sensitive sex reversal-adrenal hypoplasia congenita.
F G # Trivial name Abbreviation
1 A 1,2 Thyroid hormone receptor TRα, TRβ
B 1,2,3 Retinoic acid receptor RARα, RARβ, RARγ
C 1,2,3 Peroxisome proliferator-activated receptor PPARα, PPARβ/δ, PPARγ
D 1 Reverse erbA Rev-erbα, Rev-erbβ
F 1,2,3 RAR-related orphan receptor RORα, RORβ, RORγ
H 3,2 Liver X receptor LXRα, LXRβ
4,5 Farnesoid X receptor FXRα, FXRβa
I 1 Vitamin D receptor VDR
2 Pregnane X receptor PXR
3 Constitutive androstane receptor CAR
2 A 1,2 Human nuclear factor 4 HNF4α, HNF4γ
B 1,2,3 Retinoid X receptor RXRα, RXRβ, RXRγ
C 1,2 Testis receptor TR2, TR4
E 2 Tailless TLL
3 Photoreceptor-speciﬁc nuclear receptor PNR
F 1,2 COUP-TF COUP-TFI, COUP-TFII
6 ErbA2-related gene-2 EAR2
3 A 1,2 Oestrogen receptor ERα, ERβ
B 1,2,3 Oestrogen receptor-related receptor ERRα, ERRβ, ERRγ
C 1 Glucocorticoid receptor GR
2 Mineralocorticoid receptor MR
3 Progesterone receptor PR
4 Androgen receptor AR
4 A 1 NGF-induced factor B NGFIB
2 Nur related factor 1 NURR1
3 Neuron-derived orphan receptor 1 NOR1
5 A 1 Steroidogenic factor 1 SF1
2 Liver receptor homologous protein 1 LRH1
6 A 1 Germ cell nuclear factor GCNF
B 1 DSS-AHC critical region chrom. gene 1b DAX1
2 Short hetero-dimeric partner SHP
aFXRβ is a pseudo-gene in humans.
bDSS-AHC critical region on chromosome, gene 1.4.1 Target 141
Figure 4.1 PPARγ-RXRα hetero-dimer in complex with DNA (PDBid 3dzy; Chandra
et al., 2008). Shown are PPARγ (LBD in grey, DBD in brown, AF-2 (helix H12) in
red) with the ligand rosiglitazone (ball and stick model) and RXRα (LBD in blue, DBD
in cyan) with the ligand 9-cis-retinoic acid (ball and stick model), co-activator peptides
(green), and DNA (yellow). PPAR = peroxisome proliferator-activated receptor, RXR =
retinoid X receptor, PDBid = protein data bank identiﬁer, DNA = deoxyribonucleic acid, LBD
= ligand binding domain, DBD = DNA binding domain, AF-2 = activation function 2.142 4 Peroxisome proliferator-activated receptor
N AF-1 DBD H LBD AF-2 C
AF-1 transcriptional activation function 1
DBD DNA-binding domain (˜70 amino acids)
H hinge region (highly variable)
LBD ligand-binding domain (˜250 amino acids)
AF-2 transcriptional activation function 2
Figure 4.2 Domain structure of human PPAR (Henke, 2004). The DBD is strongly
conserved (e.g., 83% sequence identity between PPARα and PPARγ1/PPARγ2),
whereas the LBD is less conserved (e.g., 68% sequence identity between PPARα and
PPARγ1/PPARγ2).
Structure
Human PPARs consist of about 450 amino acids,7 with signiﬁcant variation in the
residues of the ligand binding pocket (Willson et al., 2000). The structures of all human
PPAR subtypes have been determined by X-ray crystallography,8 and are similar to
those of other nuclear receptors (Bourguet et al., 2000); they share the general domain
structure (Figure 4.2) of steroid, retinoid, and thyroid hormone receptors. The ﬁrst N-
terminal domain is the poorly conserved ligand-independent transactivation function 1.
It is followed by the strongly conserved DNA binding domain, consisting of two zinc
ﬁnger motifs, a highly variable hinge region, and the ligand binding domain with the
ligand-dependent transactivation function 2. The ligand binding domain consists of
13 α-helices and a four-stranded β-sheet (Figure 4.3a).
Binding pocket
The PPAR binding pockets (Figures 4.3b, 4.4) are large9 compared to other nuclear
receptors, mostly hydrophobic, and deeply buried, with PPARα having the largest and
most hydrophobic binding pocket, followed by PPARγ and PPARβ/δ. Many ligands
occupy only a small portion (˜20%) of the pockets (Gronemeyer et al., 2004), enabling
PPAR to accommodate a variety of ligands.
The binding pockets are deﬁned by 35 residues, about 80% of which are conserved
across all PPAR subtypes. They consist of three parts, a polar part (left proximal pocket,
arm I) including the AF-2 domain, a hydrophobic part (left distal pocket, arm II),
and a structurally conserved part (right distal pocket, arm III) that has hydrophobic
and hydrophilic residues (Pirard, 2003; Markt et al., 2007). The carboxyl group of
endogenous fatty acid ligands interacts with the four residues Ser289, His323, His449,
Tyr473 in the PPARγ10 pocket (Figure 4.4), stabilizing the AF-2 helix (Zoete et al.,
2007); their hydrophobic tail is buried in the left or right distal pocket.
7hPPARα 468 amino acids, hPPARβ/δ 441 amino acids, hPPARγ1 477 amino acids (Rau, 2007).
8Structures are accessible via the protein data bank (PDB; Berman et al., 2000); see Zoete et al.
(2007) for a list of identiﬁers.
9For PPARγ, binding pocket volumes have been given as 1.4nm
3 (1400˚ A
3; Zoete et al., 2007) and
1.6nm
3 (1600˚ A





3; Itoh et al., 2008).
10Ser280, Tyr314, His440, Tyr464 in PPARα, Thr289, His323, His449, Tyr473 in PPARβ/δ.4.1 Target 143
(a) Ligand-free (apo) conformation (PDBid
3prg; Nolte et al., 1998) of the PPARγ LBD.
Helices in gray, β-sheets in yellow, AF-2 (H12)
in red, dimerization interface in green.
(b) Ligand-bound (holo) form with the agonist
farglitazar (PDBid 1fm9; Gampe et al., 2000)
in the binding pocket. Coloring as in (a). The
binding pocket surface, calculated by Pocket-
Picker (Weisel et al., 2007), is shown in trans-
parent green. The ligand ﬁlls only a small part
of the large pocket.
Figure 4.3 Structure of PPARγ in ligand-free (apo) and ligand-bound (holo) form. The
subtle change in the conformation of helix 12 from (a) to (b) leads to a stabilized charge
clamp for co-activator recruitment (Gampe et al., 2000). PDBid = protein data bank
identiﬁer, PPAR = peroxisome proliferator-activated receptor, LBD = ligand binding domain,
AF-2 = activation function 2 (helix 12), H = α-helix, C = carboxyl-terminal end, N = amine-
terminal end.
Figure 4.4 Binding pocket of
PPARγ with the endogenous ago-
nist docosahexaenoic acid (PDBid
2vv0; Itoh et al., 2008). He-
lix 3 is shown in gray, the bind-
ing pocket surface, calculated by
PocketPicker (Weisel et al., 2007),
in transparent green; dashed
lines indicate amino acid interac-
tions of the ligands acidic head-
group. PDBid = protein data
bank identiﬁer, PPAR = peroxisome
proliferator-activated receptor, H =
α-helix, His = histidine, Ser = ser-
ine, Tyr = tyrosine.144 4 Peroxisome proliferator-activated receptor
4.1.2 Relevance
PPARs play essential roles in the regulation of lipid and glucose metabolism, as well as
cellular diﬀerentiation and development. They are related to a wide variety of diseases,
and consequently became established and successful11 pharmaceutical targets. The sub-
types of PPAR are distinct in expression, physiological role, and involved diseases.
Expression in humans
PPARα is highly expressed in cells that have active fatty acid oxidation capacity, i.e.,
high mitochondrial and peroxisomal β-oxidation activity, including hepatocytes, car-
diomyocytes, enterocytes, and renal proximal tubule cells (Desvergne and Wahli, 1999).
PPARβ/δ is expressed ubiquitously, often at higher levels than PPARα and PPARγ.
Expression levels vary across tissues, with higher expression in placenta and large intes-
tine (Desvergne and Wahli, 1999), as well as lipid-metabolizing tissues such as adipose
tissue, small intestine, skeletal muscles, and cardiac muscle (Grimaldi, 2007). It has
high expression rates in embryonic tissues, where it precedes expression of PPARα and
PPARγ (Michalik et al., 2002).
PPARγ is expressed predominantly in adipose tissue and cells of the immune system.
Of its isoforms, PPARγ1 has the broadest tissue expression, including adipose tissue,
liver, and heart. PPARγ2 is expressed mostly in adipose tissue, and PPARγ3 was
found in adipose tissue, macrophages, and colon epithelium. Additionally, PPARγ1
and PPARγ2 were also found at lower levels in skeletal muscle. In culture, PPARγ1 is
expressed in B lymphocytes, myeolid cell lines, and primary bone marrow stromal cells
(Desvergne and Wahli, 1999).
Physiological role
The primary function of PPARs in adult tissues is the regulation of lipid and glucose
homeostasis by inducing key enzymes of the primary metabolism of fatty acids and
glucose, mainly through expression of PPARα in the liver and PPARγ in adipose tissue.
PPARs also play a role in inﬂammatory processes (Szanto and Nagy, 2008).
The main physiological role of PPARα is to react to elevated blood levels of fatty
acids by initiating counter-regulatory signals. In particular, it increases the expression
of apolipoproteins and lipoprotein lipases, which leads to an increased uptake of very
low density lipoproteins by liver cells, and up-regulates fatty acid binding protein, acyl-
CoA-oxidase and acyl-CoA-synthase, which are key enzymes for the intra-cellular binding
and metabolization of free fatty acids. PPARα also represses the hepatic inﬂammatory
response by down-regulating the expression of numerous pro-inﬂammatory genes, such
as various acute-phase proteins (Gervois et al., 2004).
PPARβ/δ has functional roles in angiogenesis, skin homeostasis, and, in wound heal-
ing by governing keratinocyte diﬀerentiation (Burdick et al., 2006; Chong et al., 2009).
It stimulates fatty acid oxidation and glucose uptake in adipose tissue, as well as in skele-
tal and cardiac muscle (Kr¨ amer et al., 2007); it also regulates hepatic production and
catabolism of very low density lipoprotein. It can inhibit the other two PPAR subtypes.
PPARγ regulates adipogenesis depending on systemic lipid metabolism (Tontonoz
et al., 1994). It increases lipid uptake from blood, similar to PPARα, as well as glucose
uptake by induction of transporters such as glucose-transmembrane-transporters GLUT-
2 and GLUT-4 (Im et al., 2005; Wu et al., 1998). Through this mechanism, activation
of PPARγ leads to adipocyte growth and hyperplasia of adipose tissue (Miyazaki et al.,
11The 2005 global sales for the PPARγ agonists rosiglitazone and pioglitazone exceeded 5 · 10
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Table 4.3 Human processes and diseases involving PPARs. Preliminary evidence exists
for a role of PPARγ in amyotrophic lateral sclerosis (Kiaei, 2008), Huntington’s disease
(Quintanilla et al., 2008), and Parkinson’s disease (Chaturvedi and Beal, 2008). See
Willson et al. (2001) for a review of PPARγ in metabolic disease.
Disease/process References
Atherosclerosis Rosen and Spiegelman (2000)
Type 2 diabetes mellitus Patsouris et al. (2004)
Dyslipidemia Duval et al. (2007); Rau et al. (2008)
Obesity Zhang et al. (2004)
Immune system Schlezinger et al. (2004)
Inﬂammation Delerive et al. (2001); Welch et al. (2003)
Inﬂammatory bowel diseases Dubuquoy et al. (2006)
Multiple sclerosis Drew et al. (2008)
Cancer Tien et al. (2003)
Aging Cheng and Mukherjee (2005); Fernandez (2004)
Cellular proliferation Cuzzocrea et al. (2004)
Fertility Komar (2005); Corton and Lapinskas (2005)
Alzheimer’s disease Kummer and Heneka (2008)
Ischemic stroke Culman et al. (2007)
2002). PPARγ also regulates adipocyte mediators like tumor necrosis factor α, leptin,
and plasminogen activator inhibitor-1.
Diseases
PPARs have been linked to several diseases associated with altered levels of fatty acids,
most notably obesity, type 2 diabetes mellitus, atherosclerosis, and hypertension (Ta-
ble 4.3). A connection to cancer has recently been proposed, based on the reasoning that
carcinogenesis is the result of aberrant cell diﬀerentiation, in whose control PPARγ is
involved. Although it seems to play no direct role in the causation of human carcinomas,
PPARγ mutations and loss of expression have been associated with colon cancer, thyroid
follicular carcinomas, and breast cancer (Sporn et al., 2001).
4.1.3 Ligands
Most PPAR ligands consist of an acidic headgroup, an aromatic core, a hydrophobic
tail, and connecting linkers (Figure 4.5), mimicking in part the endogenous fatty acid
ligands. Nuclear receptor ligands are more lipophilic and membrane-permeable com-
pared to ligands of other receptors. PPARs accommodate a large variety of natural and
synthetic compounds, many of which ﬁll only a small part (˜20%) of the large binding
pocket (˜1.5nm3, p. 142). For further information on PPARγ ligands, see Henke (2004).
Modulation
A nuclear receptor ligand is a compound that binds to the receptors C-terminal ligand
binding domain; it is selective if there is a large enough (>100-fold) diﬀerence in aﬃnity
to other nuclear receptors. Agonists induce the active conformation of the receptor, with
full agonists causing maximal activation and partial agonists producing weaker eﬀects.146 4 Peroxisome proliferator-activated receptor
Antagonists induce conformations and receptor actions diﬀerent from agonists, and can
thereby oppose the latter. Inverse agonists are ligands that stabilize the inactive form
of the receptor, preventing constitutive activity.
PPAR agonists induce and stabilize an AF-2 (helix 12) conformation (Figure 4.3b)
that leads to the recruitment of co-activators and gene transcription. Partial PPAR
agonists are unable to form some of the hydrogen bonds that full agonists employ (Fig-
ure 4.4), using hydrophobic interactions instead. This leads to the recruitment of diﬀer-
ent co-activators, and reduced or altered gene transcription (Markt et al., 2007). PPARs
are thought to be constitutively active depending on the ratio of co-activators and co-
repressors (Tudor et al., 2007).
The concepts of agonist and antagonist have been criticized as being overly simplistic
with respect to nuclear receptors, as a ligands action may depend on the cellular context,
such as the presence of co-repressants and co-activators (Sporn et al., 2001). The terms
modulator and selective nuclear receptor modulator (SNuRM) have been suggested for
ligands that induce tissue-selective agonist or antagonist activity.
Selectivity
Due to the size and hydrophobicity of their binding pockets (p. 142), PPARα and PPARγ
seem more suited for fatty acids and hydroxylated fatty acids, respectively (Markt et al.,
2007). Because of its smaller size, the PPARβ/δ binding pocket can not accommodate
large hydrophobic tail groups. Subtype selectivity is often achieved via diﬀerences in the
left proximal and distal subpockets (arms I and II).
Adverse eﬀects
Currently marketed PPAR agonists display serious safety issues. Adverse reactions of
speciﬁc PPARγ and dual PPARα/γ agonists include potential carcinogenicity in rodents,
myopathy, rhabdomyolysis, increase in plasma creatinine and homocysteine, hemodilu-
tion, decrease in glomerular ﬁltration rate, weight gain, ﬂuid retention, peripheral edema,
and congestive cardiac failure (Rubenstrunk et al., 2007). The toxicology of PPAR lig-
ands is reviewed by Peraza et al. (2006).
Endogenous ligands
Native PPAR ligands (Scheme 4.1) are lipid metabolites such as oxidized fatty acids (Itoh
et al., 2008), phospholipids, and, arachidonic acid derivatives, such as prostaglandins
and prostacyclins (Nettles, 2008), most of which activate the receptor in the micromolar
range. The physiological concentrations of these native ligands are often lower than
those necessary for PPAR activation (up to three orders of magnitude, Schopfer et al.,
2005). However, its versatile and large binding pocket allows PPAR to bind many
ligands, making it a sensor not of a single ligand, but of a pool of ligands. Thus, it is
the physiological concentration of the pool, e.g., total fatty acid levels, that is relevant
(Itoh et al., 2008).
High aﬃnity endogenous ligands are unsaturated nitrated fatty acid derivatives that
activate PPARs in the nanomolar range (Baker et al., 2005). PPARγ in particular
is activated by nitrolinoleic acid (Compound 12), docosahexaenoic acid (Figure 4.4;
Zapata-Gonzalez et al., 2008), 5-oxo-eicosatetraenoic acid, 15-oxo-eicosatetraenoic acid,
15-oxo-eicosadecaenoic acid, 15-keto-prostaglandin F2α, and 15-keto-prostaglandin F1α
(Shiraki et al., 2005).4.1 Target 147
acidic headgroup — linker — aromatic center — linker — hydrophobic tail
Figure 4.5 Simpliﬁed topology of many synthetic PPAR agonists (based on Kuhn et al.,
2006). Linkers can be branched to access additional parts of the binding pocket.
O
HO
10 Pristanic acid (2,6,10,14-tetramethyl-
pentadecanoic acid), a fatty acid derived
(via external sources) from the phytol side
chain of chlorophyll, with phytanic acid
as intermediate (PPARα EC50 = 40µM;





11 Oleoylethanolamide, a fatty acid
ethanolamide that regulates satiety and
body weight (PPARα EC50 = 0.12µM,
PPARβ/δ EC50 = 1.1µM, inactive on






12 Nitrolinoleic acid (10- and 12-nitro-9,12-
octadecadienoic acid), an anti-inﬂammato-
ry cell signaling mediator generated by NO
and fatty acid-dependent redox reactions
(PPARγ EC50 = 0.05–0.62µM, depend-
ing on regioisomer; Schopfer et al., 2005;




13 15-deoxy-∆12,14-prostaglandin J2, an
irreversible speciﬁc PPARγ agonist, co-
valently binds to Cys-285 of the LBD by
a Michael addition reaction of its α,β-
unsaturated ketone subgroup (shown in




14 Vaccenic acid (cis-11-octade-
cenoic acid) activates PPARβ/δ






15 Prostacyclin (PGI2) is a prostaglandin that
activates PPARβ/δ (Gupta et al., 2000).
Scheme 4.1 Examples of endogenous PPAR ligands. PPAR = peroxisome proliferator-
activated receptor, EC50 = half maximal eﬀective concentration, LBD = ligand binding domain.
Activities measured in diﬀerent assays.148 4 Peroxisome proliferator-activated receptor
Natural product ligands
Substances produced by living organisms diﬀer substantially from synthetic compounds,
e.g., they have fewer aromatic atoms, more chiral centers, fewer nitrogen atoms, and
more oxygen atoms (Henkel et al., 1999; Grabowski et al., 2008). This general obser-
vation also holds for PPAR ligands (Scheme 4.2). See Salam et al. (2008) for a virtual





16 Isohumulone, an iso-α acid con-
tained in hop (Humulus lupulus L.),
gives beer its bitter ﬂavor, and ac-
tivates PPARα and PPARγ (Yajima






17 Quercetin is a ﬂavonoid that occurs in
fruits like mango and papaya, but also in
vegetables and nuts. It shows vasodilator
and antihypertensive eﬀects (PPARα EC50 =
59.6µM, PPARβ/δ EC50 = 76.9µM, PPARγ






18 Carnosic acid, a phenolic diterpene
of sage (Salvia oﬃcinalis L.), is known
for its anti-oxidative and anti-microbial
properties (PPARγ EC50 = 19.6µM;




19 Resveratrol is a polyphenol occurring in
grapes that regulates polyamine metabolism.
It is thought to be cardioprotective and use-
ful in cancer chemoprevention; it activates





20 Macelignan, a component of nut-
meg (Myristica fragrans Houtt) with
anti-diabetic properties, is a dual
PPARα/γ agonist (PPARα EC50 =






21 Ajulemic acid, a synthetic dimethylheptyl
analog of tetrahydrocannabinol-11-oic acid,
shows analgesic and anti-inﬂammatory, but
not psychotropic activity (mPPARγ EC50 =
13µM; inactive on hPPARα and hPPARβ/δ
at 50µM; Liu et al., 2003).
Scheme 4.2 Examples of natural compound PPAR ligands. PPAR = peroxisome
proliferator-activated receptor, EC50 = half maximal eﬀective concentration. Activities mea-
sured in diﬀerent assays.4.2 Retrospective evaluation 149
Synthetic ligands
Motivated by the various diseases linked to PPARs, a wide spectrum of synthetic lig-
ands with diﬀerent scaﬀolds, binding modes, activity proﬁles, side eﬀects, and thera-
peutic uses has been developed over the last decades. After several late-stage failures
of thiazolidinediones such as troglitazone (withdrawn from market), muraglitazar, and
tesaglitazar (both abandoned after phase 3 clinical trials) due to severe adverse eﬀects,
research focus has shifted from full agonists to partial agonists, especially for PPARγ.
Partial agonists, or, more generally, modulators of PPARs are thought to retain clinical
eﬃcacy without (some of) the adverse eﬀects of full agonists (Cho et al., 2008).
All marketed selective PPARα agonists are ﬁbrates, a class that has been in use since
the 1960s (Hellman et al., 1963). Speciﬁc PPARβ/δ ligands are a recent development;
consequently, there are no marketed selective PPARβ/δ drugs at the moment. PPARγ
agonists are typically thiazolidinediones (Lehmann et al., 1995) and tyrosine analogs
(Henke, 2004), although a variety of new scaﬀolds has been developed. Schemes 4.3,
4.4, and 4.5 show examples of PPARα, PPARβ/δ, and PPARγ ligands, respectively;
Scheme 4.6 shows examples of PPAR pan agonists and modulators.
4.2 Retrospective evaluation
We used a published data set of PPARγ agonists to establish a regression model for
PPARγ binding in preparation of the prospective virtual screening study in Section 4.3.
4.2.1 Data
In a regression setting, the accuracy of the measured data labels — in our case, binding
and activation of PPARγ — is important. As discussed before (p. 41), simply collecting
compounds with associated measurements from the literature is not suﬃcient. For our
study, we therefore selected a data set with homogeneous measurements from a single
assay type.
Data set
The public data set published by R¨ ucker et al. (2006, Scheme 4.7) contains 176 com-
pounds active on PPARγ. Of those, 144 compounds are annotated with the nega-
tive decadic logarithm of the PPARγ dissociation constant pKi = −log10 Ki as mea-
sured by a scintillation proximity assay (Nichols et al., 1998), 150 compounds are anno-
tated with the negative decadic logarithm of the half maximal activation concentration
pEC50 = −log10 EC50 as measured by a transient co-transfection assay (Lehmann et al.,
1995), and 118 compounds are annotated with both values.
pKi versus pEC50 values
The pKi values are measurements of association (binding) of compound to receptor, with
higher values indicating stronger binding; the pEC50 values are measurements of receptor
activation, with higher values indicating stronger activity. Binding and activity are
related phenomena in the sense that binding is necessary but not suﬃcient for activation.
The latter is usually determined in cell-based assays, which requires compounds to cross
cell and nuclear membranes, to be soluble in the cytoplasm, to not be cytotoxic, and to
not bind to other macromolecules in the cell in order to successfully activate a nuclear
receptor. This relationship is reﬂected in the distribution of the pKi and pEC50 values
(Figure 4.6). In this work, we model binding constants (pKi values), as they describe




22 Cloﬁbric acid, the active metabolite
of cloﬁbrate (hPPARα EC50 = 55µM,
hPPARγ EC50 ≈ 500µM, inactive on







23 Fenoﬁbric acid, the active metabolite
of fenoﬁbrate (hPPARα EC50 = 30µM,
hPPARγ EC50 ≈ 300µM, inactive on






24 Bezaﬁbrate (hPPARα EC50 = 50µM,
hPPARγ EC50 = 60µM, hPPARβ/δ EC50







25 LY518674, a selective PPARα ago-
nist (hPPARα EC50 = 46nM, inactive on











26 GW590735 (hPPARα EC50 = 4nM,
hPPARβ/δ EC50 = 3µM, hPPARγ EC50







27 A variant of GW590735 obtained by
fragment-based bioisosteric replacement of
the acidic head group and the hydropho-
bic tail (PPARα EC50 = 0.51µM, PPARγ
EC50 = 0.63µM; Proschak et al., 2008).
Scheme 4.3 Examples of PPARα agonists. The comparatively weak binders 22, 23,
and 24 have been used since the 1960s to lower triglyceride levels (Hellman et al., 1963).
The more recent compounds 25 and 26 are potent and highly selective against PPARγ.
PPAR = peroxisome proliferator-activated receptor, hPPAR = human PPAR, EC50 = half








nyl) acetic acid, an early lead compound
selective for PPARβ/δ (PPARα EC50
90nM, PPARβ/δ EC50 = 3nM, PPARγ






29 GW0742X (also GW610742), a selective
PPARβ/δ agonist that reduces atheroscle-
rosis in mice (hPPARα EC50 > 10µM,
hPPARβ/δ EC50 = 30nM, hPPARγ EC50






30 Treprostinil, a prostacyclin analog, ac-
tivates PPARβ/δ and PPARγ, the latter
in a prostacyclin receptor dependent way






31 L-165041, a phenoxyacetic acid deriva-
tive, is selective for PPARβ/δ (hPPARα
EC50 = 0.977µM, hPPARβ/δ EC50 =
0.125µM, hPPARγ EC50 = 1.824µM;









32 GW9371, an anthranilic acid derivative,
is a partial PPARβ/δ agonist (hPPARβ/δ
binding IC50 = 0.1µM, inactive on hPPARα
and hPPARγ at 10µM; hPPARβ/δ EC50 =









33 GSK0660 is a selective inverse ag-
onist of PPARβ/δ (no agonist activity
at 10µM on all hPPAR subtypes; bind-
ing assay hPPARβ/δ IC50 = 155nM;
Shearer et al., 2008b).
Scheme 4.4 Examples of PPARβ/δ ligands. PPAR = peroxisome proliferator-activated
receptor, hPPAR = human PPAR, EC50 = half maximal eﬀective concentration, IC50 = half






34 Rosiglitazone, a thiazolidinedione, is
a marketed drug selective for PPARγ
(hPPARα EC50 > 10µM, hPPARβ/δ
EC50 > 10µM, hPPARγ EC50 = 18nM;







35 Pioglitazone, a thiazolidinedione, is
another marketed drug that is selective
for PPARγ (hPPARα EC50 > 10µM,
hPPARβ/δ EC50 > 10µM, hPPARγ EC50








36 Farglitazar, an N-(2-benzoylphenyl)-L-
tyrosine derivative, is currently in phase 2
clinical trials (hPPARα EC50 = 250nM,
hPPARβ/δ EC50 > 10µM, hPPARγ EC50 =








37 Muraglitazar is a dual PPARα/γ ag-
onist that was abandoned after phase 3
clinical trials (hPPARα EC50 = 320nM,









38 Tesaglitazar is another dual PPARα/γ
agonist abandoned after phase 3 clin-
ical trials (hPPARα EC50 = 1.7µM,











39 BVT.13, a 5-substituted 2-benzoyl-
aminobenzoic acid (2-BABA) derivative
with a binding epitope diﬀerent from
that of the thiazolidinediones (PPARγ
EC50 = 1.3µM, inactive on PPARα and
PPARβ/δ at 10µM; ¨ Ostberg et al., 2004).
Scheme 4.5 Examples of synthetic PPARγ agonists. PPAR = peroxisome proliferator-
activated receptor, hPPAR = human PPAR, mPPAR = mouse PPAR, EC50 = half maximal







40 GW9662, a selective PPARγ
full antagonist and partial PPARα
agonist (PPARα EC50 = 26nM,
PPARβ/δ IC50 = 471nM, PPARγ








41 Metaglidasen (MBX-102, the (-) enantiomer
of the cloﬁbric acid analog halofenate), is a
PPARγ modulator currently in phase 3 clinical
trials. It exhibits partial agonist and antago-
nist activity (PPARγ EC50 = 18µM, inactive
on PPARα and PPARβ/δ; Allen et al., 2006;









42 Sodelglitazar (GW677954), a PPAR
pan agonist for the treatment of dia-
betes 2, is currently in phase 2 clin-
ical studies (PPARα EC50 = 40nM,
PPARβ/δ EC50 = 1.3nM, PPARγ EC50







43 Indanylacetic acid derivate 34r, a PPAR
pan agonist (hPPARα EC50 = 101nM,
hPPARβ/δ EC50 = 4nM, mPPARγ EC50








44 Indeglitazar is a recent PPAR
pan agonist and partial PPARγ
agonist currently in phase 2
clinical trials (PPARα EC50
= 0.99µM, PPARβ/δ EC50 =
1.3µM, PPARγ EC50 = 0.85µM;












hetero-dimer-selective RXR modulator that acti-
vates RXR:PPARα and RXR:PPARγ, but does not
suppress the thyroid hormone axis (RXR:PPARα
EC50 = 15nM, RXR:PPARγ EC50 = 3nM;
Michellys et al., 2003; Leibowitz et al., 2006).
Scheme 4.6 Examples of synthetic PPAR modulators. PPAR = peroxisome proliferator-
activated receptor, RXR = retinoid X receptor, hPPAR = human PPAR, EC50 = half maximal
eﬀective concentration, IC50 = half maximal eﬀective inhibitory concentration. Activity values
measured in diﬀerent assays.154 4 Peroxisome proliferator-activated receptor









(a) Histogram of pKi-values. n =
144 samples, 7 bins of unit length.







(b) Histogram of pEC50-values.
n = 150 samples, binning as in (a).








(c) pKi versus pEC50 values. n = 118 samples (gray
disks) with experimentally determined pKi and pEC50
values. Squared correlation r2 = 0.62. The solid black
line shows the linear model pKi = 2.98 + 0.67pEC50 with
the 95% conﬁdence band of the mean in gray.
Figure 4.6 Distribution of pKi and pEC50 values in the ppar data set. 176 compounds
in total, of which 144 have experimentally determined pKi values, 150 have experimen-
tally determined pEC50 values, and 118 have both values.
Compound classes
Based on R¨ ucker et al. (2006), we divide the compounds into eleven classes, consisting
of indoles, thiazolidinediones, thiazolidinedione-fatty acid hybrids, oxadiazoles, phenoxy-
isobutyric acids, fatty acids, and ﬁve classes of tyrosine derivatives (Scheme 4.7).
4.2.2 Descriptors and kernels
We described compounds with molecular descriptors, the annotated structure graph,
and combinations of these. For numerical representations (CATS2D, MOE 2D, Ghose-
Crippen), compounds were preprocessed with the software MOE (molecular operating
environment, Chemical Computing Group, www.chemcomp.com) by removing salts, neu-
tralizing compounds, and (de)protonating strong bases (acids). Implicit hydrogens were
removed for graph representations.
CATS2D
We used the CATS2D descriptor (chemically advanced template search, Schneider et al.,
1999; Fechner et al., 2003), a topological pharmacophore-based auto-correlation vector,
in a version extended by an aromaticity pharmacophore type. Atoms in a compound
were assigned zero or more of the pharmacophore types hydrogen-bond acceptor (A),
hydrogen-bond donor (D), negative charge (N), positive charge (P), lipophilic (L), and
aromatic (M). The number of occurrences of each of the possible 21 pairs AA, AD, AN,
AP, AL, AM, DD, DN, ..., MM within a certain topological distance were counted; we








46 Tyrosines with an oxazole derivative








47 Tyrosines with oxazole O-substituent

























50 Tyrosines with benzoxazole derivatives













52 Thiazolidinediones with substituted











53 Thiazolidinedione-fatty acid hybrids









54 1,2,4-oxadiazoles 3,5-substituted with









55 Tertiary amides with phenoxyisobutyric




56 Fatty acids of diﬀerent length and de-
grees of saturation, 9 compounds.
Scheme 4.7 Classes in data set ppar. Pri-
mary name-giving scaﬀold shown in bold.
5 compounds are not assigned to a class.156 4 Peroxisome proliferator-activated receptor
MOE 2D
All 184 two-dimensional descriptors computed by MOE were used.
Ghose-Crippen
Ghose-Crippen fragment descriptors (Ghose and Crippen, 1986, 1987; Ghose et al., 1988;
Viswanadhan et al., 1989) consist of 120 fragments, or atom types, originally introduced
for the prediction of hydrophobic interactions of small organic compounds.
Annotated structure graph
We used the structure graph in three forms:
• Topological: No annotation was used, i.e., atoms correspond to vertices and covalent
bonds correspond to edges. No information about atom or bond type was retained.
• Element types: Vertices were annotated with element type (atomic number), bonds
with bond type (single, double, triple).
• Pharmacophore types: Atoms were annotated as potential pharmacophore points
according to Table 2.5.
Kernels
For numerical representations, we used the standard (linear) inner product, the homoge-
neous polynomial kernel (p. 30), the Gaussian kernel (p. 30), and, the rational quadratic








where s > 0 is the shape parameter, l > 0 is the scale parameter, and d is the dimension
of the input space. The shape parameter s deﬁnes the thickness of the kernel tails. The
rational quadratic kernel corresponds to an inﬁnite mixture of scaled squared exponen-
tials; the squared exponential itself is recovered for s → ∞. In Gaussian process models
(Subsection 4.2.4), the rational quadratic kernel often yields predictions as accurate as
those of the Gaussian kernel, but with better conﬁdence estimates.
For graph representations, we used ISOAK (Chapter 2), with no vertex and edge
kernels (vk = ek = 1) on the topological graph, and Dirac vertex and edge kernel (p. 72)
on element type and pharmacophore type annotation.
Multiple kernel learning
Multiple kernel learning (Sonnenburg et al., 2006) combines diﬀerent kernels by using the
fact that linear combinations (with non-negative coeﬃcients) of kernels are again kernels.
Combining diﬀerent kernels on the same input allows one to learn diﬀerent types of
patterns at the same time, e.g., polynomial and exponential patterns. Combining kernels
on diﬀerent inputs enables the combination of heterogeneous input representations, e.g.,
descriptors and structure graphs. Each additional kernel adds another free parameter;
these can be optimized, e.g., using cross-validation and grid search or gradient descent.4.2 Retrospective evaluation 157
4.2.3 Baseline models
We used linear ridge regression and support vector machines as baseline methods.
Ridge regression
Ridge regression (Hastie et al., 2003) is a regularized form of linear regression with
quadratic loss. The learned model has the form f(x) = hw,xi + b, where w ∈ Rd is a
weight vector and b ∈ R is a bias term. The solution minimizes the quadratic error on








hw,xii + b − yi
¢2 + λkwk
2 , (4.2)
where λ > 0 determines the trade-oﬀ between goodness of ﬁt and regularization.
In unregularized linear regression on correlated input, like CATS2D auto-correlation
vectors, arbitrarily large weights on single components can be canceled by corresponding
negative weights on other, correlated components. The regularizer kwk
2 prevents this by
penalizing the squared regression weights, ensuring small weights of similar magnitude.
Support vector machines
We used support vector machines (Subsection 2.4.3) for regression. For vectorial de-
scriptors, we employed the Gaussian kernel, which is a suitable default choice based on
both general considerations (p. 30) and practical experience.
4.2.4 Gaussian processes
Gaussian processes (GP) are a supervised machine learning approach originating from
Bayesian statistics. A major advantage of GPs is that predictions come with a measure
of conﬁdence in the prediction, i.e., built-in domain of applicability (p. 49) estimation.
We restrict our presentation to aspects of GPs required for this chapter, in particular
GP regression. For further information, see Rasmussen and Williams (2006).
Introduction
Gaussian processes are a generalization of normal (Gaussian) distributions to functions,
i.e., to inﬁnitely many random variables such that every ﬁnite subset of these variables
has again normal distribution. Formally, let X denote the index set (corresponding to
input space) of a stochastic process p(x) ∈ R, x ∈ X, with real state space (corresponding





∼ N(µ,K) for all x1,...,xn ∈ X, where µ ∈ Rn
is the mean and K ∈ Rn×n is the (strictly positive deﬁnite) covariance matrix.12 In




















where detK is the determinant of K. A GP is completely determined by its mean and
covariance function.










, then x ∼ N(,K), i.e., consideration of a larger set of variables does
not change the distribution of the smaller set.158 4 Peroxisome proliferator-activated receptor









(a) Prior distribution. 15 samples (black lines)
drawn from a Gaussian process with zero mean
and squared exponential covariance function
k(x,x0) = exp(−1














(b) Posterior distribution with mean function
(black line). 8 samples (gray dashed lines)
drawn from the posterior distribution after in-
troduction of three observations (red crosses).
Figure 4.7 Idea of Gaussian process regression. Starting from the prior distribution
(a), one conditions on the observed samples. The mean and variance of the posterior
distribution (b) are used as predictor and conﬁdence estimate. Shaded regions denote
two standard deviations.
Idea
The intuition behind GP regression is to
1 Start with a class of admissible functions, here samples13 from a GP (Figure 4.7a).
2 Put a suitable prior distribution over these functions.
3 Condition the process on observed sample-label pairs (xi,yi) (Figure 4.7b).
4 Use the mean and the covariance of the posterior distribution as predictor and conﬁ-
dence estimate, respectively.
Note that the distribution of the input samples is not modeled explicitly.
Linear regression
For linear regression in input space, we assume X = Rd and that target labels are
corrupted by additive i.i.d. Gaussian noise with zero mean and variance σ2,




where b ∈ R is a bias term and w ∈ Rd is a weight vector. In the following, we assume
b = 0 for simplicity.14 For given weights w and training data matrix X = (xT
1 ,...,xT
n) ∈





























13In this chapter, the term sample can refer to either a sample from a GP, i.e., a function X → Y, or,
a (training or test) input sample, i.e., x ∈ X.
14The bias can be treated either by explicitly incorporating it into the following calculations, by adding
a component which is always 1 to the input vectors, or, by standardizing training data labels.4.2 Retrospective evaluation 159
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with A = σ−2XTX + Σ−1 and ˜ w = σ−2A−1XTy.15 Predicting the label y0 of a test
sample x0 is done by averaging label predictions over all possible models w, weighted by


















Note that the predictive variance does not include σ2. Computing ˜ w and A−1 requires
inversion of a d × d matrix, which can be done in time O(d3). Evaluating Equation 4.8
to predict a test sample has linear cost for the mean and quadratic cost for the variance.
Figure 4.8 shows an example.
The kernel trick
Application of the kernel trick (p. 28) using a non-linear transformation φ : X → H,
x 7→ φ(x) from input space into feature space and applying linear Bayesian regression













with A = σ−2φ(X)
Tφ(X)+Σ−1; here, the weight prior Σ has the dimensionality of the
feature space. Since n training samples can span a subspace of dimension at most n, we






















where K = φ(X)Σφ(X)
T. Note that all feature space evaluations are of the form
φ(·)
TΣφ(·), which is an inner product weighted by the positive deﬁnite matrix Σ, and
can be replaced by a positive deﬁnite kernel k(·,·).












Ty, both of which do not depend on w.160 4 Peroxisome proliferator-activated receptor









(a) Linear input data. n = 30 samples with in-
dependent x-coordinates drawn uniformly from
[−8,8] and noisy labels y = f(x) + N(0,1).









(b) Linear Bayesian regressor 0.51x + 1.98.
Enough samples result in a good ﬁt with high
conﬁdence.









(c) Linear input data. As in (a), except n = 5
with x-coordinates from [−2,2].









(d) Linear Bayesian regressor 0.37x+1.46. Few
samples result in a bad ﬁt with rapidly increas-
ing predictive variance.
Figure 4.8 Bayesian linear regression examples. Shown are samples (orange disks), the
noise-free label function f(x) = 1
2x + 2 (dashed line) ± two standard deviations (gray
area), posterior distribution samples (gray lines), and Bayesian regressors (solid lines).
Non-linear regression
Gaussian process regression is linear Bayesian regression in feature space. We replace
(weighted) inner products by kernel evaluations and shift to matrix notation. Let K ∈
Rn×n, Ki,j = k(xi,xj), K0 ∈ Rm×m, K0
i,j = k(x0
i,x0
j), and L ∈ Rn×m, Li,j = k(xi,x0
j)
denote the kernel matrices on training samples, test samples, and training versus test
samples, respectively. The prior over the noisy labels becomes
covar(y) = K + σ2I. (4.11)


























Note that the prediction for a single test sample x0 can be rewritten as
n X
i=1
αik(xi,x0) with α =
¡
K + σ2¢−1y, (4.14)4.2 Retrospective evaluation 161
Table 4.4 Applications of Gaussian processes in cheminformatics, sorted by submis-
sion date where available. T = evaluation type, with R = retrospective, B = blind
(separate test data available only after training, evaluation by diﬀerent team), and P =
prospective. Bz agonism = benzodiazepine receptor agonism, hERG inhib. = human ether-
a-go-go-related gene inhibition, M1 inhib. = M1 muscarinic receptor inhibition, T. pyriformis
toxicity = Tetrahymena pyriformis toxicity.
Application T Reference
Bz agonism, M1 inhib., T. pyriformis toxicity R Burden (2001)
Lipophilicity R Enot et al. (2001)
Ovarian cancer identiﬁcation from mass spectrometry R Yu and Chen (2005)
Aqueous solubility B Schwaighofer et al. (2007)
Blood-brain barrier, hERG inhib., aqueous solubility R Obrezanova et al. (2007)
Aqueous solubility R Schroeter et al. (2007c)
Lipophilicity B Schroeter et al. (2007b)
Lipophilicity P Schroeter et al. (2007a)
Metabolic stability P Schwaighofer et al. (2008)
Amphiphysin SH3 domain peptide binding R Zhou et al. (2008)
Spectroscopic calibration R Chen and Martin (2008)
Synthetic data R Sakiyama (2009)
Liquid chromatographic retention times R Tian et al. (2009)
Liquid chromatographic retention times R Zhou et al. (2009)
hERG inhib. R Hansen et al. (2009)
and that the predictive variance does not depend on the labels, but only on the distances
between the samples. Since only inner products are used, samples do not have to be
vectors anymore, but can be elements of any input space X endowed with a positive
deﬁnite kernel k. Figure 4.9 shows an example of non-linear Gaussian process regression.
Applications in cheminformatics
GP theory goes back at least to the 1940s (Kolmogoroﬀ, 1941; Doob, 1944; Wiener, 1949),
and perhaps even earlier (Lauritzen, 1981). Despite many applications in diverse areas
such as bioinformatics, environmental sciences, geostatistics (kriging), manufacturing,
machine learning, medicine and health, music, physics, robotics, and others, GPs have
only recently been introduced to cheminformatics, mainly for the prediction of physico-
chemical properties of small molecules (Table 4.4).
4.2.5 Performance estimation
We use clustered cross-validation and two distinct performance measures to retrospec-
tively evaluate baseline and GP models.
Statistical validation
In virtual screening data sets, the assumption of independent and identically distributed
training samples is violated (p. 35; Rupp et al., 2009); for the ppar data set this is
particularly clear from its strong structure (Scheme 4.7). In such cases, statistical es-
timation procedures like leave-one-out cross-validation and k-fold cross-validation can
overestimate performance.162 4 Peroxisome proliferator-activated receptor
We used a leave-k-cluster-out cross-validation strategy by partitioning the data set
into k = 10 clusters using GeoClust (Choudhury et al., 2002; Wen et al., 2005) and
applying 10 runs of leave-5-clusters-out cross-validation. The same folds were used for
all models.
Performance measures
Let yi denote the target labels, let ˆ yi denote their estimates, and, let Y and ˆ Y denote
corresponding random variables. As performance measures, we employed the correlation























































(yi − ˆ yi)2, (4.16)
and, cumulative histograms. For our application, i.e., the selection of a model suited
for later prospective virtual screening with a small number of assay tests, erroneous
predictions within the top-ranked compounds (false positives) are more costly than errors
for lower-ranked compounds, making early recognition (p. 42) important. We therefore
used an additional performance measure to account for the early recognition problem,
the fraction of inactives among the 20 best-ranked compounds (FI20).
Ranking
For ridge regression and support vector machines, compounds were ranked according to
predicted aﬃnity. For Gaussian process models, both the estimated aﬃnity ˆ µ and the
estimation conﬁdence ˆ σ2 had to be incorporated into the ranking. We combined both
into a single score ˆ µ − ˆ σ2 by subtracting the variance of a prediction from its mean
(Guiver and Snelson, 2008). This is valid because variance and mean have the same
scale, and prefers compounds with high predicted aﬃnity and high conﬁdence in the
prediction.
4.2.6 Results
The described molecular representations, kernels, and machine learning algorithms were
combined into 16 models (Figure 4.10), each model was subjected to 10 runs of leave-
5-clusters-out cross-validation, and all performance measures were computed, averaged
over all runs. The performance measures r, MAE, RMSE, and cumulative histograms
were highly correlated (correlation > 0.95); in the following, we report only the MAE.
Models
Models 1, 2, and 3 are baseline linear ridge regression models using three diﬀerent
vectorial descriptors. They represent linear methods with standard chemical descriptors.
Models 4, 5, and 6 are baseline support vector regression models with Gaussian kernels
and the same vectorial descriptors. They represent established non-linear methods with
standard chemical descriptors. Models 7, 8, and 9 are Gaussian process models with
Gaussian and rational quadratic kernels using the same vectorial descriptors. They
represent the Gaussian process approach with standard chemical descriptors.4.2 Retrospective evaluation 163







(a) Decaying sine input data. n = 100 samples
(orange disks) with independent x-coordinates
drawn uniformly from [−22,22] and noisy la-






15 |x|). The dashed line in-
dicates the noise-free label function f ± two
standard deviations (gray area).







(b) Gaussian process regressor (black line)
± two standard deviations (gray area), us-





+ σ21{i=j}. The length-
scale of 3 enforces a smooth regressor. Note how
variance is higher in areas with fewer samples,
e.g., at x = 19 as compared to x = −19.
Figure 4.9 Example of Gaussian process regression.

































Figure 4.10 Diagram of the used descriptors, kernels, and models.164 4 Peroxisome proliferator-activated receptor
Models 10, 11, and 12 are Gaussian process models using diﬀerent annotations of
the structure graph. They diﬀer from models 7, 8, and 9 in that they use the ISOAK
(Chapter 2) graph kernel. Models 13, 14, 15, and 16 are Gaussian process models based
on combinations of vectorial descriptors and graph representations using multiple kernel
learning. The structure graphs are un-annotated as element type and pharmacophore
information is already contained in the vectorial descriptors. Model 13 uses ISOAK as
well as a Gaussian kernel and a rational quadratic kernel, operating on the concatenated
chemical descriptors. Model 15 uses one Gaussian kernel and one rational quadratic
kernel on each chemical descriptor. Models 14 and 16 are like the previous two models,
except that training compounds are weighted according to their target value.
Performance
Based on the results (Table 4.5), three models were selected for prospective virtual
screening. Models 14 and 16 were selected for best performance as measured by MAE
and FI20, respectively. Model 7 was selected because it performed as well as model 14
while being markedly simpler.
y-scrambling
As a negative control, we carried out the described validation procedures with randomly
permuted target labels for the baseline models and the models selected for prospective
screening (Table 4.6). The performance of linear ridge regression did not change, indicat-
ing that the linear model was not able to learn from the data in the beginning, whereas
the performance of all other models decreased and the variance of their performance
estimates increased, as should be.
4.3 Prospective screening
The three models 7, 14, and 15 with best retrospective performance were used to virtually
screen a vendor library for novel agonists of PPARγ. From the results, 15 compounds
were manually selected and tested in a transfection assay for activation of the receptor.
The most PPARγ-selective compound was investigated further, including the elucidation
of its conformation, and identiﬁed as a natural product.
4.3.1 Virtual screening
Models 7, 14, and 15 (Table 4.5), selected due to their retrospective performance, were
trained on the whole ppar data set.
Screening library
The Asinex (www.asinex.com) gold and platinum libraries (version of November 2007,
including updates) were joined into data set asinex. Preprocessing and descriptor com-
putation were carried out as for retrospective evaluation (Subsection 4.2.2). Duplicates
were removed, resulting in 360150 compounds altogether.
Compound selection
The selected models were applied to the asinex data set, yielding an aﬃnity prediction
and conﬁdence estimate for each compound. The data set was ranked according to each4.3 Prospective screening 165
Table 4.5 Retrospective performance of two baseline models (linear ridge regression,
support vector machines) and various Gaussian process models. Model names have
the form descriptor/kernel, where + indicates combinations of kernels using multiple
kernel learning. Performance of the best model in each block is in bold face. Stars ?
indicate models selected for prospective screening. # = model number, MAE = mean
absolute error, FI20 = fraction of inactives among the 20 top-ranked compounds, CATS2D =
chemically advanced template search descriptor, MOE 2D = molecular operating environment
2D descriptors, all = CATS2D, MOE 2D, and Ghose-Crippen descriptors together, allmkl =
as all, but with individual kernel on each descriptor using multiple kernel learning, topo = un-
annotated structure graph, elem = structure graph with element and bond type annotation, ppp
= structure graph with potential pharmacophore point annotation, RBF = radial basis function
kernel (Gaussian kernel), RQ = rational quadratic kernel, ISOAK = iterative similarity optimal
assignment kernel, W = compounds weighted by activity.
# Model MAE FI20 ?
Linear ridge regression
1 CATS2D/none 1.70±0.14 0.80±0.08
2 MOE 2D/none 1.45±0.04 0.78±0.05
3 Ghose-Crippen/none 1.70±0.08 0.79±0.04
Support vector machines
4 CATS2D/RBF 0.68±0.06 0.33±0.08
5 MOE 2D/RBF 0.69±0.08 0.29±0.14
6 Ghose-Crippen/RBF 0.86±0.12 0.41±0.09
Gaussian process regression
7 CATS2D/RBF+RQ 0.66±0.09 0.27±0.14 ?
8 MOE 2D/RBF+RQ 0.76±0.06 0.25±0.12
9 Ghose-Crippen/RBF+RQ 0.86±0.07 0.33±0.12
10 topo/ISOAK 0.68±0.06 0.33±0.15
11 elem/ISOAK 0.74±0.06 0.32±0.14
12 ppp/ISOAK 0.70±0.06 0.38±0.09
13 topo/ISOAK+all/RBF+all/RQ 0.67±0.08 0.31±0.14
14 topo/ISOAK+all/RBF+all/RQ+W 0.66±0.07 0.32±0.15 ?
15 topo/ISOAK+allmkl/RBF+allmkl/RQ 0.70±0.11 0.21±0.09 ?
16 topo/ISOAK+allmkl/RBF+allmkl/RQ+W 0.71±0.12 0.26±0.12
model by the ˆ µ−ˆ σ2 statistic used in retrospective evaluation. A ﬁlter was used to ensure
that all compounds had either a carboxylic, a tetrazole, or, a thiazolidinedione group.16
From the 30 top-ranked compounds of each model (Schemes A.1, A.2, and A.3),
15 compounds were manually selected (“cherry-picked”) by a panel of human experts,
based on presumed activity and novelty of scaﬀold (Scheme 4.8).
16Filtering was done using MOE (molecular operating environment, Chemical Computing
Group, www.chemcomp.com) and the SMARTS strings C(=O)[OH], [#6]1[#7][#7][#7][#7]1, and
C1C(=O)NC(=O)S1. SMARTS (SMILES arbitrary target speciﬁcation; Daylight Chemical Informa-
tion Systems, www.daylight.com) is an extension of SMILES (simpliﬁed molecular input line entry
speciﬁcation; Weininger, 1988; Weininger et al., 1989), a string representation of molecules, to patterns



















































































































Scheme 4.8 Compounds selected for assay tests.4.3 Prospective screening 167
Table 4.6 Retrospective performance of baseline and selected models under
y-scrambling. Model names and abbreviations as in Table 4.5.
# Model MAE FI20
Linear ridge regression
1 CATS2D/none 1.70±0.14 0.80±0.08
2 MOE 2D/none 1.45±0.04 0.78±0.05
3 Ghose-Crippen/none 1.70±0.08 0.79±0.04
Support vector machines
4 CATS2D/RBF 1.09±0.08 0.66±0.21
5 MOE 2D/RBF 1.10±0.10 0.68±0.24
6 Ghose-Crippen/RBF 1.12±0.06 0.64±0.20
Gaussian process regression
7 CATS2D/RBF+RQ 1.08±0.02 0.57±0.17
14 topo/ISOAK+all/RBF+all/RQ+W 1.08±0.02 0.70±0.22
15 topo/ISOAK+allmkl/RBF+allmkl/RQ 1.11±0.06 0.65±0.12
4.3.2 Transactivation assay
The compounds in Scheme 4.8 were tested in an in vitro cell-based transactivation assay.
We brieﬂy summarize the procedure; the assay was established and validated by Rau
et al. (2006), and is based on work by Fu et al. (2003) and Takamura et al. (2004).
Idea
Cultured mammalian cells, here the immortalized simian kidney cell line Cos7, are co-
transfected with a PPAR expression plasmid and a PPAR response element-linked re-
porter plasmid, in our case encoding for luciferase, a bioluminescent enzyme. After
transfection, the cells express the PPAR in its inactive conformation. Upon treatment
with a PPAR agonist, the receptor is activated and the reporter gene is expressed. The
resulting luciferase-induced luminescence can be measured and compared to that of the
positive control, here pioglitazone (Compound 35), resulting in a measure of relative
activation of PPAR.
Reagents and materials
Foetal calf serum, dimethyl sulfoxide (DMSO) solvent, and ethanol absolute were ob-
tained from Sigma-Aldrich (www.sigmaaldrich.com), Dulbecco’s modiﬁed Eagle’s me-
dium (DMEM) and OptimemTM from Gibco (Carlsbad, California, USA); sodium pyru-
vate solution, glutamine, penicillin and streptomycin stock solutions from PAA Labo-
ratories GmbH (Pasching, Austria); LipofectamineTM 2000 from Invitrogen (Carlsbad,
California, USA); DualGloTM luciferase assay system from Promega (Madison, Wiscon-
sin, USA).168 4 Peroxisome proliferator-activated receptor
Plasmids
The Gal4 fusion receptor plasmids pFA-CMV-hPPARα-LBD, pFA-CMV-hPPARβ/δ-
LBD and pFA-CMV-hPPARγ-LBD, containing the respective hinge regions and the
ligand binding domains, were constructed by integrating cDNA fragments obtained
from polymerase chain reaction ampliﬁcation of human monocytes, into the SmaI/XbaI
sites of the pFA-CMV vector (Stratagene; La Jolla, California, USA). The cDNA frag-
ments contained base pairs 499–1407 (NM 005036;17 hPPARα), base pairs 412–1323
(NM 006238; hPPARβ/δ) and base pairs 610–1518 (NM 015869; hPPARγ). Frame
and sequence of the fusion receptors were veriﬁed by sequencing. pFR-Luc (Strata-
gene, www.stratagene.com) was used as reporter plasmid and pRL-SV40 (Promega,
www.promega.com) for normalization of transfection eﬃcacy.
Cell culture and transfection
Cos7 cells (kindly provided by Dieter Steinhilber; University of Frankfurt, Germany)
were cultured in DMEM high-glucose supplemented with 10% foetal calf serum contain-
ing 100U/mL penicillin, 100µg/mL streptomycin, 2mM glutamine and 1mM sodium
pyruvate at 37 ◦C and 10% CO2. Cells were seeded at 30000 cells/well in a 96 wellplate.
After 24h transfection was carried out using LipofectamineTM 2000 according to manu-
facturer’s protocol. Transfection mixes contained 0.8µL LF2000, 280ng pFR-Luc, 2ng
pRL-SV40, and 14ng of the appropriate fusion receptor plasmid for each well. 4h
after transfection the medium was changed to DMEM without phenol red containing
100U/mL penicillin, 100µg/mL streptomycin, 2mM glutamine, 1mM sodium pyru-
vate, the appropriate concentration of the test substance and 0.1% DMSO. In every
single experiment each concentration was tested in triplicate wells. Cells were incubated
overnight and assayed for reporter gene activity with the DualGloTM luciferase assay
system. Luminescence of both luciferases was measured in GENiosPro Luminometer
(Tecan; Zurich, Switzerland). Each experiment was repeated independently at least
three times.
Calculations
Luciferase activity for all assays was corrected by subtracting background activity ob-
tained from non-transfected controls. Relative light units were calculated by dividing
ﬁreﬂy light units by renilla light units. Activation factors were determined by dividing
mean values of relative light units for each concentration of the agonist by mean rela-
tive light values of the DMSO control. Relative activation was calculated by dividing
the activation factors by the activation factor obtained with 1µM pioglitazone (Com-
pound 35), the positive control in each experiment. All data are presented as mean ±
standard deviation of 3 independent experiments. EC50 values were calculated based on
the mean of the relative activation for each tested concentration of at least 3 individual
experiments. SigmaPlot (SPSS, version 2001, www.spss.com) was used to ﬁt the four







where min is the minimum activation, max is the maximum activation, EC50 is the half
maximal eﬀective concentration, and s is the slope parameter.
17NM xxxxxx codes are GenBank (www.ncbi.nlm.nih.gov/Genbank) identiﬁers.4.3 Prospective screening 169
hPPAR Activation [%] at 10µM
# α β/δ γ
57 30.6±16 i.a. 35.5±11
58 16.6±8 i.a. i.a.
59 22.9±1 i.a. i.a.
60 69.9±10 i.a. i.a.
62 92.2±17 i.a. 123.6±12
63 30.0±11 i.a. i.a.
68 34.1±8 i.a. 32.5±4
71 i.a. i.a. 73.1±17
Table 4.7 Activation of human PPAR
subtypes by the selected compounds at
10µM concentration in dimethylsulfox-
ide. Compounds 61, 64, 65, 66, 67, 69,
and 70 were inactive on all three sub-
types (not shown). Entries for which
EC50 values were determined are shown
in bold face. PPAR = peroxisome pro-
liferator activated receptor, hPPAR = hu-
man PPAR, # = compound number, i.a.
= inactive.
4.3.3 Results
Of the 15 selected compounds, 7 showed no activity on PPARα, PPARβ/δ, and PPARγ
at 10µM concentration, and were not investigated further. Based on their relative
activation values (Table 4.7), EC50 values were determined for 4 of the remaining com-
pounds (Figure 4.11). In total, a partial PPARα agonist (Compound 68), a selective
partial PPARα agonist (Compound 60), a dual PPARα/γ agonist (Compound 62), and,
a selective full PPARγ agonist (Compound 71; MR16) were discovered, resulting in an
overall hit rate of 27%.
4.3.4 Compound MR16
Compound 71 (2,4-diphenyl-3-(o-tolyloxycarbonyl)cyclobutane-carboxylic acid, MR16)
is a selective full PPARγ-agonist with EC50 = 10.03±0.2µM, a maximum activation
of 138 ± 2% (Figure 4.11d), and an interesting cyclobutane-based scaﬀold. It showed
no cytotoxicity in cell-based assay tests. Its presumed binding mode as determined by
docking is shown in Figure 4.12.
Natural product
Compound MR16 is a truxillic acid derivative (Scheme 4.9). Truxillic acid (Com-
pound 73) is synthesized in plant cell walls by photo-dimerization of trans-cinnamic acid
(Compound 74; Bernstein and Quimby, 1943), as well as the latters hydroxy deriva-
tives p-coumaric acid and ferulic acid (Compounds 75 and 76; Morrison III et al., 1992).
Plant cell walls often contain phenolic acids such as (di)ferulic acid, p-coumaric acid,
and truxillic acid. They are bound by ester linkage to the polysaccharide constituents
of cell walls, especially of grasses (Krishnamurthy, 1999).
Stereochemistry
The stereochemical conﬁguration of MR16 was determined by nuclear magnetic reso-
nance spectroscopy (NMR; Slichter, 1990). Scheme 4.10 shows all possible conﬁgurations
of MR16. Analysis of the 1H-spectrum (Figure A.1) allows a ﬁrst discrimination between
the diﬀerent conﬁgurations. The chemical shifts of the proton signals for the cyclobutane
protons next to the phenyl rings would be identical for all cis-diphenyl isomers, yielding
three peaks (1:2:1), whereas the trans-diphenyl isomers result in four peaks (1:1:1:1).












(a) Compound 60 (left) and dose-response curve for hPPARα activation (right; hPPARα EC50























(b) Compound 62 (left) and dose-response curves for hPPARα activation (middle; hPPARα EC50
= 12.98±4.21µM, maximum activation of 200±32%) and hPPARγ activation (right; hPPARγ
EC50 = 3.75±0.2µM, maximum activation = 76±3%). A dual PPARα/γ agonist, with full

















(c) Compound 68 (left) and dose-response curve for hPPARα (right; hPPARα EC50 =










(d) Compound 71 (left) and dose-response curve for hPPARγ (right; hPPARγ EC50 =
10.03±0.2µM, maximum activation = 138±2%). A full selective PPARγ agonist.
Figure 4.11 Summary of virtual screening hits. Out of 15 selected compounds, 4 were
active on PPAR (27% hit rate). Shown are assay measurements (n ≥ 3, orange disks)
with standard deviation (error bars), ﬁtted dose-response curves (solid lines), minimum
and maximum activation (dotted lines), and EC50 values (dashed lines). Note that plot
axes have linear scale. r.A. = activation relative to control, c. = ligand concentration, PPAR
= peroxisome proliferator-activated receptor, hPPAR = human PPAR, EC50 = half maximal
eﬀective concentration.4.3 Prospective screening 171
Figure 4.12 Binding mode of Compound MR16 for PPARγ, as obtained by the docking
software GOLD (version 4.0.1, Cambridge crystallographic data centre, Cambridge, Eng-
land). Shown are MR16 (green ball-and-stick model), helix 3 (gray cartoon model) and
helix 12 (activation function 2, red cartoon model) of the PPARγ ligand binding domain
(PDBid 1fm9; Gampe et al., 2000), four amino acids (green ball-and-stick models) and
their interactions with the carboxylic acid group of MR16 (dashed black lines), as well
as the binding mode of the PPARγ agonist farglitazar (black line model; Compound 36,
Figure 4.3) for comparison. PPAR = peroxisome proliferator-activated receptor, PDBid =
protein data bank identiﬁer, H = helix, Ser = serine, His = histidine, Tyr = tyrosine.172 4 Peroxisome proliferator-activated receptor
To discriminate between the remaining two pairs, the ratio of the coupling constants
and the nuclear Overhauser eﬀect (Overhauser, 1953; Anet and Bourn, 1965) were used.
Consider the neighborhood of the cyclobutane-phenyl protons in Compounds 77 and 78:
One of them has two cis-neighboring protons, the other has two trans-neighboring pro-
tons. In Compounds 79 and 80, both protons have one cis- and one trans-neighboring
proton. The coupling constants of the two protons have diﬀerent values (∆J = 0.7Hz),
and therefore identify the conﬁguration of Compound MR16 to be the one given by
Compounds 77 and 78. Diﬀerential nuclear Overhauser eﬀect spectra (Figures A.2, A.3)
and a rotating frame nuclear Overhauser eﬀect spectrum (Figure A.4) conﬁrmed this.
In summary, nuclear magnetic resonance spectroscopy identiﬁed a racemate of Com-
pounds 77 and 78 as the investigated conﬁguration of Compound MR16.
4.4 Conclusions
Kernel-based learning approaches, in particular graph kernels and Gaussian processes,
were successfully applied to ligand-based virtual screening, resulting in the discovery of
MR16, a selective full PPARγ agonist with novel scaﬀold.
4.4.1 Summary
The peroxisome proliferator-activated receptor (PPAR) is a nuclear transcription factor
involved in the regulation of lipid and glucose metabolism that plays a crucial role
in the development of diseases like type 2 diabetes and dyslipidemia. We established
a Gaussian process regression model for PPARγ agonism using a public data set of
144 compounds annotated with pKi-values measured in scintillation proximity assays.
The compounds were represented using a combination of chemical descriptors and the
iterative similarity optimal assignment kernel (Chapter 2) via multiple kernel learning.
Screening of a large (3.6 · 105 compounds) vendor library and subsequent testing of 15
selected compounds in a cell-based transactivation assay resulted in 4 active compounds.
One compound, a natural product with cyclobutane scaﬀold, is a full selective PPARγ-
agonist (EC50 = 10 ± 0.2µM, inactive on PPARα and PPARβ/δ at 10µM). Our study
delivered a novel agonist, de-orphanized a natural bioactive product, and, hints at the
natural product origins of pharmacophore patterns in synthetic ligands.
4.4.2 Retrospective evaluation
We discuss retrospective evaluation results (Tables 4.5 and 4.6).
Non-linear nature of PPARγ agonism
The performance of ridge regression models with diﬀerent descriptors, which were used
as linear baseline models, did not change under y-scrambling, whereas the performance
of all other methods did. Together with the good performance (Table 4.5) of non-linear
models with the same descriptors, this implies that PPARγ binding is a non-linear
process that linear models are not able to capture.
Suitability of Ghose-Crippen descriptors
In all non-linear models explicitly based on descriptors (models 4–9), Ghose-Crippen
fragment descriptors perform markedly worse than CATS2D and MOE 2D descriptors,
with an average RMSE diﬀerence of 0.16, and 0.09 for FI20. Ghose-Crippen fragment

















Scheme 4.9 Structures of MR16, truxillic acid, and monomer components. MR16 is a
truxillic acid derivative, which in turn can be synthesized from Compounds 74, 75, and
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Scheme 4.10 Possible absolute conﬁgurations of Compound MR16. The labeling gives
the number of peaks of the cyclobutane protons in the 1H-NMR spectrum (Figure A.1),
as well as conﬁguration isomerism.174 4 Peroxisome proliferator-activated receptor
Compound weighting
Models 13 and 14, as well as models 15 and 16, diﬀer only in that models 14 and 16
weight compounds by their activity. Models 13 and 14 perform equally well (diﬀerences
in RMSE and FI20 were less than 0.01); models 15 and 16 diﬀer by 0.01 in RMSE, while
for FI20, performance is worse for the weighted model (by 0.05, within the standard
deviation of 0.09). Focusing on highly active compounds did not improve predictive
performance, not even for other highly active compounds, as indicated by FI20. This
might indicate that in this study, the advantage of improved generalization capability
gained by consideration of all samples outweighed the speciﬁcity advantage gained by
concentrating on a small sample group.
Multiple kernel learning
Using separate kernels for the vectorial descriptors (models 15 and 16 versus models 13
and 14) slightly worsened mean absolute error, but improved (lessened) the fraction of
inactives in the 20 top-ranked compounds. Descriptors were standardized, i.e., using the
same length scale, which allowed using a single kernel for several descriptors in the ﬁrst
place. A tentative explanation is that a single kernel might generalize better, thereby
improving MAE, while separate kernels might ﬁt speciﬁc compound groups more closely,
possibly leading to improved FI20.
4.4.3 Prospective screening
We discuss topics related to the discovered hits.
Activity on PPARα and PPARβ/δ
All selected compounds were predicted by our models to be active on PPARγ. Of the
four hits, one was selective for PPARγ, one was active on PPARα and PPARγ, and two
were selective for PPARα. No compound was active on PPARβ/δ. We attribute this to
properties of the binding pockets, and the fuzzy nature of ligand-based virtual screening.
The binding pocket of PPARβ/δ is the smallest of the three, and can not accommo-
date many of the other two subtypes ligands for sterical reasons. The pocket of PPARα
is the largest one, and more similar to the one of PPARγ. Together, this might explain
why compounds were inactive on PPARβ/δ.
Subtype selectivity is often achieved via diﬀerences in the left proximal and dis-
tal subpockets, which are not necessarily directly relevant to activity. The model was
trained on activity alone, with no consideration of selectivity. This might account for
the compound active on PPARα and PPARγ.
Ligand-based virtual screening is based on the similarity principle, and therefore in-
herently fuzzy in the sense that changes in activity induced by structural modiﬁcations
can be estimated only with limited accuracy. From another point of view, the complex-
ity of the modeled biochemical process, the high (measurement) noise levels, and the
relative scarcity of samples render activity estimation diﬃcult. This eﬀect is particu-
larly pronounced when, as in this study, scaﬀold hopping is involved, which by deﬁnition
leaves or at least strains the domain of applicability. The inactive compounds, as well as
the presence of compounds selective for PPARα might be attributed to these aspects.
The above considerations oﬀer a possible explanation of the observed facts; however,
due to the small sample size (n = 15), no deﬁnite conclusions can be drawn.4.4 Conclusions 175
De-orphanization of a natural product
The identiﬁcation of Compound MR16 as a selective full PPARγ agonist de-orphanizes
truxillic acid derivatives in the sense that it provides a possible explanation for the em-
pirically known anti-inﬂammatory eﬀects of this compound class. Traditional medicines,
e.g., herbal plant extracts, often rely exclusively on empirically observed eﬀects. The
identiﬁcation of the molecular mechanisms behind such drugs beneﬁts both their thera-
peutic use and the development of novel lead compounds based on natural substances.
Natural product origins
Known ligands are the result of incremental drug research processes, with origins in (Ji
et al., 2009) and continuing input from (Newman and Cragg, 2007) natural products.
Consequently, pharmacophoric patterns of natural products are encoded in synthetic
drugs. We believe this to be the underlying fact that allowed us to discover the phar-
maceutical activity of a natural product on the basis of mostly synthetic compounds.
4.4.4 Outlook
We propose ideas for further research.
• Utility of graph kernels: The present study adds to the growing body of research
(Subsection 2.2.7) where graph kernels improve predictive performance in bio- and
cheminformatics applications. Evidence is, however, still preliminary, and further sys-
tematic studies of the utility of graph kernels, in particular with regard to ligand-based
virtual screening and quantitative structure-property relationships, are warranted.
• Reliability of Gaussian process conﬁdence estimates: Gaussian process regression
provides an implicit domain of applicability in the form of conﬁdence estimates, or
predictive variance. Advantages of these estimates include their analytical form, and
that they constitute an implicit and integral part of the algorithm. Considering that
their utility for quantitative structure-property relationships has already been demon-
strated (Table 4.4), Gaussian processes should be of particular interest for reliable
toxicity prediction within the European Unions registration, evaluation, authoriza-
tion and restriction of chemicals legislative (REACH; regulation EC 1907/2006). In
the next 5–7 years, the evaluation of large numbers of chemicals with production
volumes of less than 1000tons/year will have to rely increasingly on computational
methods. To further qualify Gaussian process regression for regulatory-purpose toxi-
city prediction, quantitative validations of the reliability of their conﬁdence estimates
in this context would be beneﬁcial.
• Cynodon dactylon: For some herbals there is evidence from animal studies that
they improve diabetic disorders, but no molecular mechanism is known. One example
for such a plant is the the grass Cynodon dactylon, whose extract was shown to have
anti-diabetic potential by lowering blood glucose levels and additionally improving hy-
perlipidemia in rats (Singh et al., 2007). Cynodon dactylon contains several ﬂavonoids
and sterols which could potentially cause these eﬀects, but it also contains a high
amount of substituted truxillic acids in its cell walls (Hartley et al., 1990). Truxil-
lic acid shows anti-inﬂammatory activity in mice formalin tests (signiﬁcantly reduced
pawn licking time after formalin injection; its dimeric structure is thought to be rele-
vant for this eﬀect; Chi et al., 2005), and PPARγ is involved in inﬂammatory response
regulation (p. 144; compare Compounds 12 and 21). We are currently investigating
whether the anti-diabetic eﬀects of Cynodon dactylon are mediated by truxillic acids
or their derivatives such as Compound MR16.176 4 Peroxisome proliferator-activated receptor
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Supplementary data
The following data are provided supplementary to the main text.
• Top predictions: Schemes A.1, A.2, and A.3 show the 30 top-ranked compounds of
models 7, 14, and 15, respectively, deﬁned in Chapter 4 on p. 162.
• Nuclear magnetic resonance spectra: 1H-nuclear magnetic resonance spectrum (1H-
NMR, Figure A.1), nuclear Overhauser eﬀect diﬀerential spectra (NOE, Figures A.2
and A.3), and rotating frame nuclear Overhauser eﬀect spectrum (ROESY, Fig-
ure A.4), used in identiﬁcation of Compound MR16’s conﬁguration (p. 169).
Experiments were performed on a Bruker NMR spectrometer (Bruker optics, www.
brukeroptics.com; AV300MHz for 1H-NMR, NOE; AV400MHz for ROESY). All













































































































Scheme A.1 30 top-ranked compounds of model 7 (CATS2D/RBF+RQ). ? = selected


















































































































































































































































































Scheme A.2 30 top-ranked compounds of model 14 (topo/ISOAK+all/RBF+all/RQ+























































































































































































































































































Scheme A.3 30 top-ranked compounds of model 15 (topo/ISOAK + allmkl/RBF +






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Zentrales Thema der Arbeit ist die Untersuchung der N¨ utzlichkeit moderner Kern-ba-
sierter maschineller Lernverfahren f¨ ur das Liganden-basierte virtuelle Screening. Dies
beinhaltet die Weiterentwicklung der Lernverfahren und ihre Anpassung an die speziﬁ-
schen Anforderungen dieser Anwendung. Die zu Grunde liegende Hypothese lautet ”mo-
derne Kern-basierte maschinelle Lernverfahren k¨ onnen das Liganden-basierte virtuelle
Screening verbessern.“
Beitrag
Die wesentlichen Beitr¨ age dieser Arbeit sind
• eine Einf¨ uhrung in das Liganden-basierte virtuelle Screening,
• eine Untersuchung von Distanzph¨ anomenen in hochdimensionalen chemischen De-
skriptorr¨ aumen und ihrer Auswirkungen auf ¨ Ahnlichkeits-basierte Verfahren,
• ein Literatur¨ uberblick ¨ uber Empfehlungen zur retrospektiven Validierung,
• ein Literatur¨ uberblick ¨ uber Graphkerne,
• Entwicklung und Validierung eines neuen Graphkerns basierend auf iterativer Graph-
¨ ahnlichkeit und optimalen Knotenzuordnungen,
• eine Einf¨ uhrung in die Kernhauptkomponentenanalyse,
• ein Machbarkeitsnachweis f¨ ur Projektionsfehler-basiertes Novelty Detection f¨ ur Ligan-
den-basiertes virtuelles Screening mit ausschließlich positiven Proben,
• ein Literatur¨ uberblick ¨ uber den Peroxisom-Proliferator-aktivierten Rezeptor,198 B Zusammenfassung & curriculum vitæ
• eine prospektive virtuelle Screeningstudie mit Gaußprozessen, resultierend in einem
selektiven Agonisten des Peroxisom-Proliferator-aktivierten Rezeptors γ mit neuem
Grundger¨ ust.
Eine Liste bereits ver¨ oﬀentlichter Publikationen sowie zur Ver¨ oﬀentlichung eingereichter
Manuskripte ﬁndet sich auf Seite 18 und im Lebenslauf am Ende der Arbeit.
Kapitel 1: Liganden-basiertes virtuelles Screening
Virtuelles Screening ist ”die rechnergest¨ utzte Sortierung von chemischen Verbindun-
gen gem¨ aß ihrer vorhergesagten Aktivit¨ at“, z.B. auf einem Rezeptor, Kanal oder Gen.
Es spielt in der Medikamentenentwicklung (in der fr¨ uhen Treﬀerﬁndungsphase, Abbil-
dung 1.1) eine Rolle. Im Folgenden beziehen wir uns stets auf das Liganden-basierte vir-
tuelle Screening; dieses unterscheidet sich vom Struktur-basierten virtuellen Screening
(Docking) dadurch, dass es nur Informationen ¨ uber bekannte Liganden, nicht jedoch die
Struktur des Rezeptors ben¨ otigt.
Kern-basierte maschinelle Lernverfahren
Induktive maschinelle Lernverfahren suchen algorithmisch nach Mustern in vorhandenen
Daten (den Trainingsdaten), um sie dann auf neue Daten (die Testdaten) anzuwenden.
Man unterscheidet zwischen un¨ uberwachten, semi¨ uberwachten und ¨ uberwachten Lern-
verfahren, je nachdem, ob f¨ ur keine, manche oder alle Daten Zielwerte vorliegen. Novelty
Detection ist ein un¨ uberwachtes Lernproblem mit der Fragestellung, ob die Testdaten der
gleichen Verteilung entstammen wie die Trainingsdaten. Beispiele f¨ ur ¨ uberwachte Lern-
probleme sind Klassiﬁkation (endlich viele Zielwerte) und Regression (reelle Zielwerte).
Virtuelles Screening wird oft als bin¨ ares Klassiﬁkationsproblem formuliert. Ein Problem
dabei ist, dass echte Negativbeispiele (experimentell veriﬁzierte inaktive Substanzen)
meist nicht verf¨ ugbar sind und als Ersatz zuf¨ allig ausgew¨ ahlte Substanzen verwendet
werden.
Bei Kern-basierten maschinellen Lernverfahren werden die Eingabedaten nichtlinear
in einen hochdimensionalen Raum projiziert. Dort wird ein lineares Verfahren, z.B. die
Berechnung einer trennenden Hyperebene oder Regression, eingesetzt (Abbildung 1.2).
Um nicht explizit in solchen R¨ aumen rechnen zu m¨ ussen, werden Kernfunktionen einge-
setzt, die im Ursprungsraum berechnet werden, aber inneren Produkten im transformier-
ten Raum entsprechen. Das Lernverfahren kann, so es sich auf die Berechnung innerer
Produkte zur¨ uckf¨ uhren l¨ asst, implizit im Ursprungsraum ausgef¨ uhrt werden.
Repr¨ asentation und ¨ Ahnlichkeit von Molek¨ ulen
Entscheidend f¨ ur den Erfolg solcher Verfahren ist die Wahl einer geeigneten molekularen
Repr¨ asentation; diese muss die notwendigen Informationen zur Vorhersage der Zielwerte
enthalten. Da quantenmechanische Verfahren zu rechenaufw¨ andig sind, werden einfa-
chere Repr¨ asentationen verwendet, in der Regel Vektoren, deren Komponenten einfache
numerische Kennzahlen (Deskriptoren) sind. In der Folge lassen sich Molek¨ ule als Vek-
toren (Punkte) in hochdimensionalen chemischen Deskriptorr¨ aumen auﬀassen. In die-
sen treten, bedingt durch die exponentielle Zunahme des Volumens mit der Dimension,
¨ uberraschende Eﬀekte auf: das Ph¨ anomen des leeren Raumes, Kugelvolumen-bedingte
Ph¨ anomene und Distanzkonzentration. Alle Ph¨ anomene setzen bereits bei geringer Di-
mensionalit¨ at ein und sollten bei ¨ Ahnlichkeits-basierten Verfahren ber¨ ucksichtigt wer-
den. Es stellt sich heraus, dass chemische Datens¨ atze fast immer von niedrigerer Di-199
mensionalit¨ at sind als der einbettende chemische Deskriptorraum und diese intrinsische
Dimensionalit¨ at die ausschlaggebende ist.
Retrospektive Validierung
Die retrospektive Validierung, also die Validierung auf bekannten Daten, wird durch zahl-
reiche Verzerrungen in chemischen Datens¨ atzen erschwert, u.A. durch Verzerrungen in
der Verteilung einfacher Eigenschaften (property bias), das Auftreten von Molek¨ ulserien
(analogue bias), die Entstehung der Datens¨ atze (inductive bias), das Verh¨ altnis von ak-
tiven zu inaktiven Substanzen und die Genauigkeit der Zielwerte. Der h¨ auﬁg zur Bewer-
tung des Erfolgs eingesetzte Anreicherungsfaktor (Gleichung 1.11) hat schwerwiegende
Nachteile; es wird empfohlen, stattdessen die Fl¨ ache unter der Receiver Operating Cha-
racteristic Curve (ROCAUC) bzw. die Wurzel aus dem durchschnittlichen quadratischen
Fehler (RMSE) zu verwenden. Zahlreiche weitere Empfehlungen aus der Literatur sind
in Tabelle 1.5 zusammengefasst.
Kapitel 2: Ein Graphkern f¨ ur Molek¨ ule
Graphkerne sind Kernfunktionen, die direkt auf Graphen, z.B. den annotierten Struk-
turgraphen von Molek¨ ulen, deﬁniert sind.
Graphkerne
Existierende Graphkerne basieren meist auf zuf¨ alligen Irrfahrten (random walks, Unter-
abschnitt 2.2.2), Baum- sowie zyklischen Mustern (tree patterns, Unterabschnitt 2.2.3;
cyclic patterns, Unterabschnitt 2.2.4) oder optimalen Knotenzuordnungen (optimal assi-
gnments, Unterabschnitt 2.2.5). Sie stellen prinzipiell eine Abw¨ agung zwischen Laufzeit
und Vollst¨ andigkeit (der F¨ ahigkeit zur Unterscheidung nicht-isomorpher Graphen) dar.
Iterative ¨ Ahnlichkeit und optimale Knotenzuordnungen
Basierend auf Arbeiten zur iterativen Graph¨ ahnlichkeit deﬁnieren wir den neuen Graph-
kern ISOAK (iterative similarity optimal assignment graph kernel). Die zentrale re-
kursive Gleichung 2.64 deﬁniert eine paarweise ¨ Ahnlichkeit zwischen den Knoten zweier
Graphen, unter Ber¨ ucksichtigung von Atom- und Bindungsannotationen. Auf Grundlage
der resultierenden ¨ Ahnlichkeitsmatrix wird dann eine Zuordnung der Knoten zueinander
berechnet, welche die Gesamt¨ ahnlichkeit maximiert. Letztere dient (normiert) als Maß
f¨ ur die ¨ Ahnlichkeit der beiden Graphen. Wir beschreiben einen iterativen Algorithmus
zur eﬃzienten Berechnung unseres Graphkerns (kubische Laufzeit), beweisen die Ein-
deutigkeit der L¨ osung und geben eine obere Schranke f¨ ur die Anzahl der ben¨ otigten
Iterationen an.
Retrospektive Validierung
In einer retrospektiven virtuellen Screening-Studie zeigen St¨ utzvektormaschinen (sup-
port vector machines) mit unserem Graphkern eine durchgehend bessere Leistung als
bei der Verwendung von chemischen Deskriptoren und anderen Graphkernen, die auf
optimalen Knotenzuordnungen basieren.200 B Zusammenfassung & curriculum vitæ
Kapitel 3: Dimensionsreduktion und Novelty Detection
Chemische Datens¨ atze liegen oft auf Mannigfaltigkeiten (lokal Euklidischen R¨ aumen)
von niedrigerer Dimensionalit¨ at als die des umgebenden Deskriptorraums. Dimensions-
reduktionsmethoden identiﬁzieren solche Mannigfaltigkeiten und stellen dadurch letzten
Endes deskriptive Modelle der Daten zur Verf¨ ugung.
Spektrale Dimensionsreduktionsmethoden
Spektrale Dimensionsreduktionsmethoden verwenden das Spektrum eines Datensatzes,
z.B. die Eigenwerte einer aus den Daten berechneten Matrix. Viele solcher Methoden
basieren auf der Hauptkomponentenanalyse (principle component analysis, PCA), ei-
ner Technik, die orthogonale Richtungen maximaler Varianz in den Daten ﬁndet. Die
Hauptkomponentenanalyse kann auf die Berechnung innerer Produkte zur¨ uckgef¨ uhrt
werden, indem die Hauptkomponenten als Linearkombination innerer Produkte mit den
Trainingsdaten dargestellt werden (Kernhauptkomponentenanalyse, kernel PCA, Algo-
rithmus 3.2). F¨ ur spektrale Dimensionsreduktionsmethoden auf Basis der PCA ist der
Projektionsfehler ein quantitatives Maß daf¨ ur, wie gut ein Datum durch ein solches Mo-
dell beschrieben wird. Dies kann zur Identiﬁkation von Daten (Molek¨ ulen) verwendet
werden, die sich strukturell von den Trainingsdaten unterscheiden: Projektionsfehler-
basiertes Novelty Detection f¨ ur virtuelles Screening unter alleiniger Verwendung von
Positivbeispielen.
Beispiel Fetts¨ auren
Wir zeigen die grundlegende Machbarkeit dieses Ansatzes anhand einer detaillierten re-
trospektiven Studie zur Lernbarkeit des Konzepts von Fetts¨ auren (aliphatische einkettige
Monokarboxyls¨ auren). Anhand eines von uns erstellten Datensatzes von 80 Fetts¨ auren
(Schema 3.2) und 80 Fetts¨ aure-¨ ahnlichen Molek¨ ulen (decoys, Schema 3.3) zeigen wir,
dass die prim¨ aren Eigenschaften von Fetts¨ auren, n¨ amlich L¨ ange und S¨ attigung der Koh-
lenstoﬀkette, den ersten beiden Hauptkomponenten entsprechen. Wir interpretieren die
Gewichtung der einzelnen Deskriptoren und erkl¨ aren Aspekte wie Ausreißer, die Rolle
von Invarianten, Stabilit¨ at und den Einﬂuss von Rauschen.
Kapitel 4: Der Peroxisom-Proliferator-aktivierte Rezeptor
Der Peroxisom-Proliferator-aktivierte Rezeptor (PPAR) ist ein im Zellkern vorkommen-
der Rezeptor, der den Fett- und Glukosestoﬀwechsel reguliert. Er spielt eine zentrale
Rolle bei der Entstehung von Krankheiten wie Diabetes und Dyslipid¨ amie.
Der Rezeptor
PPAR ist ein Rezeptor des Zellkerns (Abbildung 4.2); er bildet Heterodimere mit dem
RXR-Rezeptor und reguliert die Expression von Genen mit PPAR-speziﬁschen Antwort-
elementen (Abbildung 4.1). Es gibt drei Subtypen des Rezeptors, PPARα, PPARβ/δ
und PPARγ, die sich in ihrer Expression und Funktion unterscheiden. Sie verf¨ ugen ¨ uber
große Bindetaschen (Abbildung 4.4) mit diversen Fetts¨ auren als endogenen Liganden
(Schema 4.1).201
Retrospektive Validierung
Wir verwenden Techniken der retrospektiven Validierung, um auf Grundlage eines ver¨ of-
fentlichten Datensatzes von 176 PPARγ-Agonisten die besten drei Modelle aus verschie-
denen Kombinationen von Methoden (Ridge Regression, St¨ utzvektormaschinen, Gauß-
prozesse) und Repr¨ asentationen (Deskriptoren, Graphkern aus Kapitel 2) auszuw¨ ahlen.
Gaußprozesse sind Bayes-Verfahren zur Regression mit impliziter Sch¨ atzung der Unsi-
cherheit der Vorhersage (Anwendbarkeitsdom¨ ane).
Prospektives Screening
Das Screening einer kommerziellen Substanzbibliothek (etwa 300000 Molek¨ ule) ergab
drei Listen mit den jeweils 30 am besten bewerteten Substanzen. Aus diesen wur-
den manuell 15 Substanzen zur Testung in einem Transaktivierungsassay ausgew¨ ahlt.
Von diesen waren vier aktiv (27% Treﬀerrate). Einer der Treﬀer ist ein Naturstoﬀ mit
Cyclobutan-Grundger¨ ust und selektiver Aktivit¨ at auf PPARγ (EC50 = 10 ± 0,2µM,
inaktiv auf PPARα und PPARβ/δ bei 10µM). Unsere Studie hat dadurch eine Wirkung
eines Naturstoﬀs oﬀengelegt und gibt dar¨ uber hinaus einen Hinweis auf die Urspr¨ unge
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